Conditions: Acute Postoperative Pain
Keywords: postoperative pain post-surgical pain total knee arthroplasty total knee replacement ATX-101 bupivacaine bupivacaine implant
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 112
Healthy volunteers: no

Brief summary:
This is a Phase 2B randomized, double blind, active controlled, multi-center clinical trial to evaluate the safety and efficacy of ATX-101 in participants following total knee arthroplasty. The following is short title and acronym for the study: Study Assessing Pain Relief after Replacement of the Knee (SPARK)

Detailed description:

Arms:
arm 1: ATX-101 Dose A arm 2: ATX-101 Dose B arm 3: bupivacaine hydrochloride without epinephrine via local infiltration and/or nerve block

Interventions: intervention 1: ATX-101 intervention 2: ATX-101 intervention 3: bupivacaine hydrochloride without epinephrine
Intervention descriptions: intervention 1: ATX-101 (bupivacaine) implant, one-time administration into the surgical site intervention 2: ATX-101 (bupivacaine) implant, one-time administration into the surgical site intervention 3: bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block

Protocol document:
Prot_000.pdf: 
 
 
 
Official Title: 
A Phase 2B, Randomized, Double Blind, Active Comparator, Multicenter, Safety, 
and Efficacy Trial of ATX-101 in Subjects Undergoing Total Knee Arthroplasty 
(SPARK) 
NCT Number:  
NCT05260008 
Document Date:  02 June 2023 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 1 of 128 
 
 
 
Protocol No. 
ATX-101-TKA-003 
Title: 
A Phase 2B, Randomized, Double Blind, Active Comparator, 
Multicenter, Safety, and Efficacy Trial of ATX-101 in 
Subjects Undergoing Total Knee Arthroplasty (SPARK) 
Short Title/Acronym 
Study Assessing Pain Relief after Replacement of the Knee / 
SPARK 
 
Protocol Version Number: 
Amendment 03 
Issue Date: 
02 June 2023 
Investigational Product: 
ATX-101 
Drug Development Phase: 
2B 
Sponsor: 
Allay Therapeutics, Inc. 
2720 Zanker Road San Jose, CA 95134 
Local Sponsor in Australia:  
Foundry Therapeutics 1 Pty. Ltd a wholly owned subsidiary 
of Allay Therapeutics, Inc. 
Level 19 HWT Tower 
40 City Road 
Southbank, VIC 3006 
Medical Monitor: 
 
 
 
 
 
 
 
 
CONFIDENTIAL 
All information contained within this protocol is confidential. It may not be reproduced, copied or disseminated in 
any manner without the prior written consent of Allay Therapeutics Inc. 
 
 






Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 4 of 128 
INVESTIGATOR SIGNATURE PAGE 
A Phase 2B, Randomized, Double Blind, Active Comparator, Multicenter, Safety, and 
Efficacy Trial of ATX 101 in Subjects Undergoing Total Knee Arthroplasty 
ATX-101-TKA-003 
Version: Amendment 03 
Issue Date:  02 June 2023 
Investigator Agreement 
I have read the above-mentioned protocol and am aware of my responsibilities as Investigator for 
this trial. As such, I agree to: 
• Personally supervise the conduct of this trial. 
• Conduct the trial in accordance with International Conference on Harmonization E6 Good 
Clinical Practice (ICH GCP) Consolidated Guidance, applicable regulatory requirements, and 
the protocol. 
• Comply with the procedures for data recording and reporting as required by the regulatory 
authorities and the Sponsor. 
• Permit monitoring, auditing, and inspection of trial records as required by ICH GCP. 
• Retain the essential clinical trial documents as required by ICH GCP and the Sponsor. 
 
The information contained in this protocol is proprietary and provided to me in confidence, and 
may not be disclosed to any other party, in any form, without prior authorization from Allay 
Therapeutics, except to the extent necessary for conduct of the trial. 
 
 
 
 
Investigator Signature 
 
Date 
 
 
 
Investigator Name (Print) 
 
 
 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 5 of 128 
HISTORY OF PROTOCOL CHANGES 
Version 
History of Changes 
Date 
Original  
Not Applicable 
21 December 2021 
Amendment 01 
Updated Sponsor address, emergency contact, additional contact 
information, and administrative changes. Removed tramadol testing 
from the drug screen.  Modification of medication names for multiple 
regions (epinephrine is now epinephrine/adrenaline, acetaminophen is 
now acetaminophen/paracetamol). Clarification was provided on the 
frequency of rescue opioid medication and the dosage of aspirin being 
based upon regionally approved doses of 75-100 mg. The exclusion 
criteria has been updated to allow previous surgery on the contralateral 
knee and to exclude further contraindications to celecoxib, as well as 
clarify CYP3A inhibitors and inducers in Appendix M. 
13 May 2022 
Amendment 02 
Added short title and acronym. Changed the saline placebo arm in Part 
A to a bupivacaine HCl active comparator arm and removed the saline 
placebo arm in Part B. Updated applicable sections (ie objectives, 
methodology, reference product, and statistics) for the change in 
comparator arms. Increased the number of subjects per treatment group 
due to the change in study design. Updated exclusionary laboratory 
values for renal function at screening. Added ECG pre-surgery in Part 
B. Clarified rescue opioid medication information. Administrative 
changes to update study contacts with reformatted table.  
6 December 2022 
Amendment 03 
Updated Protocol Contact information. Added information to allow for 
an interim analysis for Part A in the applicable sections (ie synopsis 
and section 10 Statistics). Correction of typographical error on 
Exclusion Criteria 12. Added clarification of acetaminophen/ 
paracetamol dose to include the option of either as well as the 500 mg 
every 4 hours or 1000 mg every 6 to 8 hours, for the maximum dose 
not to exceed 3000 mg per any 24-hours in appropriate section.  
Updated exclusion 11: Body Mass Index (BMI) ≥40 kg/m2  to a BMI 
≥45 kg/m2. Minor editorial changes. 
02 June 2023 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 6 of 128 
1.0 
TRIAL SYNOPSIS 
NAME OF SPONSOR 
Allay Therapeutics, Inc. 
NAME OF INVESTIGATIONAL DRUG PRODUCT 
ATX-101 
NAME OF ACTIVE INGREDIENT 
Bupivacaine 
PROTOCOL/TRIAL TITLE 
A Phase 2B, Randomized, Double Blind, Active Comparator, Multicenter, Safety, and Efficacy Trial of ATX-101 
in Subjects Undergoing Total Knee Arthroplasty 
SHORT TITLE AND ACRONYM 
Study Assessing Pain Relief after Replacement of the Knee (SPARK) 
PROTOCOL NUMBER 
ATX-101-TKA-003 
INVESTIGATORS & TRIAL CENTERS 
The trial is planned to be conducted at approximately 20 multi-national clinical centers  
CLINICAL PHASE 
2B 
OBJECTIVES 
• 
To compare the efficacy of ATX-101 (1,000 mg or 1,500 mg) with that of bupivacaine hydrochloride (HCl) in 
subjects undergoing primary unilateral total knee arthroplasty (TKA) 
• 
To evaluate the safety and tolerability of ATX-101 
• 
To characterize the pharmacokinetic (PK) profile following administration of ATX-101 (Part A only) 
• 
To compare opioid consumption of subjects administered ATX-101 with that of bupivacaine HCl (Part B only) 
• 
To estimate the sample size, determine dose, and primary endpoint duration from Part A needed for Part B  
• 
To compare the efficacy of ATX-101 with that of bupivacaine HCl  
METHODOLOGY 
This is a two-part (Part A and Part B) Phase 2B, randomized, double blind, active comparator (bupivacaine HCL) 
(Part B only) multicenter trial in subjects undergoing primary unilateral TKA. Part A will be used to determine the 
sample size, dose, and primary endpoint duration for Part B of the trial.  
 
Subjects will participate in the trial for up to approximately 12 weeks, including a 30-day screening period. All 
subjects will be screened within 30 days prior to surgery. Subjects who meet eligibility criteria will be randomized 
up to 1 business day prior to the day of surgery. On the day of surgery (Day 1), subjects who continue to meet the 
eligibility criteria will undergo primary unilateral TKA under bupivacaine spinal anesthesia without adjunct 
medications used in the spinal anesthesia. The surgical operating team, including the surgeon, will be unblinded to 
the assigned treatment. All other research staff (unless expressly specified in the site’s blinding plan that is 
approved by Allay), and the subject will remain blinded until the end of the trial. The Sponsor will remain blinded 
during the treatment phase of Part A and Part B.  
 
Total enrollment will be split into Part A and Part B, where Part A is expected to randomize approximately 165 
subjects and Part B up to 140 subjects. In Part A (ATX-101, or active comparator and Part B (ATX-101 or active 
comparator) investigational product will be administered to each subject intraoperatively. Part A will include a 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 7 of 128 
one-time dose of ATX-101 (either 1,000 mg or 1,500 mg), whereas Part B will include a one-time dose of 
ATX-101 at a dose level determined from data analysis of Part A.  
 
Part A 
Approximately 165 subjects will be randomized to one (1) of the following three (3) treatment groups in a 1:1:1 
ratio with approximately 55 subjects per group:   
• ATX-101, 1,000 mg dose (two ATX-101 implants)  
• ATX-101, 1,500 mg dose (three ATX-101 implants)  
• Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local periarticular 
infiltration or adductor canal block, or in combination  
 
Part B 
Up to 140 subjects (total number will be determined from Part A) will be randomized to one (1) of the following 
two (2) treatment groups in a 1:1 ratio with up to 70 subjects per group: 
• ATX-101 dose to be determined from Part A 
• Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local periarticular 
infiltration or adductor canal block, or in combination  
 
Before surgery, all subjects will be administered acetaminophen/paracetamol 1,000 mg and celecoxib 200 mg [1]. 
Spinal anesthesia with bupivacaine (with or without dextrose) will be used in all subjects; no other adjunct 
medication may be used in the spinal anesthesia. General anesthesia is optional, but if used must be in conjunction 
with spinal anesthesia. Local nerve blocks (eg adductor canal blocks) are prohibited in the ATX-101 treatment 
group (but permissible in the bupivacaine HCl group), however topical anesthetics such as lidocaine can be used to 
aid in intravenous (IV) access and subcutaneously for spinal needle placement. At the time of induction, the use of 
fentanyl (no more than 300 µg) for airway management is permitted when general anesthesia is used. Other than 
fentanyl for airway management, no other opioids may be administered during surgery.  
 
Surgical drains are not permitted. Two doses of IV tranexamic acid (1 g each) will be administered to the subject. 
One dose of tranexamic acid will be administered prior to investigational product administration and the second 
dose after investigational product administration, with the timing at the discretion of the treating Investigator. A 
one-time dose of IV dexamethasone (4 mg) will be administered during the surgical procedure, with the timing at 
the discretion of the treating Investigator. Intravenous or oral antibiotic regimen may also be given per the center’s 
standard of care. One dose of prophylactic ondansetron will be given before or during surgery, with the timing at 
the discretion of the treating investigator. All other doses of antiemetics will be given only after an adverse event 
has been observed or reported.  
 
Subjects should only receive rescue opioid medication upon request for pain control, as needed, after surgery. 
Rescue opioid medication may be given/taken for pain treatment, but not for pain prophylaxis. Prior to the 
administration of any rescue opioid medication, from surgery through the Day 30 Visit, a Numeric Rating Score at 
Rest (NRS-R) assessing the subject’s pain intensity must be obtained.  
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 8 of 128 
If required to treat pain, the following standardized rescue opioid medication protocol will be used. Preferred 
rescue opioid medication will consist of oral immediate-release oxycodone (5 mg or 10 mg). If a subject cannot 
tolerate oral medication, morphine may be administered IV (including via patient-controlled analgesia [PCA] 
pump) or IM as needed (morphine is preferred, however hydromorphone can also be used with the dose 
determined by the treating physician). If a subject cannot tolerate the medication or the breakthrough pain is not 
responsive to oral oxycodone, then oral hydromorphone (2 mg or 4 mg) may be given for rescue opioid 
medication. Should the subject have an adverse event (AE) and is unable to tolerate the rescue opioid medications 
of oral oxycodone (5 mg or 10 mg), IV morphine, oral hydromorphone (2 mg or 4 mg), and IV hydromorphone, 
then hospital standard of care may be utilized. No long-lasting opioids should be administered. (See Section 7.6.3.1 
for further information on rescue opioids.) 
 
The subjects will be administered celecoxib (200 mg) twice a day for 30 days, unless an AE occurs that requires 
discontinuation. Acetaminophen/paracetamol 500 mg should be taken every 4 hours or 1,000 mg should be taken 
every 6 to 8 hours not to exceed 3,000 mg per any 24-hour period for a minimum of 21 days. Deep vein thrombosis 
(DVT) prophylaxis is required, and 75-100 mg aspirin (based upon regional approved dose) is recommended twice 
a day, unless otherwise contraindicated for the subject, for 30 days. Celecoxib, acetaminophen/paracetamol, and 
aspirin may be provided by the Sponsor. 
 
Following surgery, subjects will be transferred to the post-anesthesia care unit (PACU). Subjects in Part A of the 
trial will remain under in-patient observation until Hour 96. While under observation subjects will have 
assessments of vital signs, neurological assessments, pain scores, ECGs, PK sampling, and AE/concomitant 
medication review as per the study schedule. Subjects in Part B of the trial will remain under observation until 
Hour 24 and then may be discharged per standard of care. 
 
Regardless of in-patient observation/hospitalization or discharge status, all procedures in the Schedule of Events 
will be followed. Home visits as detailed in Appendix A and Appendix B may be completed at the subject’s home, 
a physical therapy facility, in the clinic/hospital/facility, or any other place agreed upon by the trial staff and the 
subject. In clinic visits may also be completed at a physical therapy facility or in the clinic/hospital/facility as long 
as all procedures can be conducted. 
 
During trial participation subjects will utilize an electronic diary (e-diary) to capture pain intensity using the 
NRS-R and Numeric Rating Scale with Activity (NRS-A) and location of pain. The e-diary will also be utilized to 
collect medication and trial questionnaires/surveys.  
 
The Day 6 and Day 8 Visit may occur in the hospital/clinic/facility, at the subject’s home, at a physical therapy 
facility, or any other place agreed upon by the subject and site staff. Subjects will return to the clinic at Day 15, 
Day 22, Day 30, and Day 56 and at any visit where the subject is not able to be seen at their home or alternate 
location by a home health care nurse/the trial staff.  
Pharmacokinetic Sampling  
For Part A, venous blood samples for plasma PK analysis are drawn before surgery (before bupivacaine spinal), 
during surgery prior to administration of ATX-101 or the bupivacaine HCl active comparator, then approximately 
6 hours after surgical closure 12 hours after surgical closure, and on Days 2 (Hour 24), 3 (Hour 48), 4 (Hour 72), 5 
(Hour 96), 6, 8, 15, 22, and 30. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 9 of 128 
For Part A and Part B, PK sampling will be done for bupivacaine monitoring anytime there is a Serious Adverse 
Event (SAE) or Adverse Events of Special Interest (AESI).  
SAFETY REVIEW & STOPPING CRITERIA 
Safety Monitoring Committee  
A Safety Monitoring Committee (SMC) will review blinded summary safety data in Part A after 25%, 50%, and 
100% enrollment of the study and in Part B after 25%, 50%, and 75% enrollment of the study. The SMC will be 
composed of independent members and Sponsor representatives. Representatives from the Sponsor will include 
clinical, regulatory and the study medical monitor. The biostatistician, anesthesiologist, cardiologist and orthopedic 
surgeon will be independent members. The SMC will operate under a written, detailed SMC plan. 
The SMC will evaluate study data including adverse events, pharmacokinetic data, cardiac information, and safety 
laboratory results from subjects. The SMC will investigate all reports of PK greater than or equal to 1,000 ng/mL 
of plasma bupivacaine. Should data arise where further information is needed to address a safety concern, the SMC 
will escalate the data review to an unblinded, independent statistician and physician.   
Stopping Rules: 
The SMC may recommend that the trial be stopped and evaluated at any time. The trial will also be stopped should 
there be: 
• 
One death where a clear alternative cause (other than ATX-101) is not identified or 
• 
Two non-fatal SAE’s where a clear alternate cause (other than ATX-101) is not identified or 
• 
Five moderate cardiac or central nervous system AESI’s with a PK concentration of more than 
1,000 ng/mL and a clear alternate cause (other than ATX-101) is not identified or 
• 
Three severe cardiac or central nervous system AESI’s with a PK concentration of more than 1,000 
ng/mL and a clear alternate cause (other than ATX-101) is not identified. 
In these instances, the study blind may be broken for the SMC for the identified subjects. 
NUMBER OF SUBJECTS  
This trial will enroll approximately 165 subjects in Part A and up to 140 subjects in Part B. 
DIAGNOSIS & MAIN CRITERIA FOR INCLUSION  
This trial will evaluate the treatment of postsurgical pain in TKA subjects. 
Inclusion Criteria 
1. Primary indication of TKA is knee pain due to osteoarthritis or post-traumatic arthritis. 
2. Scheduled to undergo primary unilateral TKA with a cemented prosthesis, without use of a surgical drain, 
and under bupivacaine spinal anesthesia (dextrose is permitted).  
3. American Society of Anesthesiology (ASA) Physical Classification System of class 1, 2 or 3.  
4. Male or female, ≥18 and ≤80 years of age at the Screening Visit. 
5. Female subjects only: Postmenopausal, surgically sterile, or willing to use acceptable means of 
contraception from the Screening Visit through the Day 56 Visit.   
a. 
Medically acceptable methods of contraception that may be used by the subject include birth 
control pills, diaphragm with spermicide, intrauterine device (IUD), condom with spermicide, 
vaginal spermicidal suppository, or progestin implant or injection (used consistently for 
≥3 months at the time of screening).   


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 10 of 128 
b. Female subjects who are not of childbearing potential must have a medical history recorded of 
surgical sterilization (≥6 months post-surgery at the time of screening) or post-menopausal (not 
experienced a menstrual period ≥2 years at the time of screening). 
6. Capable, able, and willing to comply with all trial visits and procedures. Subject must also be able to use 
trial required electronic applications (eg electronic diary) for patient reported outcome measures.  
7. English speaking, willing, and capable of providing written informed consent. 
 
Exclusion Criteria: 
1. Has a planned concurrent surgical procedure (eg bilateral TKA) at the time of surgery or a planned 
surgical procedure any time before the Day 56 Visit. 
2. Has had any previous arthroplasty, unicompartmental knee arthroplasty or TKA in the study knee or 
previous arthroplasty, unicompartmental knee arthroplasty, or TKA in the contralateral knee within 6 
months prior to screening.     
3. Has been administered any type of intra-articular injection within 3 months of surgery in the trial knee. 
4. Has a pre-existing concurrent, acute, or chronic, painful/restrictive physical condition for which they 
routinely take opioid analgesics and are expected to require opioid analgesics in the postsurgical period 
that is not strictly related to the trial knee osteoarthritis/post-traumatic arthritis and/or trial knee surgery. 
5. Unable to abstain from opioid use for knee pain (including codeine) within 2 weeks (14 days) of surgery. 
6. Has been administered systemic steroids within 14 days prior to surgery. (Note: Steroids provided on the 
day of surgery as part of a standard surgical medication regimen are permitted. Local steroids such as 
inhalers or ophthalmologic drops are permitted). 
7. Is unwilling or unable to discontinue use of medications or products that can impact pain control from the 
Screening Visit until the Day 56 Visit (eg cannabidiol (CBD) oil, Kratom, herbal supplements). 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) and acetaminophen/paracetamol are permitted prior 
to surgery at the treating Investigator’s discretion. Subjects prescribed gabapentin and/or pregabalin will 
require medical monitor approval.   
8. Has been administered any anesthetic including but not limited to bupivacaine, ropivacaine, or lidocaine 
within 5 days prior to the scheduled surgery. See protocol Section 7.6.1 for uses and permitted anesthetics 
on the day of surgery. 
9. Requires medication that will impact the metabolism, absorption, or excretion of bupivacaine. 
Epinephrine/adrenaline should be used with caution.  Strong inhibitors and inducers of CYP3A4 should 
be avoided (See Appendix M). Coadministration of ATX-101or bupivacaine HCl with local anesthetics is 
prohibited. 
10. Has a contraindication or a known or suspected history of allergy, hypersensitivity, or idiosyncratic 
reaction to trial medications including but not limited to those used during surgery or post-surgery (eg 
anesthesia, IV dexamethasone, IV tranexamic acid, antibiotics, ondansetron, and opioids such as 
morphine, oxycodone, and hydromorphone), also to medications taken prior to surgery and/or dispensed 
for home use (ie acetaminophen/paracetamol and celecoxib), or to the investigational product or its 
components (bupivacaine, poly[DL-lactide-co-glycolide] (PLGA), and/or polysorbate). 
11. Has a Body Mass Index (BMI) ≥45 kg/m2. 
12. Has laboratory values at screening that will exclude enrollment including: 
a. 
Bilirubin >2 times the upper normal limit unless due to Gilberts syndrome  
b. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase 
(ALP) >1.5 times the upper normal limit  
c. 
Creatinine > 2 times the upper normal limit 
d. Estimated serum creatinine clearance <30 mL/min 
e. 
Hemoglobin below the lower normal limit 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 11 of 128 
13. Screening electrocardiograms (ECG) with significant abnormalities such as left bundle-branch blocks, 
bifascicular blocks, second- or third-degree AV block, possible current ischemia, or other findings 
associated with significant heart disease. The average QTc of the screening triplicate ECGs must not be 
>450 ms in males or >470 ms in females. Significant findings are to be clearly documented. 
14. Has symptomatic central nervous system (CNS) injury or disorder including epilepsy.  
15. Has any chronic condition or disease that would compromise neurological or vascular assessments. 
16. Immunocompromised or has a known history of Hepatitis B, human immunodeficiency virus (HIV), or 
Hepatitis C. 
17. Has a medical condition or receiving medication such that, in the opinion of the Investigator, participating 
in the trial would pose a health risk to the subject or confound the postsurgical assessments or might 
confound or interfere with the outcome of the trial. Examples include but are not limited to inability to 
ambulate, diabetic neuropathy, complex regional pain syndrome, prior infection in operative joint, known 
or suspected coagulopathy, uncontrolled anticoagulation, long COVID diagnosis, history of 
thromboembolic events, active gastrointestinal ulcers/bleeding, or cerebrovascular bleeding. 
18. Has uncontrolled depression, anxiety, psychiatric, or neurological disorder that might interfere with trial 
assessments or might confound or interfere with the outcome of the trial.   
a. 
Subjects currently taking anti-psychotic medication will be excluded.   
b. Anti-depressant medication (selective serotonin reuptake inhibitors only) is allowed if the subject 
has been on a stable dose for at least 30 days prior to screening and no dose changes are planned 
during the conduct of the trial.    
19. At any time prior to randomization, subjects with moderately severe or severe depression, as defined by  
a. 
Patient Health Questionnaire (PHQ-9) total score of ≥10; or  
b. Suicidal ideation, as defined by a PHQ-9 score of ≥1 in response to question 9, “thoughts that 
you would be better off dead, or hurting yourself.” 
20. Has a known or suspected history of drug or alcohol abuse. A subject with a history of alcohol use 
disorder that has ≥10 years sobriety will be permitted. 
21. Has a positive drug screen at the Screening Visit or on the day of surgery including positive results from 
prescribed medications. The exception being a positive drug screen resulting from infrequent use of short 
acting benzodiazepines that can be washed out 7 days prior to surgery and not utilized during the trial 
duration.  
22. Has received/used an investigational drug, product, or device for a clinical trial within 30 days of 
screening. COVID-19 vaccines (approved or under emergency use authorization locally) are permitted if 
the subject is not in a clinical trial for the vaccine.   
23. Pregnant, breastfeeding, or planning to become pregnant during the trial or before the Day 56 Visit. 
In addition, the subject will not have met eligibility if the following occurs during surgery.   
24. Any clinically significant (CS) event or condition uncovered during surgery (eg excessive bleeding, femur 
fracture), which occurs before investigational product administration, that might render the subject 
medically unstable or complicate the subject’s postsurgical course. 
25.
 
TEST PRODUCT, DOSE AND MODE OF ADMINISTRATION  
ATX-101 (bupivacaine) implant, 500 mg, implant. 
Each bioabsorbable implant contains 500 mg bupivacaine free base (equal to 563 mg bupivacaine HCl or 594 mg 
bupivacaine HCl monohydrate and hereafter referred to as bupivacaine).  
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 12 of 128 
In Part A of this trial, subjects will receive a single-dose administration of 1,000 mg of ATX-101 (2 implants each 
containing 500 mg bupivacaine), or 1,500 mg of ATX-101 (3 implants each containing 500 mg bupivacaine).  
In Part B of this trial, subjects will receive a single dose level of ATX-101 determined from the analysis of Part A. 
 
A one-time administration of a single dose level of ATX-101 will be placed in the subject’s knee capsule 
following fixation of the knee prosthesis when tissue will not be disrupted any further by surgery, after any 
betadine or saline rinse, and after suction has occurred, but prior to initiation of surgical closure. ATX-101 will be 
placed in the suprapatellar pouch, medial gutter, and/or lateral gutter according to the Dosage and Administration 
Instructions.   
REFERENCE PRODUCT, DOSE AND MODE OF ADMINISTRATION 
Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local periarticular 
infiltration or adductor canal block, or in combination  
Bupivacaine HCl may be provided by the Sponsor for trial use. 
TRIAL ENDPOINTS AND CRITERIA FOR EVALUATION 
Primary Efficacy Endpoint (evaluated in Part B): Area under the curve (AUC) for the NRS-R of pain intensity from 
30 Minutes through a time point to be determined from Part A. 
The primary efficacy endpoint for Part A is AUC for the NRS-R of pain intensity from 30 Minutes through Hour 
168 (Day 8 of the trial). 
Key Secondary Endpoints (evaluated in Part B): 
• 
Area under the curve for the NRS-R of pain intensity from 30 Minutes through Hour 168 (Day 8 of the 
trial), Hour 240 (Day 11 of the trial), and Hour 336 (Day 15 of the trial). 
• 
Percentage of subjects who remain opioid free from Hour 72 through Day 30. 
• 
Total post-surgical consumption of opioid medications from surgical closure through Day 30. 
 
Secondary Endpoints: 
• 
Area under the curve for the NRS-R of pain intensity for each 24-hour period through Hour 336 (Day 15 of 
the trial)  
• 
Percentage of subjects who remain opioid free  
• 
Total post-surgical consumption of rescue opioid medications  
• 
Time to first postsurgical use of rescue opioid medication 
 
Safety Endpoints: 
• 
Incidence of AEs, AESIs, and SAEs  
• 
Wound healing assessment using the Southampton Wound Scoring System 
• 
Characterization of the bupivacaine PK from ATX-101 
Exploratory Endpoints: 
• 
Percentage of subjects reporting being pain free on the NRS-R of pain intensity 
• 
Time to various degrees of flexion and extension  
• 
Reduction/incidence of opioid-related AEs 
• 
Evaluation of Quality of Recovery 15 Scale (QOR-15) 
• 
Evaluation of Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, JR) 
• 
Difference in pain intensity scores (NRS-R and NRS-A) between treatment groups  
• 
If a statistical difference in AUC of pain intensity NRS-R at 336 Hours (Day 15 of the trial) is observed, 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 13 of 128 
the AUC for the NRS-R of pain intensity will be further evaluated between Days 16 and 30  
• 
Evaluation of the Knee Society Score 
 
For consideration of efficacy, safety, and PK assessments the time of surgical closure (skin closure) will be 
considered Time 0 for all assessments.  
STATISTICAL METHODS  
Sample Size Calculation:  
Part A 
Approximately 165 subjects will be randomized to one (1) of the following three (3) treatment groups in a 1:1:1 
ratio with approximately 55 subjects per group:  
• 
ATX-101, 1,000 mg dose (two ATX-101 implants)  
• 
ATX-101, 1,500 mg dose (three ATX-101 implants) 
• 
Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local 
periarticular infiltration or adductor canal block, or in combination  
Based on the literature review of other products used in TKA and discussion with experts in post-operative pain, it 
is believed that 55 subjects per group would provide sufficient information to inform dose response and dose 
selection for Part B. 
 
Part B 
Up to 140 subjects will be randomized to one (1) of the following two (2) treatment groups in a 1:1 ratio with up to 
70 subjects per group: 
• 
ATX-101, dose to be determined from Part A 
• 
Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local 
periarticular infiltration or adductor canal block, or in combination  
The current planned sample size for Part B is up to 140 subjects. The actual number of subjects to be randomized 
will be determined based on data from Part A. 
Analysis Populations:  
• 
Full Analysis Set (FAS): all subjects who are randomized and administered ATX-101or bupivacaine HCl. 
The FAS will be used for the efficacy analyses and subject demographic and baseline characteristics. 
• 
Safety Analysis Set: all subjects who are randomized and administered ATX-101 or bupivacaine HCl. The 
Safety Analysis Set will be used for all safety analyses. 
• 
PK Analysis Set: all subjects who provide enough plasma samples for PK assessment of bupivacaine that 
allows for generation of at least one PK parameter of Tmax, Cmax, or AUC.   
Efficacy Evaluations: 
The primary efficacy endpoint (evaluated in Part B) is the AUC for the NRS-R of pain intensity from 30 Minutes 
through a time point to be determined from Part A. The time-weighted AUC will be calculated using the 
trapezoidal rule based on the available NRS pain scores. Missing values will not be imputed with the exception of 
the final time point. Prior to administration of rescue opioid medications, NRS-R scores will be recorded. NRS-R 
values will be censored for the duration of the effectiveness of rescue opioid medications before the trapezoidal 
rule is applied. 
 
The primary efficacy endpoint will be analyzed using an Analysis of Variance (ANOVA) model with a main effect 
of the treatment group. Summary statistics will be reported as well as the least square (LS) means, difference in the 
LS means, 95% confidence intervals (CI) and p-value for the contrast comparing the LS means. 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 14 of 128 
For Part B, the primary comparison will be ATX-101 versus bupivacaine HCl. A two-sided alpha 0.05 will be 
spent on the primary comparison.  
 
To control the type I error for the analyses of key secondary endpoints, a stepdown procedure will be used. If the 
primary comparison for the primary endpoint is statistically significant, comparisons between ATX-101 and 
bupivacaine HCl for the key secondary endpoints will be carried out in the order as shown below. Comparisons 
will be stopped once any proceeding comparison is not statistically significant. 
• 
Area Under the Curve for NRS-R of pain intensity from 30 Minutes through Hour 168 (Day 8 of the trial) 
• 
Area Under the Curve for NRS-R of pain intensity from 30 Minutes through Hour 240 (Day 11 of the 
trial) 
• 
Area Under the Curve for NRS-R of pain intensity from 30 Minutes through Hour 336 (Day 15 of the 
trial) 
• 
Percentage of subjects who remain opioid free from Hour 72 through Day 30 
• 
Total post-surgical consumption of opioid medications from surgical closure through Day 30 
 
For Part A, each single dose level of ATX-101 will be compared to the bupivacaine HCl active comparator group. 
In addition, the LS mean of each dose level group will be plotted with 95% CI to evaluate dose response.  
For Part A, an interim analysis may be performed when approximately 50% of the initially planned enrollment has 
completed Day 30.  Enrollment will continue during the interim analysis. This interim analysis will be performed 
by the unblinded statistician separate from the team responsible for the conduct and analysis of the study. A 
Review Committee of at least two unblinded statisticians and a designated sponsor representative will review the 
data and recommend one of the following: 
• 
Keep the current sample size and continue Part A as planned 
• 
Stop Part A for efficacy (no further enrollment) 
• 
Increase the sample size in Part A  
The basis of this decision will be whether sufficient data have been collected to plan Part B, taking into account 
both safety and efficacy (including outcomes other than the primary). All part A data will be evaluated. In 
particular, data pertaining to selection of Part B primary endpoint, eg treatment effect and primary endpoint 
variability, will be evaluated for the planning of Part B.    
The Sponsor may make adjustments other than those detailed above; however, the blinded Sponsor team will 
receive no information other than the recommendations listed. If the interim analysis demonstrates sufficient data 
have been collected to plan Part B, then Part A may be stopped, unblinded and the final analysis will be completed 
on the population enrolled to date. 
Full details of the interim analysis will be described in a separate document including data available to the Review 
Committee, timing, and communication procedures. Details for an interim analysis are provided in Protocol 
Section 10.8.7.  
 
For the analysis of other efficacy endpoints, refer to Protocol Sections 10.4 and 10.5 for details. 
Safety Evaluations: All subjects who have received ATX-101 or bupivacaine HCl (regardless of whether or not 
they completed the trial) will be included in the safety evaluation.  


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 15 of 128 
Adverse events will be collected from the time of administration of ATX-101 or active comparator through the 
Day 56 Visit and will be summarized by System Organ Class (SOC) using the Medical Dictionary for Regulatory 
Activities (MedDRA). Central Nervous System and Cardiovascular AESIs will also be summarized by SOC using 
MedDRA. Adverse Events of Special Interest include CNS Symptoms/Events: tongue and perioral numbness, 
tinnitus, muscle fasciculations, tremors, seizures, global CNS depression, apnea (not sleep apnea); as well as the 
following Cardiovascular Symptoms/Events: sinus bradycardia, atrioventricular blocks, conduction defects 
(prolonged PR or prolonged QRS), ventricular dysrhythmias, cardiac arrest, or asystole. Additional AESIs 
regarding Wound Healing Symptoms/Events include wound dehiscence, wound pus/purulent discharge, deep 
wound infection, or cellulitis near the incision site. 
Prior and concomitant medication usage is to be recorded from 30 days before the Screening Visit through the Day 
56 Visit. Safety evaluations, including vital signs, physical examinations, neurological assessments, ECGs, and 
laboratory tests are performed as indicated in the Schedule of Events. 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 16 of 128 
2.0 
TABLE OF CONTENTS 
PROTOCOL CONTACTS ...........................................................................................................2 
PROTOCOL SIGNATURE PAGE ..............................................................................................3 
INVESTIGATOR SIGNATURE PAGE......................................................................................4 
HISTORY OF PROTOCOL CHANGES ....................................................................................5 
1.0 
TRIAL SYNOPSIS ............................................................................................................6 
2.0 
TABLE OF CONTENTS ................................................................................................16 
LIST OF TABLES .......................................................................................................................20 
LIST OF FIGURES .....................................................................................................................20 
LIST OF APPENDICES .............................................................................................................21 
3.0 
LIST OF ABBREVIATIONS .........................................................................................22 
4.0 
BACKGROUND ..............................................................................................................25 
4.1 
Bupivacaine Pharmacology ...................................................................................26 
4.2 
Bupivacaine Exposure and Clinical Safety ............................................................27 
4.3 
Overall Dose Safety Summary and ATX-101 Dose Justification .........................27 
4.4 
ATX-101 Clinical Experience ...............................................................................28 
5.0 
TRIAL OBJECTIVES AND ENDPOINTS...................................................................29 
5.1 
Objectives ..............................................................................................................29 
5.2 
Endpoints ...............................................................................................................30 
5.2.1 
Primary Endpoints .................................................................................30 
5.2.2 
Key Secondary Endpoints (Evaluated in Part B) ..................................30 
5.2.3 
Secondary Endpoints .............................................................................30 
5.2.4 
Safety Endpoints ...................................................................................30 
5.2.5 
Exploratory Endpoints ..........................................................................30 
6.0 
INVESTIGATIONAL PLAN .........................................................................................31 
6.1 
Overall TRIAL Design ..........................................................................................31 
6.1.1 
Trial Procedures ....................................................................................31 
6.1.1.1 
Screening Visit ...............................................................................32 
6.1.1.2 
Day of Surgery (Day 1)..................................................................33 
6.1.1.2.1 
Before Surgery ...............................................................................33 
6.1.1.2.2 
During Surgery...............................................................................34 
6.1.1.2.3 
After Surgery .................................................................................35 
6.1.1.3 
Part A: Days 2, 3, 4, & 5 During 96 Hour Observation .................37 
6.1.1.4 
Part A, Day 6..................................................................................38 
6.1.1.5 
Part B: Day 2 ..................................................................................39 
6.1.1.6 
Part B: Days 3, 4, 5, & 6 ................................................................40 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 17 of 128 
6.1.1.7 
Day 8 ..............................................................................................40 
6.1.1.8 
Day 15 and Day 22 Visits ..............................................................41 
6.1.1.9 
Day 30 Visit ...................................................................................42 
6.1.1.10 
Day 56 Visit ...................................................................................43 
6.1.1.11 
Early Termination Visit .................................................................44 
6.1.1.12 
Serious Adverse Event or Adverse Event of Special Interest ........45 
6.2 
Number of Subjects................................................................................................45 
6.3 
Trial Population .....................................................................................................45 
6.3.1 
Subject Inclusion Criteria ......................................................................45 
6.3.2 
Subject Exclusion Criteria.....................................................................46 
6.3.3 
Subject Withdrawal Criteria ..................................................................48 
6.4 
Safety Monitoring Committee ...............................................................................49 
6.5 
Stopping Rules .......................................................................................................49 
6.6 
Criteria for Trial Termination ................................................................................50 
7.0 
TRIAL TREATMENTS ..................................................................................................50 
7.1 
Description of Investigational Product (ATX-101) ...............................................50 
7.1.1 
ATX-101 Packaging, Labeling & Storage ............................................51 
7.2 
Description of Active Comparator (Bupivacaine HCl) .........................................51 
7.3 
Dose Adjustment Criteria ......................................................................................51 
7.4 
Investigational Product Handling and Disposal .....................................................51 
7.4.1 
Safety and Handling ..............................................................................51 
7.4.2 
Disposal .................................................................................................52 
7.5 
Investigational Product Accountability ..................................................................52 
7.6 
Concomitant Medications ......................................................................................52 
7.6.1 
Pre-Surgical Medications ......................................................................52 
7.6.2 
Surgical Concomitant Medications .......................................................52 
7.6.3 
Post-Surgical Concomitant Medications ...............................................53 
7.6.3.1 
Rescue Opioid Medications ...........................................................53 
7.6.3.1.1 
In Hospital Rescue Opioid Medications ........................................53 
7.6.3.1.2 
Post-Discharge Rescue Opioid Medications ..................................54 
7.7 
Randomization .......................................................................................................55 
7.8 
Blinding..................................................................................................................55 
8.0 
TRIAL PROCEDURES ..................................................................................................55 
8.1 
Demographic/Medical History...............................................................................56 
8.2 
Vital Signs ..............................................................................................................56 
8.3 
Physical Examination and Height/Weight .............................................................56 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 18 of 128 
8.3.1 
Kellgren Lawrence Classification .........................................................56 
8.4 
Electrocardiogram ..................................................................................................57 
8.5 
Laboratory Assessments ........................................................................................57 
8.5.1 
Hematology ...........................................................................................58 
8.5.2 
Chemistry ..............................................................................................58 
8.5.3 
Drug Screen ...........................................................................................58 
8.5.4 
Pregnancy Test ......................................................................................58 
8.6 
Range of Motion Assessment ................................................................................59 
8.7 
Patient Health Questionnaire 9 ..............................................................................59 
8.8 
Neurological Assessments .....................................................................................59 
8.9 
e-diary Training .....................................................................................................60 
8.10 
e-diary Dispensation/Return ..................................................................................60 
8.11 
Subject Pain Score Training...................................................................................60 
8.12 
Randomization and Investigational Product Allocation ........................................60 
8.13 
Bupivacaine Pharmacokinetic Assessment ............................................................61 
8.13.1 
Blood Sample Collection for Pharmacokinetic Analysis ......................61 
8.13.2 
Bupivacaine Concentration Analysis ....................................................61 
8.14 
Investigational Product Administration .................................................................61 
8.14.1 
ATX-101 ...............................................................................................61 
8.14.2 
Bupivacaine Hydrochloride-Active Comparator ..................................61 
8.15 
Wound Healing Assessment ..................................................................................62 
8.16 
Knee Society Score ................................................................................................62 
8.17 
Subject Self-Administered e-diary Assessments ...................................................62 
8.17.1 
Numeric Rating Scale at Rest for Pain Intensity & Location of Pain ...62 
8.17.2 
Numeric Rating Scale with Activity for Pain Intensity & Location 
of Pain ...................................................................................................62 
8.17.3 
Quality of Recovery 15 Scale ...............................................................63 
8.17.4 
Knee Injury and Osteoarthritis Outcome Scale for Joint 
Replacement ..........................................................................................63 
8.17.5 
Pain Manageability Assessment ............................................................63 
8.17.6 
Recording Rescue Opioid Medication and Medication Compliance ....63 
8.17.7 
Physical Therapy Survey.......................................................................63 
9.0 
REPORTING SAFETY INFORMATION ....................................................................64 
9.1 
Adverse Events and Serious Adverse Events ........................................................64 
9.1.1 
Definition of Adverse Event .................................................................64 
9.1.2 
Procedures for Eliciting Adverse Events ..............................................65 
9.1.3 
Reporting a Diagnosis, Not Signs or Symptoms ...................................65 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 19 of 128 
9.1.4 
Definition of Serious Adverse Event ....................................................65 
9.1.5 
Medical Emergency ..............................................................................66 
9.2 
Relationship to Investigational Product .................................................................66 
9.3 
Relationship to the TKA Surgery ..........................................................................68 
9.4 
Recording Adverse Events .....................................................................................69 
9.5 
Reporting Adverse Events .....................................................................................70 
9.5.1 
Serious Adverse Event Reporting .........................................................70 
9.5.2 
Adverse Events of Special Interest .......................................................70 
9.5.3 
Suspected Unexpected Serious Adverse Reactions ..............................71 
9.5.4 
Reporting of Adverse Events and Serious Adverse Events to the 
Investigational Review Board/Ethics Committee .................................72 
9.6 
Pregnancy Reports .................................................................................................72 
9.7 
Possible Adverse Events ........................................................................................72 
9.7.1 
Due to Bupivacaine ...............................................................................72 
9.7.2 
Due to General Surgery, TKA and Blood Collections ..........................75 
10.0 
STATISTICS ....................................................................................................................76 
10.1 
Sample Size Calculation ........................................................................................76 
10.2 
Analysis Populations ..............................................................................................76 
10.3 
Primary Endpoint Analysis ....................................................................................77 
10.4 
Key Secondary Endpoint Analysis for Part B ........................................................77 
10.4.1 
Type I Error Control Procedure ............................................................77 
10.4.2 
Area Under the Curve for Numeric Rating Scale at Rest of Pain 
Intensity from 30 Minutes through Hours 168, 240, and 336 ...............78 
10.4.3 
Percentage of Subjects Who Remain Opioid Free from Hour 72 
Through Day 30 ....................................................................................78 
10.4.4 
Total Post-Surgical Consumption of Opioid Medications from 
Surgical Closure Through Day 30 ........................................................78 
10.5 
Secondary Endpoint Analysis ................................................................................78 
10.5.1 
Area Under the Curve for Numeric Rating Scale at Rest for Each 
24-Hour Period Through Hour 336 .......................................................78 
10.5.2 
Percentage of Subjects Opioid Free ......................................................79 
10.5.3 
Total Post-Surgical Consumption of Opioids .......................................79 
10.5.4 
Time to First Rescue Opioid Medication ..............................................79 
10.6 
Safety Endpoints ....................................................................................................79 
10.6.1 
Adverse Events......................................................................................79 
10.6.2 
Wound Healing Assessment .................................................................80 
10.6.3 
Pharmacokinetic Analysis .....................................................................80 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 20 of 128 
10.7 
Exploratory Endpoints ...........................................................................................80 
10.8 
Other Safety Analysis ............................................................................................81 
10.8.1 
Clinical Laboratory Tests ......................................................................81 
10.8.2 
Electrocardiograms ...............................................................................81 
10.8.3 
Vital Signs .............................................................................................81 
10.8.4 
Physical Examination and Neurological Assessment Findings ............81 
10.8.5 
Patient Health Questionnaire 9..............................................................81 
10.8.6 
Treatment Exposure and Disposition ....................................................81 
10.8.7 
Interim Analysis ....................................................................................81 
11.0 
ETHICS ............................................................................................................................82 
11.1 
Ethical Conduct of the Trial ...................................................................................82 
11.2 
Investigational Review Board/ Ethics CommitteeReview .....................................82 
12.0 
ADMINISTRATIVE CONSIDERATIONS ..................................................................83 
12.1 
Recording Data ......................................................................................................83 
12.2 
Direct Access to Source Data/Documents .............................................................83 
12.2.1 
Trial Monitoring ....................................................................................83 
12.2.2 
Audits and Inspection ............................................................................84 
12.3 
Quality Control and Quality Assurance .................................................................85 
12.3.1 
General Responsibilities........................................................................85 
12.3.2 
Retention of Records .............................................................................86 
12.3.3 
Protocol Compliance .............................................................................87 
12.3.4 
Subject Informed Consent .....................................................................87 
12.4 
Laboratory Accreditation .......................................................................................87 
12.5 
Confidentiality Regarding Trial Subjects ..............................................................87 
12.6 
Publication Policy ..................................................................................................88 
13.0 
APPENDICES ..................................................................................................................88 
14.0 
REFERENCES ...............................................................................................................127 
 
LIST OF TABLES 
Table 1. FT1-TKA-001 Dosage, Number of Subjects, and Placement .........................................28 
 
LIST OF FIGURES 
Figure 1. Example of the ATX-101 ...............................................................................................50 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 21 of 128 
LIST OF APPENDICES 
Appendix A. Schedule of Events for Part A ..................................................................................89 
Appendix B. Schedule of Events for Part B ..................................................................................95 
Appendix C. Subject Self-Administered e-diary Procedures ......................................................100 
Appendix D. Quality of Recovery-15 Patient Survey .................................................................102 
Appendix E. Knee Injury and Osteoarthritis Outcome Score for Joint Replacement .................103 
Appendix F. Ability To Manage Pain ..........................................................................................105 
Appendix G. Patient Health Questionnaire 9 ...............................................................................106 
Appendix H. Pain Intensity Assessments Using The Numeric Rating Scale ..............................107 
Appendix I. Wound Healing Assessment - Southampton Wound Scoring System ....................110 
Appendix J. Knee Society Score ..................................................................................................111 
Appendix K. Adverse Event Toxicity Grading Scale ..................................................................122 
Appendix L. Location of Pain ......................................................................................................124 
Appendix M. CYP3A Inhibitors and Inducers ............................................................................125 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 22 of 128 
3.0 
LIST OF ABBREVIATIONS 
Abbreviation 
Definition 
AE 
Adverse Event 
AESI 
Adverse Event of Special Interest 
ALP 
Alkaline Phosphatase 
ALT 
Alanine Aminotransferase  
ANOVA 
Analysis of Variance 
ASA  
American Society of Anesthesiology 
AST 
Aspartate Aminotransferase 
ATX-101 
Allay Therapeutics Investigational Product 
AUC 
Area Under the Curve 
AUC0-∞ 
Area Under the Concentration-Time Curve Through Infinity 
AUClast 
Area Under the Concentration-Time Curve up to the Time of Last Quantifiable 
Concentration 
BMI 
Body Mass Index 
BUN 
Blood Urea Nitrogen 
CBD 
Cannabidiol 
CDC 
Center of Disease Control 
CI 
Confidence Intervals 
Cmax 
Maximum Observed Plasma Concentration 
CNS 
Central Nervous System 
COVID-19 
Coronavirus disease of 2019 
CRF 
Case Report Form 
CS 
Clinically Significant 
CYP3A4 
Cytochrome P450 3A4  
dL 
Deciliter 
DSMB 
Data Safety Monitoring Board 
DVT 
Deep Vein Thrombosis 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
EDC 
Electronic Data Capture 
e-diary 
Electronic Diary  
FAS 
Full Set Analysis 
FDA 
Food and Drug Administration 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 23 of 128 
Abbreviation 
Definition 
G 
Gram 
GCP 
Good Clinical Practice 
GGT 
Gamma-glutamyl Transferase 
HCl 
Hydrochloride 
HIV 
Human Immunodeficiency Virus 
IB 
Investigator’s Brochure 
ICH 
International Conference on Harmonization 
IRB 
Investigational Review Board 
IUD 
Intrauterine Device 
IV  
Intravenous  
KOOS, JR 
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement 
LAST 
Local Anesthetic Systemic Toxicity 
LS 
Least Square 
MDMA 
3,4-Methylenedioxymethamphetamine or Ecstasy 
MedDRA 
Medical Dictionary for Regulatory Activities 
mg 
Milligram 
mL 
Milliliter 
mm 
Millimeter 
MME 
Milligram-Morphine Equivalents 
ms 
Millisecond 
ng 
Nanogram 
NRS 
Numeric Rating Scale 
NRS-A 
Numeric Rating Scale with Activity 
NRS-R 
Numeric Rating Scale at Rest 
NSAID 
Non-steroidal Anti-inflammatory Drug 
OA 
Osteoarthritis 
PACU 
Post-Anesthesia Care Unit 
PHQ-9 
Patient Health Questionnaire 9 
PK 
Pharmacokinetic(s) 
PLGA 
Poly(DL-lactide-co-glycolide) 
PS20 
Polysorbate 20 
QOR-15 
Quality of Recovery 15 Scale 
RA 
Rheumatoid Arthritis 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 24 of 128 
Abbreviation 
Definition 
ROM 
Range of Motion 
SAE 
Serious Adverse Event 
SD 
Standard Deviation 
SMC 
Safety Monitoring Committee 
SOC 
System Organ Class 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
TEAE 
Treatment Emergent Adverse Events 
TKA 
Total Knee Arthroplasty 
T1/2 
Terminal Elimination Half-Life 
Tmax 
Observed Time to Reach Maximum Concentration 
µg 
Microgram 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 25 of 128 
4.0 
BACKGROUND 
Allay Therapeutics, Inc. (Allay) is developing an extended-release bupivacaine bioabsorbable 
implant designed to provide postsurgical analgesia following total knee arthroplasty (TKA). 
Primary TKA is most commonly performed for knee joint failure caused by osteoarthritis (OA). 
Other indications for TKA include rheumatoid arthritis (RA), osteonecrosis, and other types of 
inflammatory arthritis [2]. Total knee arthroplasty is performed after other non-operative 
treatment options (eg weight loss, aerobic exercise, physical therapy, pain relievers, nonsteroidal 
anti-inflammatory drugs, and corticosteroid injections) [3] have failed. The goals of TKA include 
pain relief and improvement in function and mobility.  While the goal of a TKA is pain relief, 
following surgery the patient experience is often moderate to severe post-operative pain that can 
last for days or weeks and mild to moderate pain lasting for weeks to months following surgery. 
The current post-operative pain management solutions described below are not adequate to 
address longer duration of pain during recovery. 
Potential complications following TKA include infection, deep vein thrombosis (DVT), joint 
stiffness, and early failure. To reduce the risk of DVT and to facilitate rehabilitation and 
recovery, early mobilization, including full compliance with the prescribed regimen of physical 
therapy exercises, is encouraged [4]. However, significant immediate post-operative pain and 
pain during recovery associated with TKA can compromise the rehabilitation process and 
adversely affect outcomes and extends recovery times [5]. Pain following TKA is currently 
addressed by a multi-modal strategy comprising at least one of several short-term local therapies 
followed by the use of oral pain management products. Pre-operatively, several options are 
available, including epidural and spinal anesthetics with adjuncts such as long-acting morphine 
and/or peripheral nerve blocks. Intra-operative injections of bupivacaine (eg, MARCAINE) or 
other local anesthetics may be administered at the surgical site. Post-operatively, peripheral 
nerve blocks, and multi-modal pain control which combines two or more analgesics that act by 
different mechanisms may be used.   
The 2 to 3 days of postoperative analgesia typically achieved by the aforementioned approaches 
are inadequate for the weeks to months of pain following a TKA. Within hours of the TKA 
surgery patients are expected to be ambulatory and articulating the prosthetic joint. Walk 
distance and range of motion (ROM) tests, a variety of therapeutic exercises and a rigorous 
physical therapy regimen are quite painful, but necessary to the successful rehabilitation and 
recovery process. Since poor compliance may result in loss of joint function, due to development 
of scar tissue, requiring additional procedures, surgeons will typically prescribe several weeks of 
oral opioids with instructions to use prior to the onset of any breakthrough pain. 
Although prescription opioids have made pain treatable, medical use of opioids can lead to 
addiction and dependence. Namba et al. indicated that 41.5% (9,914 of 24,105 patients studied) 
continued using opioids after the initial 90-day post-operative period following TKA for OA [6]. 
Prevention of opioid addiction has become an urgent public health emergency [7]. Of several 
highly invasive surgeries studied, it was determined that TKA puts patients at the highest risk of 
chronic opioid use [8]. Moreover, generous prescriptions written following TKA put a 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 26 of 128 
tremendous amount of opioids into circulation. More effective local pain management after TKA 
will preclude the need for opioids.   
ATX-101 is intended to provide sustained post-surgical analgesia for a targeted several week 
duration with bupivacaine as the active pharmaceutical ingredient. Bupivacaine, a sodium ion 
channel blocker, is the active, non-opioid, pharmaceutical ingredient in US-approved 
MARCAINE (NDA 016964), which has been in use as an infiltrative and intravenous (IV) local 
anesthetic or analgesia since 1972. Marcaine has a half-life of 2.7 hours and a maximum 
recommended daily dose of 400 milligrams (mg). Bupivacaine is widely used in surgical 
procedures. Additional dosage forms of bupivacaine approved for postsurgical local anesthesia 
include: Exparel® (US 2011, EU 2020) a slower-releasing bupivacaine liposome suspension 
approved for doses up to 266 mg; Xaracoll (US 2020) a bupivacaine implant approved for doses 
up to 300 mg; most recently Posimir® (US 2021), a bupivacaine solution for infiltration for 
doses up to 660 mg and Zynrelef® (EU 2020, US 2021) an extended-release solution of 
bupivacaine and meloxicam with bupivacaine doses up to 400 mg for TKA. The safety and 
efficacy of bupivacaine for postsurgical analgesia, therefore, has been well characterized in 
humans and various animal models. 
ATX-101 is intended to be placed at the conclusion of the TKA procedure utilizing a 
straightforward technique, which differs from the injection, infiltration, and instillation 
techniques of the current local bupivacaine treatments that can typically yield significant, 
technique-dependent variability in outcomes. ATX-101 will be placed by the orthopedic surgeon 
in predetermined locations under direct visualization. It is anticipated that sustained delivery of 
bupivacaine from ATX-101 will achieve a sustained, local analgesic effect that reduces pain, 
minimizes opioid use, decreases the length of hospitalization, facilitates rehabilitation and 
recovery, and avoids concerns over systemic toxicity.    
4.1 
BUPIVACAINE PHARMACOLOGY 
The pharmacology and pharmacokinetics (PK) of bupivacaine have been evaluated in guinea 
pigs and rabbits (MARCAINE NDA 016964) and other animals in a large, publicly available 
body of research from multiple labs. Following absorption, bupivacaine is rapidly and widely 
systemically distributed with higher concentrations detected in highly perfused organs such as 
the brain, lungs, heart, liver, and kidney. After direct IV injection, bupivacaine kinetics fit a 
three-compartment model, with the first compartment characterized by intravascular distribution, 
the second compartment resulting from distribution and equilibration to highly perfused organs, 
and the third compartment due to distribution and equilibration in poorly perfused tissues [9]. 
Bupivacaine is known to be highly protein bound (95%), and binding is associated with the 
α1-acid glycoprotein and albumin fractions in human plasma [10,11,12]. In humans, the half-life 
is 2.7 hours after IV administration. 
Bupivacaine is extensively metabolized, primarily by Cytochrome P450 3A4 (CYP3A4) in the 
liver with only approximately 6% of unchanged bupivacaine excreted in urine by humans [9]. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 27 of 128 
The major metabolite in humans is desbutylbupivacaine (pipecoloxylidide), while the major 
route of excretion in humans is in urine.   
4.2 
BUPIVACAINE EXPOSURE AND CLINICAL SAFETY 
Most of the available literature data on the safety and toxicity of bupivacaine are based on 
information available from use of bupivacaine through needle infiltration and instillation. Cases 
of systemic toxicity often result from accidental injection of bupivacaine into or around a blood 
vessel or acute injection of an excessive dose, the majority of which absorbs into the blood 
stream. In contrast, ATX-101 is surgically placed and cannot be injected like other formulations 
of bupivacaine. Moreover, the release of bupivacaine from ATX-101 is gradual and sustained 
over time with minimal systemic concentrations throughout the duration of the drug release.   
Bupivacaine is a nonselective voltage-gated sodium ion channel blocker. Blockade of 
voltage-gated sodium ion channels inhibits depolarization and thus conduction of pain signaling. 
Uncontrolled high plasma levels of bupivacaine can lead to cardiotoxicity and neurotoxicity. 
These adverse drug reactions typically occur due to accelerated absorption from the injection site 
or unintentional intravascular injection. Injectable bupivacaine products have a maximum 
recommended human dose of 400 mg/day [9]. However, multiple studies, with a few 
summarized herein, have demonstrated that doses higher than 400 mg from extended-release 
products are safe due to their slower release of bupivacaine over an extended period of time. 
Moreover, the knee capsule provides a built-in compartment to isolate the bupivacaine delivered 
or released within the joint capsule from the blood stream [13]. Goyal et al provided 75 TKA 
patients with a continuous intra-articular infusion of bupivacaine solution at a rate of 600 mg/day 
(5 mL/hour of 0.5% bupivacaine solution) via an elastomeric pain pump for two consecutive 
days with no adverse events (AEs) related to systemic toxicity [14].  
The maximum tolerated plasma concentration with respect to central nervous system (CNS) 
effects in healthy volunteers administered bupivacaine in solution has been reported to be 
2,100 ng/mL (2.1 µg/mL, range of 0.8-4.5 µg/mL) [15] and 2,250 ng/mL (2.25 µg/mL) [16]. 
Onset of CNS toxicity has been reported in the range of 2,000-4,000 ng/ml (2-4 µg/mL) [17] 
with serious risk of toxicity possibly at 2,300-5,000 ng/mL (2.3-5 µg/mL) [18]. 
4.3 
OVERALL DOSE SAFETY SUMMARY AND ATX-101 DOSE JUSTIFICATION 
Though CNS associated AEs can occur as low as 2,000 ng/mL, safe levels of plasma 
bupivacaine concentrations have been reported up to 9,270 ng/mL (9.27 μg/mL) in humans and 
more frequently at approximately 4,500 ng/mL (4.5 μg/mL) [19]. While extended bupivacaine 
delivery from ATX-101 is designed to deliver lower systemic exposure over a greater duration as 
compared with infusion and infiltration approaches, safety thresholds for systemic exposure may 
be adequately derived from the human infusion and infiltration experience. Human clinical data 
from bupivacaine delivered via infusion or infiltration are summarized in the Investigator’s 
Brochure (IB). The first in human trial FT1-TKA-001 administered 252 mg, 756 mg, and 
1,512 mg of bupivacaine free base to 4, 3, and 15 subjects respectively and it appeared to be well 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 28 of 128 
tolerated. Based upon tolerability in FT1-TKA-001, this clinical trial will plan to evaluate 
ATX-101 at 1,000 mg and at 1,500 mg.   
4.4 
ATX-101 CLINICAL EXPERIENCE 
Trial FT1-TKA-001 was a Phase 1/2A safety trial in humans evaluating ATX-101. The trial was 
an open-label ascending dose PK, safety and tolerability clinical trial that was conducted in 
Australia. The primary objective of the trial was to characterize the PK concentration profile 
associated with bupivacaine via ATX-101 (formerly referred to as the TKAine System). The 
secondary objectives were to evaluate the safety and tolerability as well as the dose-related 
response of ATX-101.   
Three dose groups were evaluated in the trial. Before escalating to the next dose, a Data Safety 
Monitoring Board (DSMB) reviewed PK concentrations, cardiac data, and the AE profile. 
Depending upon the Cohort, a single dose level of ATX-101 was implanted in the knee capsule 
following the TKA procedure when tissue was not disrupted any further by surgery but prior to 
surgical closure. ATX-101 was placed in the suprapatellar pouch, medial gutter alongside 
capsular tissue, and/or lateral gutter alongside capsular tissue under direct visualization (Table 
1). 
Table 1. FT1-TKA-001 Dosage, Number of Subjects, and Placement 
Cohort 
Dose (bupivacaine 
free base) 
Dose (bupivacaine 
HCl monohydrate)  
Number of 
Subjects 
Location of 
Implants 
Cohort 1 
252 mg 
300 mg 
4 
Medial Gutter 
Cohort 2 
756 mg 
900 mg 
3 
Medial Gutter and 
Suprapatellar Pouch 
Cohort 3 
1512 mg 
1800 mg 
15 
Medial Gutter, 
Suprapatellar Pouch, 
and Lateral Gutter 
HCl = Hydrochloride 
The Australian patient population enrolled in the FT1-TKA-001 clinical trial had similar surgical 
techniques, standard perioperative care, and demographics to US population receiving TKAs 
(refer to the Investigator’s Brochure for additional information). In trial FT1-TKA-001 there 
were no deaths. There were no withdrawals in the trial for any reason. There were two (2) 
Serious Adverse Events (SAEs) and three (3) Adverse Events of Special Interest (AESIs). One 
subject experienced an SAE of drug (acetaminophen/paracetamol) induced liver injury that 
started about one month after the TKA surgery. The SAE was determined by the Investigator as 
unlikely related to the trial drug and not related to the trial procedure.   
One subject experienced an SAE of acute spontaneous urticaria with angioedema (preferred term 
urticaria) that started about 11 days after the TKA surgery. The SAE was determined by the 
Investigator as not related to the trial drug and not related to the trial procedure. The event was 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 29 of 128 
likely triggered from aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), or opioids per 
the medical records.   
Three AESIs were identified. Two events were asymptomatic sinus bradycardia both indicated as 
unlikely related to the trial drug and unlikely related to the trial procedure. One event was 
symptomatic sinus bradycardia and was indicated as not related to the trial drug and not related 
to the trial procedure.   
The most common AEs in the trial were nausea (54.5%), constipation (27.3%), haematoma 
(27.3%), dizziness (22.7%), diarrhoea (18.2%), vomiting (18.2%), and peripheral oedema 
(18.2%).   
Adverse events were classified by the Investigator as Not Related, Unlikely Related, Possibly 
Related, Probably Related or Definitely Related to the study drug (bupivacaine) or to the TKA 
surgical procedure.   
The most common AE indicated as related (Possibly, Probably, or Definitely Related) to the 
study drug, ATX-101 was paraesthesia (9.1%).   
The most common AEs indicated as related (Possibly, Probably, or Definitely Related) to the 
TKA surgical procedure include haematoma (22.7%) nausea, (13.6%), peripheral oedema 
(13.6%), hypotension (13.6%), and erythema (9.1%). 
The majority of AEs were mild or moderate in severity. There were 3 severe AEs (syncope, 
urticaria, and drug [acetaminophen/paracetamol] induced liver injury).   
5.0 
TRIAL OBJECTIVES AND ENDPOINTS 
5.1 
OBJECTIVES 
The objectives of this Phase 2B trial are: 
• To compare the efficacy of ATX-101 (1,000 mg or 1,500 mg) with that of bupivacaine 
hydrochloride (HCl) in subjects undergoing primary unilateral TKA 
• To evaluate the safety and tolerability of ATX-101 
• To characterize the PK profile following administration of ATX-101 (Part A only) 
• To compare opioid consumption of subjects administered ATX-101 with that of bupivacaine 
HCl (Part B only)   
• To estimate the sample size, determine dose, and primary endpoint duration from Part A 
needed for Part B  
• To compare the efficacy of ATX-101 with that of bupivacaine HCl in this trial population  
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 30 of 128 
5.2 
ENDPOINTS 
5.2.1 
Primary Endpoints 
The primary efficacy endpoint (evaluated in Part B) is to determine the area under the curve 
(AUC) for the Numeric Rating Scale at Rest (NRS-R) of pain intensity from 30 Minutes through 
a time point to be determined from Part A. 
The primary efficacy endpoint for Part A is AUC for the NRS-R of pain intensity from 30 
Minutes through Hour 168 (Day 8 of the trial). 
5.2.2 
Key Secondary Endpoints (Evaluated in Part B) 
Key secondary endpoints are to evaluate the: 
• Area under the curve for the NRS-R of pain intensity from 30 Minutes through Hour 168 
(Day 8 of the trial), Hour 240 (Day 11 of the trial), and Hour 336 (Day 15 of the trial). 
• Percentage of subjects who remain opioid free from Hour 72 through Day 30. 
• Total post-surgical consumption of opioid medications from surgical closure through Day 30. 
5.2.3 
Secondary Endpoints 
Secondary endpoints for both Part A and Part B are to evaluate the: 
• Area under the curve for the NRS-R of pain intensity for each 24-hour period through Hour 
336 (Day 15 of the trial)  
• Percentage of subjects who remain opioid free  
• Total post-surgical consumption of rescue opioid medications  
• Time to first postsurgical use of rescue opioid medication 
5.2.4 
Safety Endpoints 
Safety endpoints for both Part A and Part B are to evaluate the: 
• Incidence of AEs, AESIs, and SAEs  
• Wound healing assessment using the Southampton Wound Scoring System 
• Characterization of the bupivacaine PK from ATX-101 
5.2.5 
Exploratory Endpoints 
Exploratory endpoints for both Part A and Part B will evaluate the: 
• Percentage of subjects reporting being pain free on the NRS-R of pain intensity 
• Time to various degrees of flexion and extension  
• Reduction/incidence of opioid-related AEs 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 31 of 128 
• Evaluation of Quality of Recovery 15 Scale (QOR-15) 
• Evaluation of Knee Injury and Osteoarthritis Outcome Score for Joint Replacement 
(KOOS, JR) 
• Difference in pain intensity scores (NRS-R and Numeric Rating Scale with Activity 
[NRS-A]) between treatment groups  
• If a statistical difference in AUC of pain intensity NRS-R at Hour 336 (Day 15 of the trial) is 
observed, the AUC for the NRS-R of pain intensity will be further evaluated between Days 
16 and 30  
• Evaluation of the Knee Society Score 
6.0 
INVESTIGATIONAL PLAN 
6.1 
OVERALL TRIAL DESIGN 
This is a two-part (Part A and Part B) Phase 2B, randomized, double-blind, active comparator 
multicenter trial in subjects undergoing primary unilateral TKA. Part A will be used to determine 
the sample size, dose, and primary endpoint duration for Part B of the trial.  
In Part A of the trial, approximately 165 subjects will be randomized to one (1) of the following 
three (3) treatment groups in a 1:1:1 ratio with approximately 55 subjects per group: 
• ATX-101, 1,000 mg dose (two ATX-101 implants)  
• ATX-101, 1,500 mg dose, (three ATX-101 implants)  
• Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local 
periarticular infiltration or adductor canal block, or in combination  
In Part B of the trial, up to 140 subjects (total number will be determined from Part A) will be 
randomized to one (1) of the following two (2) treatment groups in a 1:1 ratio with up to 70 
subjects per group: 
• ATX-101 dose to be determined from Part A 
• Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local 
periarticular infiltration or adductor canal block, or in combination   
6.1.1 
Trial Procedures 
Subjects will participate in the trial for up to approximately 12 weeks, including a 30-day 
screening period. All subjects will be screened within 30 days prior to surgery. Subjects who 
meet eligibility criteria will be randomized up to 1 business day prior to the day of surgery.   
Unless otherwise specified, all procedures are applicable for both Part A and Part B of the trial.   
In addition to the below trial procedures, all subject visits to the emergency department, urgent 
care and/or clinic will be documented and indicated if the visit was related to pain. Throughout 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 32 of 128 
the trial all phone calls or digital interactions (eg email) with the subject will be documented in 
the source documentation.   
6.1.1.1 
Screening Visit 
Subjects will attend the hospital/clinic/facility up to 30 days prior to the scheduled surgical 
procedure. After obtaining informed consent from the subject, as documented by the signed 
informed consent form, the following assessments will be conducted: 
• Demographic data collection 
• Review of medical history  
• Review of trial entry criteria 
• Vital signs  
• Physical examination including an orthopedic evaluation of Kellgen Lawrence Classification, 
varus, valgus, and an evaluation of ipsilateral hip osteoarthritis. 
• Height and weight  
• 12-lead electrocardiogram (ECG) 
• Laboratory testing (Chemistry, Hematology, Drug Screen, and Pregnancy Test for females of 
childbearing potential) 
• ROM assessment 
• Patient Health Questionnaire 9 (PHQ-9) 
• Neurological assessments 
• Electronic (e-diary) training 
• Numeric Rating Scale (NRS) pain score training for pain intensity 
• Prior and concomitant medication review 
• Knee Society Score 
• Subject self-administered questionnaires/survey completion (NRS-R and location of pain; 
QOR-15; KOOS, JR; Pain Manageability; and NRS-A and location of pain) 
Subjects will complete the self-administered questionnaires/surveys after being trained on the 
e-diary and NRS pain score training for pain intensity. The subject may utilize an e-diary 
maintained by the site for completion of the questionnaires/survey. For further information 
please see Section 8.9 and 8.10. 
When possible, subjects should stop taking gabapentin and/or pregabalin before the TKA 
surgery. If a subject is otherwise a good candidate for the trial and unable or unwilling to stop 
taking gabapentin and/or pregabalin as of the Screening Visit, then medical monitor approval 
will be required prior to permitting enrollment into the trial.    


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 33 of 128 
Subjects should be encouraged to stop taking opioids from the Screening Visit and are not 
considered eligible for the trial if unable to abstain from taking opioids at least 14 days prior to 
surgery.   
Confirmation of eligibility based upon cardiac and laboratory data must be confirmed prior to 
surgery. Availability of receipt of this data may vary based upon the site location to the cardiac 
laboratory and central labs and should be planned for accordingly.   
6.1.1.2 
Day of Surgery (Day 1) 
6.1.1.2.1 
Before Surgery 
On the day of surgery, before surgery and before bupivacaine spinal is administered, the 
following assessments will be conducted: 
• Medical history will be confirmed and updated as appropriate 
• Review of trial entry criteria 
• Vital signs 
• 12-lead ECG  
• Laboratory testing (Drug Screen only for opioids and Pregnancy Test for females of 
childbearing potential)   
• Neurological assessments 
• e-diary training 
• e-diary dispensation if the subject is not using their own device 
• NRS pain score training for pain intensity 
• Prior and concomitant medication review 
• Randomization and investigational product allocation 
• Pharmacokinetic sampling before bupivacaine spinal (Part A only) 
Randomization and investigational product allocation may occur up to one business day before 
surgery. Subjects who fail to meet eligibility criteria during screening (any time before 
randomization) will be considered screen failures. Subjects who fail to meet eligibility from the 
time of randomization through surgery will be considered randomization failures. In Part A 
subjects will be randomized to one of three treatment groups:  1,000 mg ATX-101, 1,500 mg 
ATX-101, or bupivacaine HCl.  
In Part B subjects will be randomized to one of two treatment groups: either ATX-101 (dose 
determined after Part A) or bupivacaine HCl. All needed investigational product will be brought 
to the operating room. It is recommended that spare investigational products be brought to the 
operating room in the event the originally assigned product is broken, damaged, dropped outside 
of the sterile field, or the product becomes unusable. All reasons for utilizing the spare product 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 34 of 128 
will be documented on unblinded records and only viewable to unblinded staff and unblinded 
monitors. Section 7.8 contains further information regarding blinding.  
After checking in for surgery on Day 1, the subject will receive acetaminophen/paracetamol 
1,000 mg and celecoxib 200 mg before surgery.   
In addition, the subject will complete the self-administered e-diary questionnaire/survey which 
will include: 
• NRS-R and location of pain 
6.1.1.2.2 
During Surgery 
Subjects will undergo primary unilateral TKA surgical procedure completed under spinal 
anesthesia. Spinal anesthesia with bupivacaine (with or without dextrose) will be used in all 
subjects; no other adjunct medications such as morphine or ketamine may be used in the spinal 
anesthesia. General anesthesia is optional, but if used must be in conjunction with spinal 
anesthesia. Local nerve blocks (eg adductor canal blocks) are prohibited in the ATX-101 
treatment group (but permissible in the bupivacaine HCl group), however topical anesthetics 
such as lidocaine can be used to aid in IV access and subcutaneously for spinal needle 
placement.   
At the time of induction, the use of fentanyl (no more than 300 µg) for airway management is 
permitted when general anesthesia is used. Other than fentanyl for airway management, no other 
opioids may be administered during surgery. If not administered before surgery, one dose of 
prophylactic ondansetron will be given. All other doses of antiemetics will be given only after an 
adverse event has been observed or reported.   
 
Surgical drains are not permitted. Two doses of IV tranexamic acid (1 g each) will be 
administered to the subject. One dose of tranexamic acid will be administered prior to 
investigational product administration and the second dose after investigational product 
administration, with the timing at the discretion of the treating Investigator. A one-time dose of 
IV dexamethasone (4 mg) will be administered during the surgical procedure, with the timing at 
the discretion of the treating Investigator. Intravenous or oral antibiotic regimen may also be 
given per the center’s standard of care. Antibiotic powders or beads in the knee joint are 
prohibited.   
Subjects will not be administered the investigational product if any clinically significant (CS) 
event or condition is uncovered during surgery (eg excessive bleeding, femur fracture), that 
occurs before investigational product administration and might render the subject medically 
unstable or complicate the subject’s postsurgical course. 
If randomized to ATX-101, a one-time dose of a single dose level of ATX-101 will be placed in 
the subject’s knee capsule under direct visualization following fixation of the knee implant 
prosthesis when tissue will not be disrupted any further by surgery, after any betadine or saline 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 35 of 128 
rinse, and after any suction has occurred, but prior to initiation of surgical closure. ATX-101 will 
be placed in the suprapatellar pouch, medial gutter, and/or lateral gutter by a trained surgeon 
according to the Dosage and Administration Instructions. 
If randomized to active comparator, bupivacaine HCl 0.25% without epinephrine/adrenaline 
maximum dose of 2 mg/kg via local periarticular infiltration or an adductor canal block, or in 
combination will be administered during surgery. Bupivacaine HCl alone will be used for 
infiltration or adductor canal block, additional anesthetics or medications are not allowed. 
Subjects who fail to meet the entry criteria at the time of the surgical procedure will not be 
enrolled in the trial. Subjects who are randomized but do not receive investigational product (eg 
did not meet exclusion criterion #24 or #25), will be considered randomization failures.  
The surgical staff will not be blinded to the trial treatment, all other research staff (unless 
expressly specified in the site’s blinding plan that is approved by Allay) and the subject will 
remain blinded throughout the trial. Section 7.8 contains further information regarding blinding. 
The following activities/assessments will be conducted during the surgery: 
• Review of entry criteria and confirmation of eligibility prior to investigational product 
administration 
• In Part A, a PK blood sample will be taken during surgery before investigational product 
administration (within -10 minutes before ATX-101 administration or first administration of 
bupivacaine HCl) 
• 12-lead ECG (Part A only) 
• Investigational product administration of ATX-101, or bupivacaine HCl 
• Concomitant medication collection 
• Recording of AEs after the investigational product administration 
The time of surgical closure (skin closure/final stitch placed) will be documented and considered 
Time 0 for all assessments conducted. 
6.1.1.2.3 
After Surgery 
Following surgery, subjects will be transferred to the post-anesthesia care unit (PACU). The time 
the subject arrives and departs PACU will be recorded. The time the subject first ambulates will 
also be recorded. 
While in the hospital/facility subjects will have regular assessments of vital signs, neurological 
assessments, pain scores, AEs, and concomitant medication review.  
In Part A only, the subject must remain under observation until Hour 96. Subjects may remain in 
the hospital/facility for 96 hours. Alternatively, subjects may be discharged from the 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 36 of 128 
hospital/facility per standard of care and moved to another unit until the conclusion of the 
96-hour in-patient monitoring period. In Part B, subjects will remain under observation until 
Hour 24 and then may be discharged per standard of care.   
Subjects should only receive rescue opioid medication upon request for pain control, as needed, 
after surgery. Rescue opioid medication may be given/taken for pain treatment, but not for pain 
prophylaxis. Prior to the administration of any rescue opioid medication from surgery through 
the Day 30 Visit, a NRS-R assessing the subject’s pain intensity and location of pain must be 
obtained.  
If required to treat pain, the following standardized rescue opioid medication protocol will be 
used. Preferred rescue opioid medication will consist of oral immediate-release oxycodone (5 mg 
or 10 mg). If a subject cannot tolerate oral medication, IV (including patient-controlled analgesia 
pump) or IM medication may be administered as needed (morphine is preferred, however 
hydromorphone can also be used with the dose determined by the treating physician). If a subject 
cannot tolerate the medication or the breakthrough pain is not responsive to oral oxycodone (5 
mg or 10 mg), then oral hydromorphone (2 mg or 4 mg) may be given for rescue opioid 
medication. Should the subject have an AE and is unable to tolerate the rescue opioid 
medications of oral oxycodone (5 mg or 10 mg), IV morphine, oral hydromorphone (2 mg or 4 
mg), and IV hydromorphone, then hospital standard of care may be utilized, however, local 
anesthetic nerve blocks may not be administered after surgery. (See Section 7.6.3.1 for further 
information on rescue opioids.) 
The subjects will be administered celecoxib (200 mg) twice a day for 30 days, unless an AE 
occurs that requires discontinuation. Acetaminophen/paracetamol 500 mg should be taken every 
4 hours or 1,000 mg every 6 to 8 hours not to exceed 3,000 mg per any 24-hour period for a 
minimum of 21 days. Deep vein thrombosis (DVT) prophylaxis is required, and 75-100 mg 
aspirin (based upon regional approved dose) is recommended twice a day for 30 days. Aspirin is 
recommended in trial subjects unless there are additional risks of thromboembolic events 
identified requiring a different DVT prophylaxis. Celecoxib, acetaminophen/paracetamol, and 
aspirin may be provided by the Sponsor. 
Should the subject experience an SAE or AESI, refer to Section 6.1.1.12 for required 
assessments. 
The following activities/assessments will be conducted on Day 1 after surgery: 
• Vital signs  
• 12-lead ECG (Part A only) 
• Neurological assessments  
• Concomitant medication review 
• PK sampling (Part A only) 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 37 of 128 
• Recording of AEs  
See Appendix A (Table: Part A Schedule of Events for Day of Surgery through Hour 96 (Day 5)) 
and Appendix B (Table: Part B Schedule of Events for Day of Surgery through Hour 24 (Day 2)) 
for specific timing of assessments. After surgical closure the subject will be completing self-
administered e-diary questionnaires/surveys which will include: 
• NRS-R and location of pain, multiple times a day as specified in Appendix C 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance 
• Physical therapy survey 
The subject will continue to complete self-administered e-diary questionnaires/surveys per 
Appendix C on the trial visit day and in-between visits.   
6.1.1.3 
Part A: Days 2, 3, 4, & 5 During 96 Hour Observation 
Subjects will remain under observation for 96 hours following surgery. Subjects may remain in 
the hospital/facility for 96 hours. Alternatively, subjects may be discharged from the 
hospital/facility per standard of care and moved to another unit until the conclusion of the 
96-hour monitoring period. All procedures in the Schedule of Events (Appendix A) will be 
followed. Once the subject is ready to leave the facility, the date and time of discharge will be 
recorded. Upon discharge, the location/facility where subjects are being discharged will be 
recorded (eg home, rehabilitation facility, facility for 96-hour in-patient monitoring). Subjects 
may have more than one discharge date and time if they were transferred to a different location 
for the in-patient monitoring period.    
Site staff should confirm the subject has been regularly completing the self-administered 
questionnaires and surveys. As needed, the site staff should conduct any training to ensure 
compliance with medication consumption, rescue opioid medication, e-diary completion/use, 
and/or prescribed physical therapy regimens.   
The following assessments will be conducted on Days 2, 3, 4, & 5: 
• Vital signs  
• 12-lead ECG 
• ROM assessment 
• Neurological assessments  
• Subject NRS pain score training for pain intensity (Days 2 and 3 only) 
• Concomitant medication review 
• PK sampling  
• Recording of AEs  


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 38 of 128 
See Appendix A (Table: Part A Schedule of Events for Day of Surgery through Hour 96 (Day 5)) 
for specific timing of assessments. In addition, the subject will continue to complete self-
administered e-diary questionnaires/surveys which will include: 
• NRS-R and location of pain, multiple times a day as specified in Appendix C 
• QOR-15 
• NRS-A and location of pain 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance 
• Physical therapy survey 
6.1.1.4 
Part A, Day 6   
The Day 6 Visit may occur in the hospital/clinic/facility, at the subject’s home, at a physical 
therapy facility, or any other place agreed upon by the subject and site staff.   
Before or during the visit, site staff should confirm the subject has been regularly completing the 
self-administered questionnaires and surveys. As needed, the site staff should conduct any 
training to ensure compliance with medication consumption, rescue opioid medication, e-diary 
completion/use, and/or prescribed physical therapy regimens.   
The following assessments will be conducted on Day 6: 
• Vital signs  
• 12-lead ECG 
• ROM assessment 
• Neurological assessments  
• Concomitant medication review 
• PK sampling  
• Recording of AEs  
In addition, the subject will continue to complete self-administered e-diary 
questionnaires/surveys which will include: 
• NRS-R and location of pain, multiple times a day as specified in Appendix C 
• QOR-15 
• NRS-A and location of pain 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance 
• Physical therapy survey 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 39 of 128 
The subject will continue to complete self-administered e-diary questionnaires/surveys per 
Appendix C on the trial visit day and in-between visits.   
6.1.1.5 
Part B: Day 2 
All procedures in the Schedule of Events (Appendix B) will be followed. For Part B, subjects 
will remain under observation for a minimum of one overnight (approximately 24 hours) and 
then may be discharged per standard of care after the Day 2 procedures have been conducted. 
The date and time of discharge will be recorded. Upon discharge, the location/facility where 
subjects are being discharged to will be recorded (eg home, rehabilitation facility).   
Site staff should confirm the subject has been regularly completing the self-administered 
questionnaires and surveys. As needed, the site staff should conduct any training to ensure 
compliance with medication consumption, rescue opioid medication, e-diary completion/use, 
and/or prescribed physical therapy regimens.   
The following assessments will be conducted on Day 2: 
• Vital signs  
• ROM assessment 
• Neurological assessments  
• Subject NRS pain score training for pain intensity 
• Concomitant medication review 
• Recording of AEs  
See Appendix B (Table: Part B Schedule of Events for Day of Surgery through Hour 24 (Day 2)) 
for specific timing of assessments. 
In addition, the subject will continue to complete self-administered e-diary 
questionnaires/surveys which will include: 
• NRS-R and location of pain, multiple times a day as specified in Appendix C 
• QOR-15 
• NRS-A and location of pain 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance 
• Physical therapy survey 
The subject will continue to complete self-administered e-diary questionnaires/surveys per 
Appendix C on the trial visit day and in-between visits.   


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 40 of 128 
6.1.1.6 
Part B: Days 3, 4, 5, & 6 
For Part B, following the Day After Discharge Visit the scheduled visits on Days 3, 4, 5, & 6 
will be conducted. All procedures in the Schedule of Events (Appendix B) will be followed.   
Trial visits on Days 3, 4, 5, & 6 may occur in the hospital/clinic/facility, at the subject’s home, at 
a physical therapy facility, or any other place agreed upon by the subject and site staff.   
Before or during the visit, site staff should confirm the subject has been regularly completing the 
self-administered questionnaires and surveys. As needed, the site staff should conduct any 
training to ensure compliance with medication consumption, rescue opioid medication, e-diary 
completion/use, and/or prescribed physical therapy regimens.   
The following assessments will be conducted on Days 3, 4, 5, & 6: 
• Vital signs  
• ROM assessment 
• Neurological assessments  
• Subject NRS pain score training for pain intensity (Day 3 only) 
• Concomitant medication review 
• Recording of AEs  
In addition, the subject will continue to complete self-administered e-diary 
questionnaires/surveys which will include: 
• NRS-R and location of pain, multiple times a day as specified in Appendix C 
• QOR-15 
• NRS-A and location of pain 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance 
• Physical therapy survey 
The subject will continue to complete self-administered e-diary questionnaires/surveys per 
Appendix C on the trial visit day and in-between visits.   
6.1.1.7 
Day 8 
The Day 8 Visit (±1 day) may occur in the hospital/clinic/facility, at the subject’s home, at a 
physical therapy facility, or any other place agreed upon by the subject and site staff.   


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 41 of 128 
Before or during the visit, site staff should confirm the subject has been regularly completing the 
self-administered questionnaires and surveys. As needed, the site staff should conduct any 
training to ensure compliance with medication consumption, rescue opioid medication, e-diary 
completion/use, and/or prescribed physical therapy regimens.   
The following assessments will be conducted on Day 8: 
• Vital signs  
• 12-lead ECG (Part A only) 
• ROM assessment 
• Neurological assessments  
• Concomitant medication review 
• PK Sampling (Part A only) 
• Recording of AEs  
In addition, the subject will continue to complete self-administered e-diary 
questionnaires/surveys which will include: 
• NRS-R and location of pain, multiple times a day as specified in Appendix C 
• QOR-15 
• KOOS, JR  
• Pain manageability survey  
• NRS-A and location of pain 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance 
• Physical therapy survey 
The subject will continue to complete self-administered e-diary questionnaires/surveys per 
Appendix C on the trial visit day and in-between visits.   
6.1.1.8 
Day 15 and Day 22 Visits  
The Day 15 Visit (±3 days) and Day 22 Visit (±3 days) may occur in the hospital/clinic or at a 
physical therapy facility.   
Before or during the visit, site staff should confirm the subject has been regularly completing the 
self-administered questionnaires and surveys. As needed, the site staff should conduct any 
training to ensure compliance with medication consumption, rescue opioid medication, e-diary 
completion/use, and/or prescribed physical therapy regimens.   


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 42 of 128 
The following assessments will be conducted on Day 15 and Day 22: 
• Vital signs  
• 12-lead ECG (Part A only) 
• Laboratory testing (drug screen) (Day 15 only) 
• ROM assessment 
• Neurological assessments  
• Subject NRS pain score training for pain intensity (Day 15 only) 
• Concomitant medication review. Opioid accountability at Day 15 only 
• PK sampling (Part A only) 
• Wound healing assessment 
• Knee Society Score (Day 15 only) 
• Recording of AEs  
In addition, the subject will continue to complete self-administered e-diary 
questionnaires/surveys which will include: 
• NRS-R and location of pain, multiple times a day as specified in Appendix C  
• QOR-15 
• KOOS, JR  
• Pain manageability survey  
• NRS-A and location of pain 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance 
• Physical therapy survey 
The subject will continue to complete self-administered e-diary questionnaires/surveys per 
Appendix C on the trial visit day and in-between visits.   
6.1.1.9 
Day 30 Visit 
The Day 30 Visit (±3 days) may occur in the hospital/clinic or at a physical therapy facility.   
Before or during the visit, site staff should confirm the subject has been regularly completing the 
self-administered questionnaires and surveys. As needed the site staff should conduct any 
training to ensure compliance with medication consumption, rescue opioid medication, e-diary 
completion/use, and/or prescribed physical therapy regimens.   
The following assessments will be conducted on Day 30: 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 43 of 128 
• Vital signs  
• 12-lead ECG (Part A only) 
• ROM assessment 
• Neurological assessments  
• e-diary return if the subject used a provisioned device 
• Concomitant medication review including opioid accountability 
• PK sampling (Part A only) 
• Wound healing assessment 
• Knee Society Score 
• Recording of AEs  
If not completed in advance of the Day 30 Visit, then prior to the conclusion of the Day 30 Visit, 
the subject should complete all Day 30 e-diary questionnaires/surveys and return the e-diary to 
the site staff (if using a provisioned device). The self-administered e-diary 
questionnaires/surveys will include: 
• NRS-R and location of pain 
• QOR-15 
• KOOS, JR  
• Pain manageability survey  
• NRS-A and location of pain 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance 
• Physical therapy survey 
If the subject did not complete the Day 30 self-administered questionnaires/surveys before the 
visit and did not return the provisioned e-diary during the Day 30 Visit, then they may utilize an 
e-diary maintained by the site for completion of the self-administered questionnaires/surveys. 
The subject will be instructed to return the e-diary to the site before or during the Day 56 Visit.   
6.1.1.10 
Day 56 Visit 
The Day 56 Visit (±7 days) may occur in the hospital/clinic or at a physical therapy facility.   
The following assessments will be conducted on Day 56: 
• Vital signs  
• Physical examination 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 44 of 128 
• Weight 
• 12-Lead ECG 
• Laboratory testing (Chemistry, Hematology, and Pregnancy Test for females of childbearing 
potential) 
• ROM assessment 
• Neurological assessments 
• Concomitant medication review 
• Wound healing assessment 
• Knee Society Score 
• Recording of AEs  
The subject may utilize an e-diary maintained by the site for completion of the final 
self-administered questionnaires/surveys. The questionnaires/surveys will include: 
• NRS-R and location of pain 
• QOR-15 
• KOOS, JR  
• Pain manageability survey  
• NRS-A and location of pain 
If the subject did not return the provisioned e-diary at the Day 30 Visit, it should be returned to 
the site staff during this visit.    
6.1.1.11 
Early Termination Visit 
The Early Termination Visit may occur in the hospital/clinic or at a physical therapy facility.   
If a subject early terminates, when possible and with subject consent, all end of trial (Day 56) 
procedures should be completed. In addition to the Day 56 assessments, if the subject early 
terminates on or before Day 30, a PK sample should be obtained (Part A only) and opioid 
accountability should occur.   
If used, the subject should return the provisioned e-diary during this visit if not previously 
returned.   
The subject may utilize an e-diary maintained by the site or their assigned e-diary for completion 
of the final self-administered questionnaires/surveys. The questionnaires/surveys will include: 
• NRS-R and location of pain 
• QOR-15 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 45 of 128 
• KOOS, JR  
• Pain manageability survey  
• NRS-A and location of pain 
• Rescue opioid medication questions, any time before an opioid is consumed and assessment 
of medication compliance (if early terminated on or before the Day 30 Visit)  
• Physical therapy survey (if early terminated on or before the Day 30 Visit) 
6.1.1.12 
Serious Adverse Event or Adverse Event of Special Interest 
In the event of a SAE or AESI, the subject will be asked to come to the hospital/clinic or at a 
physical therapy facility and the following assessments will be conducted: 
• Vital signs  
• 12-Lead ECG 
• Laboratory testing (Blood Chemistry and Hematology) 
• Neurological assessments 
• Concomitant medication review 
• PK sampling 
• Recording of AEs  
For further information regarding treatment of SAEs and AESIs please see Section 9.5.1 and 
9.5.2. 
6.2 
NUMBER OF SUBJECTS 
This trial will enroll approximately 165 subjects in Part A and up to 140 subjects in Part B at up 
to 20 multinational clinical centers. 
6.3 
TRIAL POPULATION 
6.3.1 
Subject Inclusion Criteria 
To be eligible for trial participation subjects must meet the following inclusion criteria: 
1. Primary indication of TKA is knee pain due to osteoarthritis or post-traumatic arthritis. 
2. Scheduled to undergo primary unilateral TKA with a cemented prosthesis, without use of 
a surgical drain, and under bupivacaine spinal anesthesia (dextrose is permitted).    
3. American Society of Anesthesiology (ASA) Physical Classification System of class 1, 2, 
or 3.     
4. Male or female, ≥18 and ≤80 years of age at the Screening Visit. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 46 of 128 
5. Female subjects only: Postmenopausal, surgically sterile, or willing to use acceptable 
means of contraception from the Screening Visit through the Day 56 Visit.   
a. Medically acceptable methods of contraception that may be used by the subject 
include birth control pills, diaphragm with spermicide, intrauterine device (IUD), 
condom with spermicide, vaginal spermicidal suppository, or progestin implant or 
injection (used consistently for ≥3 months at the time of screening).   
b. Female subjects who are not of childbearing potential must have a medical history 
recorded of surgical sterilization (≥6 months post-surgery at the time of 
screening) or post-menopausal (not experienced a menstrual period ≥2 years at 
the time of screening). 
6. Capable, able, and willing to comply with all trial visits and procedures. Subject must 
also be able to use trial required electronic applications (eg electronic diary) for patient 
reported outcome measures.  
7. English speaking, willing, and capable of providing written informed consent. 
 
It is recommended that participating subjects are vaccinated for COVID-19 per local 
requirements.  
6.3.2 
Subject Exclusion Criteria 
Exclude subjects from this trial if they do not fulfill the inclusion criteria, or if any of the 
following conditions are observed: 
1. Has a planned concurrent surgical procedure (eg bilateral TKA) at the time of surgery or 
a planned surgical procedure before the Day 56 Visit. 
2. Has had any previous arthroplasty, unicompartmental knee arthroplasty or TKA in the 
study knee or previous arthroplasty, unicompartmental knee arthroplasty, or TKA in the 
contralateral knee within 6 months prior to screening. 
3. Has been administered any type of intra-articular injection within 3 months of surgery in 
the trial knee. 
4. Has a pre-existing concurrent, acute, or chronic, painful/restrictive physical condition for 
which they routinely take opioid analgesics and are expected to require opioid analgesics 
in the postsurgical period that is not strictly related to the trial knee 
osteoarthritis/post-traumatic arthritis and/or trial knee surgery. 
5. Unable to abstain from opioid use for knee pain (including codeine) within 2 weeks 
(14 days) of surgery. 
6. Has been administered systemic steroids within 14 days prior to surgery. (Note: Steroids 
provided on the day of surgery as part of a standard surgical medication regime are 
permitted. Local steroids such as inhalers or ophthalmologic drops are permitted). 
7. Is unwilling or unable to discontinue use of medications or products that can impact pain 
control from the Screening Visit until the Day 56 Visit (eg cannabidiol (CBD) oil, 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 47 of 128 
Kratom, herbal supplements). Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) and 
acetaminophen/paracetamol are permitted prior to surgery at the treating Investigators 
discretion. Subjects prescribed gabapentin and/or pregabalin will require medical monitor 
approval.   
8. Has been administered any anesthetic including but not limited to bupivacaine, 
ropivacaine, or lidocaine within 5 days prior to the scheduled surgery. See protocol 
Section 7.6.1 for uses and permitted anesthetics on the day of surgery. 
9. Requires medication that will impact the metabolism, absorption, or excretion of 
bupivacaine.  Epinephrine/adrenaline should be used with caution.  Strong inhibitors and 
inducers of CYP3A4 should be avoided (See Appendix M). Coadministration of 
ATX-101, or bupivacaine HCl with local anesthetics is prohibited. 
10. Has a contraindication or a known or suspected history of allergy, hypersensitivity, or 
idiosyncratic reaction to trial medications including but not limited to those used during 
surgery or post-surgery (eg anesthesia, IV dexamethasone, IV tranexamic acid, 
antibiotics, ondansetron, and opioids such as morphine, oxycodone, and hydromorphone), 
also to medications taken prior to surgery and/or dispensed for home use (ie 
acetaminophen/paracetamol and celecoxib), or to the investigational product or its 
components (bupivacaine, poly[DL-lactide-co-glycolide] (PLGA), and/or polysorbate). 
11. Has a Body Mass Index (BMI) ≥45 kg/m2. 
12. Has laboratory values at screening that will exclude enrollment including: 
a. Bilirubin >2 times the upper normal limit unless due to Gilberts syndrome  
b. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline 
phosphatase (ALP) >1.5 times the upper normal limit  
c. Creatinine > 2 times the upper normal limit 
d. Estimated serum creatinine clearance <30 mL/min 
e. Hemoglobin below the lower normal limit 
13. Screening ECGs with significant abnormalities such as left bundle-branch blocks, 
bifascicular blocks, second- or third-degree AV block, possible current ischemia, or other 
findings associated with significant heart disease. The average QTc of the screening 
triplicate ECGs must not be >450 ms in males or >470 ms in females. Significant 
findings are to be clearly documented. 
14. Has symptomatic central nervous system (CNS) injury or disorder including epilepsy.  
15. Has any chronic condition or disease that would compromise neurological or vascular 
assessments. 
16. Immunocompromised or has a known history of Hepatitis B, human immunodeficiency 
virus (HIV), or Hepatitis C. 
17. Has a medical condition or receiving medication such that, in the opinion of the 
Investigator, participating in the trial would pose a health risk to the subject or confound 
the postsurgical assessments or might confound or interfere with the outcome of the trial. 
Examples include but are not limited to inability to ambulate, diabetic neuropathy, 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 48 of 128 
complex regional pain syndrome, prior infection in operative joint, known or suspected 
coagulopathy, uncontrolled anticoagulation, long COVID diagnosis, history of 
thromboembolic events, active gastrointestinal ulcers/bleeding, or cerebrovascular 
bleeding. 
18. Has uncontrolled depression, anxiety, psychiatric, or neurological disorder that might 
interfere with trial assessments or might confound or interfere with the outcome of the 
trial.   
a. Subjects currently taking anti-psychotic medication will be excluded.   
b. Anti-depressant medication (selective serotonin reuptake inhibitors only) is 
allowed if the subject has been on a stable dose for at least 30 days prior to 
screening and no dose changes are planned during the conduct of the trial.    
19. At any time prior to randomization, subjects with moderately severe or severe depression, 
as defined by  
a. Patient Health Questionnaire (PHQ-9) total score of ≥10; or  
b. Suicidal ideation, as defined by a PHQ-9 score of ≥1 in response to question 9, 
“thoughts that you would be better off dead, or hurting yourself.” 
20. Has a known or suspected history of drug or alcohol abuse. A subject with a history of 
alcohol use disorder that has ≥10 years sobriety will be permitted.  
21. Has a positive drug screen at the Screening Visit or on the day of surgery including 
positive results from prescribed medications. The exception being a positive drug screen 
resulting from infrequent use of short acting benzodiazepines that can be washed out 7 
days prior to surgery and not utilized during the trial duration.  
22. Has received/used an investigational drug, product, or device for a clinical trial within 
30 days of screening. COVID-19 vaccines (approved or under emergency use 
authorization locally) are permitted if the subject is not in a clinical trial for the vaccine. 
23. Pregnant, breastfeeding, or planning to become pregnant during the trial or before the 
Day 56 Visit. 
In addition, the subject will not have met eligibility if the following occurs during surgery.   
24. Any clinically significant (CS) event or condition uncovered during surgery (eg excessive 
bleeding, femur fracture), which occurs before investigational product administration, 
that might render the subject medically unstable or complicate the subject’s postsurgical 
course. 
25. 
 
 
6.3.3 
Subject Withdrawal Criteria 
Subjects must be withdrawn from the clinical trial if they wish to do so or if they are unwilling or 
unable to comply with the procedures of the clinical trial. The reasons for the subject’s 
withdrawal from the clinical trial must be recorded in the subject’s records, which should be 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 49 of 128 
completed as soon as possible after the subject’s withdrawal is determined. Any subject who 
withdraws from the clinical trial must complete all protocol Early Termination Visit assessments 
whenever possible.   
When an AE or SAE is the cause of withdrawal, the Investigator should record this in the case 
report form (CRF). The subject should be followed and treated by the Investigator until the AE 
has resolved or until the Day 56 Visit whichever occurs first. 
Subjects are free to withdraw from the trial at any time and for any reason and will document 
their understanding by signing the informed consent form. 
6.4 
SAFETY MONITORING COMMITTEE 
A Safety Monitoring Committee (SMC) will review blinded safety data in Part A after 25%, 
50%, and 100% enrollment of the study and in Part B after 25%, 50%, and 75% of the study. The 
SMC will be composed of independent members and Sponsor representatives. Representatives 
from the Sponsor will include clinical, regulatory and the study medical monitor. The 
biostatistician, anesthesiologist, cardiologist and orthopedic surgeon will be independent 
members. The SMC will operate under a written, detailed SMC plan. 
The SMC will evaluate study data including adverse events, pharmacokinetic data, cardiac 
information, and safety laboratory results from subjects. The SMC will investigate all reports of 
PK greater than or equal to 1,000 ng/mL of plasma bupivacaine. Should data arise where further 
information is needed to address a safety concern, the SMC will escalate the data review to an 
unblinded, independent statistician and physician.    
6.5 
STOPPING RULES 
The SMC may recommend that the trial be stopped based upon identification of any relevant PK 
and/or safety data at any time. The trial will also be stopped should there be: 
• One death where a clear alternative cause (other than ATX-101) is not identified or  
• Two non-fatal SAEs where a clear alternate cause (other than ATX-101) is not identified 
or 
• Five moderate cardiac or central nervous system AESIs with a PK concentration of more 
than 1,000 ng/mL and a clear alternate cause (other than ATX-101) is not identified or 
• Three severe cardiac or central nervous system AESI’s with a PK concentration of more 
than 1,000 ng/mL and a clear alternate cause (other than ATX-101) is not identified. 
In these instances, the study blind may be broken for the SMC for the identified subjects. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 50 of 128 
6.6 
CRITERIA FOR TRIAL TERMINATION  
In the event that the Investigator is unable to continue the trial at the site, another suitable person 
will be designated as Investigator, and documentation testifying to this will be submitted to Allay 
within 10 days. The new Investigator must be approved by Allay and the Investigational Review 
Board (IRB)/Ethics Committee (EC) before the trial can be continued. 
If Allay and/or the Investigator should discover conditions arising during the trial that indicate 
that the trial should be terminated at their site, an appropriate schedule for termination will be 
instituted. If the Investigator terminates the trial at their site, an explanatory letter will be 
provided to Allay. 
Allay also reserves the right to discontinue this trial for administrative reasons at any time.  
7.0 
TRIAL TREATMENTS 
7.1 
DESCRIPTION OF INVESTIGATIONAL PRODUCT (ATX-101) 
ATX-101 is a bioabsorbable implant. Each implant contains 500 mg bupivacaine free base (equal 
to 563 mg bupivacaine HCl or 594 mg bupivacaine HCl monohydrate). 
In this trial, subjects will be randomized to receive a single-dose administration of 1,000 mg or 
1,500 mg of ATX-101, corresponding to 2 or 3 implants, respectively. ATX-101 will be placed 
under direct visualization in the knee capsule, per the Dosage and Administration Instructions.  
Each ATX-101 contains the drug bupivacaine, a poly (DL-lactide-co-glycolide) polymer 
(PLGA), and polysorbate 20 (PS20). The dosage form for ATX-101 is a triangular implant, 
nominally 28 millimeters (mm) along each side and 2 mm thick with four suture holes in the 
approximate center and near each tip of the triangle and is white to light yellow or light tan in 
color (Figure 1).  
Figure 1: 
Example of the ATX-101 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 51 of 128 
7.1.1 
ATX-101 Packaging, Labeling & Storage 
Each ATX-101 implant will be provided
 
 The foil pouch will be provided in an outer box. ATX-101 must be stored 
in an ambient (15-25°C/59-77°F), secure location with access limited to the pharmacist and/or 
authorized staff. 
 At a minimum, the ATX-101 packaging will include the following information: 
• Sponsor Name 
• Protocol Number 
• Product Name/Drug Code 
• Dose/Product Strength 
• Route of Administration 
• Lot Number 
• Storage Temperature/Conditions. 
Any additional information and specific cautionary statements will be included according to 
local law.   
7.2 
DESCRIPTION OF ACTIVE COMPARATOR (BUPIVACAINE HCL) 
Bupivacaine HCl 0.25% without epinephrine/adrenaline maximum dose of 2 mg/kg will be used 
via local periarticular infiltration or adductor canal block or in combination per the 
administration instructions in section 8.14.2. Do not exceed a total daily dosage of 400 mg [9].   
7.3 
DOSE ADJUSTMENT CRITERIA 
The trial includes a one-time dose of ATX-101 or bupivacaine HCl administered during surgery. 
Doses of investigational product will not be able to be adjusted after administration.   
7.4 
INVESTIGATIONAL PRODUCT HANDLING AND DISPOSAL 
7.4.1 
Safety and Handling 
Although exposure of healthcare workers to bupivacaine from ATX-101 should be minimal, care 
should be taking to avoid unnecessary contact with ATX-101. Proper surgical and sterile 
techniques should be used when handling ATX-101. 
Standard of care procedures should be employed when handling the 0.25% bupivacaine HCl. 
Proper surgical and sterile technique should be used when handling 0.25% bupivacaine HCl. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 52 of 128 
7.4.2 
Disposal  
Allay will provide instructions regarding the destruction and/or return of all investigational 
product.   
If ATX-101 has not been used but is not able to be placed in a subject (eg dropped on the floor), 
disposal should be handled per hospital procedures through the pharmacy and/or biohazard 
disposal for bupivacaine. Disposal should be done in such a way as to not unblind members of 
the site staff that are to remain blinded.  
7.5 
INVESTIGATIONAL PRODUCT ACCOUNTABILITY 
Complete receipt, inventory, accountability, reconciliation, and return records will be maintained 
for all used and unused investigational products and trial provided medications. Documentation 
will include lot numbers, dates and quantity of shipment, dates and subject identification of 
dispensation, reconciliation, returns, and destruction.   
The packaging lot numbers will be recorded on the unblinded investigational product 
accountability records and on each subject’s unblinded drug administration source 
documentation and unblinded electronic form. Unblinded documentation will only be available 
to the specific individuals that are unblinded in the trial. Section 7.8 contains further information 
on blinding.   
7.6 
CONCOMITANT MEDICATIONS 
Prior and concomitant medication usage will be recorded from 30 days before the Screening 
Visit through the Day 56 Visit.  
Prohibited medications are listed in Appendix M. 
7.6.1 
Pre-Surgical Medications 
Before surgery, subjects will be administered acetaminophen/paracetamol 1,000 mg and 
celecoxib 200 mg [1]. Spinal anesthesia with bupivacaine (with or without dextrose) will be used 
in all subjects; no other adjunct medication such as morphine or ketamine may be used in the 
spinal anesthesia. General anesthesia is optional, but if used must be in conjunction with spinal 
anesthesia. Local nerve blocks (eg adductor canal blocks) are prohibited in the ATX-101 
treatment group, however topical anesthetics such as lidocaine can be used to aid in IV access 
and subcutaneously for spinal needle placement. 
7.6.2 
Surgical Concomitant Medications  
At the time of induction, the use of fentanyl (no more than 300 µg) for airway management is 
permitted when general anesthesia is used. Other than fentanyl for airway management, no other 
opioids may be administered during surgery.  


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 53 of 128 
Two doses of IV tranexamic acid (1 g each) will be administered to the subject. One dose of 
tranexamic acid will be administered prior to investigational product administration and the 
second dose after investigational product administration, with the timing at the discretion of the 
treating Investigator. Intravenous or oral antibiotic regimen may also be given per the center’s 
standard of care. Antibiotic powders or beads in the knee joint are prohibited. A one-time dose of 
IV dexamethasone (4 mg) will be administered during the surgical procedure, with the timing at 
the discretion of the treating Investigator. One dose of prophylactic ondansetron will be given 
before or during surgery, with the timing at the discretion of the treating investigator. All other 
doses of antiemetics will be given only after an adverse event.  
7.6.3 
Post-Surgical Concomitant Medications 
All trial subjects will receive a standardized approach for managing postsurgical pain that 
includes a scheduled multimodal regimen of celecoxib (200 mg) twice a day for 30 days, unless 
an AE occurs that requires discontinuation. Acetaminophen/paracetamol 500 mg should be taken 
every 4 hours or 1,000 mg every 6 to 8 hours not to exceed 3,000 mg per any 24-hour period for 
a minimum of 21 days.   
Deep vein thrombosis prophylaxis is required, and 75-100 mg aspirin (based upon regional 
approved dose) is recommended two times a day for 30 days. Aspirin is recommended in trial 
subjects unless there are additional risks of thromboembolic events identified requiring a 
different DVT prophylaxis. Celecoxib, acetaminophen/paracetamol, and aspirin may be provided 
by the Sponsor. 
7.6.3.1 
Rescue Opioid Medications 
Subjects should only receive rescue opioid medication upon request for pain control, as needed, 
after surgery. Rescue opioid medication may be given/taken for pain treatment, but not for pain 
prophylaxis. If required to treat pain, the following standardized postsurgical rescue opioid 
medication protocol will be used. 
From Day 1 after Surgery through Day 30 every time a rescue opioid medication is required, 
prior to opioid administration, the subject must complete the NRS-R scale for pain intensity and 
record information about the opioid consumed.     
7.6.3.1.1 
In Hospital Rescue Opioid Medications 
Preferred rescue opioid medication will consist of oral immediate-release oxycodone (5 mg or 
10 mg). The prescription should indicate the patient take 1 to 2 pills (5 mg to 10 mg) every 4-6 
hours as needed. The prescription must indicate that substitutions with any other opioid-
containing product are not permitted, including combination opioid/non-opioid products. If a 
subject cannot tolerate oral medication, morphine may be administered IV (including via patient-
controlled analgesia [PCA] pump) or IM as needed (morphine is preferred, however 
hydromorphone can also be used with the dose determined by the treating physician). If a subject 
cannot tolerate the medication or the breakthrough pain is not responsive to oral oxycodone (5 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 54 of 128 
mg or 10 mg), then oral hydromorphone (2 mg or 4 mg) may be given for rescue opioid 
medication. The prescription should indicate the patient take 1 to 2 pills (2 mg to 4 mg) every 
4-6 hours as needed. The prescription must indicate that substitutions with any other opioid-
containing product are not permitted, including combination opioid/non-opioid products. Should 
the subject have an AE and is unable to tolerate requested rescue opioid medications of oral 
oxycodone (5 mg or 10 mg), IV morphine, oral hydromorphone (2 mg or 4 mg), and IV 
hydromorphone, then hospital standard of care may be utilized however, local anesthetic nerve 
blocks may not be administered after surgery. No long-lasting opioids should be administered. 
7.6.3.1.2 
Post-Discharge Rescue Opioid Medications 
Preferred rescue opioid medication will consist of oral immediate-release oxycodone (5 mg or 
10 mg). If a subject cannot tolerate the oral oxycodone or the breakthrough pain is not responsive 
to oral oxycodone (5 mg or 10 mg), then oral hydromorphone (2 mg or 4 mg) may be given for 
rescue opioid medication. Should the subject have an AE and is unable to tolerate requested 
rescue opioid medications of oral oxycodone (5 mg or 10 mg), or oral hydromorphone (2 mg or 
4 mg), then hospital standard of care may be utilized, however, local anesthetic nerve blocks may 
not be administered after surgery 
No more than thirty (30) 5 mg immediate-release oxycodone tablets (or as limited by local law) 
will be provided as part of the first prescription. The prescription should indicate the patient take 
1 to 2 pills (5 mg to 10 mg) every 4-6 hours as needed. The prescription must indicate that 
substitutions with any other opioid-containing product are not permitted, including combination 
opioid/non-opioid products. Additional prescriptions can be provided at Investigator discretion, 
with instructions the same as the first prescription.   
If the subject has been prescribed hydromorphone, no more than thirty (30) 2 mg immediate-
release hydromorphone tablets (or as limited by local law) will be provided as part of the first 
prescription. The prescription should indicate the patient take 1 to 2 pills (2 mg to 4 mg) every 
4-6 hours as needed. The prescription must indicate that substitutions with any other opioid-
containing product are not permitted, including combination opioid/non-opioid products. 
Additional prescriptions can be provided at Investigator discretion, with instructions the same as 
the first prescription. 
If a subject is prescribed both 5 mg immediate release oxycodone and 2 mg immediate release 
hydromorphone, no more than 30 total tablets combined may be prescribed.   
All unused, prescribed opioids should be returned to the clinical site for accountability during the 
Day 15 and Day 30 in-clinic visits. If the subject has a need to continue to take opioids after the 
accountability visit, the opioids may be returned to the subject.    
Total number of opioid prescriptions during the trial will be documented.   


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 55 of 128 
7.7 
RANDOMIZATION  
A randomization schedule will be computer generated.  
Subjects will be randomized in a 1:1:1 ratio in Part A to a one-time administration of 1,000 mg 
ATX-101, 1,500 mg of ATX-101, or bupivacaine HCl.   
Subjects will be randomized in a 1:1 ratio in Part B to a one-time administration of ATX-101 
(1,000 mg or 1,500 mg determined from Part A) or bupivacaine HCl. 
7.8 
BLINDING 
In the event of a medical emergency when knowledge of the actual treatment becomes medically 
necessary to affect treatment options, prior to the end of trial unblinding, the Investigator will be 
able to obtain details of the treatment assigned to a subject. The Medical Monitor is to be 
informed immediately that the blind has been broken.   
The method for unblinding through the electronic data capture (EDC) system includes: 
• The Investigator will consult with the Medical Monitor if possible.   
• The Investigator/Medical Monitor accesses the Code Break Module in the EDC.   
• The Investigator/Medical Monitor retrieves the treatment assignment from the EDC Code 
Break Module 
• An unblinded email notification will be sent to the Investigator or Medical Monitor who 
broke the code. 
The surgical staff will not be blinded to the trial treatment, all other research staff (unless 
expressly specified in the site’s blinding plan that is approved by Allay) and the subject will 
remain blinded throughout the trial. The trial Sponsor will remain blinded during the treatment 
phase of Part A and Part B unless individual subjects need to be unblinded due to safety after a 
SMC meeting. Trained and pre-identified monitors will be unblinded throughout the trial to 
ensure compliance with trial protocols and investigational product accountability. Further 
information regarding accountability can be found in Section 7.5. Blinded monitors will be 
assessing safety and efficacy data at the site.   
8.0 
TRIAL PROCEDURES 
A signed and dated informed consent will be obtained from trial subjects using the consent form 
approved by the IRB/EC, prior to any trial procedures being performed. A copy will be provided 
to the subject. 
For each subject, AEs will be collected from the time of investigational product administration 
through the Day 56 Visit. Prior and concomitant medication usage will be collected throughout 
the trial from 30 days prior to the Screening Visit until end of trial participation or at the Day 56 
Visit. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 56 of 128 
Refer to the Schedule of Events (Appendix A for Part A and Appendix B for Part B) for 
complete details regarding the timing of trial procedures. Subject self-administered procedures 
are detailed in Appendix C.    
8.1 
DEMOGRAPHIC/MEDICAL HISTORY 
The subject’s demographic information will be collected at the Screening Visit. The subject’s 
medical history will be collected at the Screening Visit and confirmed/updated prior to surgery 
on Day 1 before surgery. Any medical events that occur prior to investigational product 
administration will be considered medical history.   
8.2 
VITAL SIGNS 
Vital signs will be measured at the Screening Visit, on the day of surgery before surgery and 
after surgery (Assessment timing will be based on surgery closure which will be time 0) at Hours 
3 and 6 (±30 minutes); Hours 9 and 12 (±1 hour). Starting at Hour 18 vital signs will be required 
every 6 hours (±2 hours) unless the subject is sleeping. In Part A vital signs will be taken through 
Hour 96 (Day 5). In Part B after Hour 18, vital signs will be taken every 6 hours (±2 hours) 
unless the subject is sleeping until Hour 24 or discharge, whichever is later. In a 24-hour period, 
vital signs can only be missed one time for the subject sleeping. 
Upon discharge (Part A only), vital signs will be measured on trial visit Days 6, 8, 15, 22, 30, 
and 56.   
Upon discharge (Part B only), vital signs will be measured Days 3, 4, 5, 6, 8, 15, 22, 30 and 56.   
Vital Signs are required anytime a subject has an SAE or AESI. 
The following vital signs will be measured after the subject has been supine for 5 minutes: pulse, 
temperature, respiratory rate, systolic/diastolic blood pressure, and oxygen saturation.     
8.3 
PHYSICAL EXAMINATION AND HEIGHT/WEIGHT 
A physical exam will be performed at the Screening Visit and at the Day 56 Visit. At the 
screening visit, the physical exam must include a Kellgren Lawrence Classification, (varus 
evaluation, valgus evaluation, and evaluation of ipsilateral hip osteoarthritis). The subject’s 
weight will be measured during the physical exam at the Screening Visit and at the Day 56 Visit. 
The subject’s height will be measured only at the Screening Visit.   
8.3.1 
Kellgren Lawrence Classification 
Kellgren Lawrence Classification is used to classify the severity of knee osteoarthritis [20]. The 
Kellgren Lawrence Classification will occur on the subject’s proposed trial knee and one of five 
grades (Grade 0 through Grade 4). Grades include:  
• Grade 0 (none): definite absence of x-ray changes of osteoarthritis 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 57 of 128 
• Grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic lipping  
• Grade 2 (minimal): definite osteophytes and possible joint space narrowing 
• Grade 3 (moderate): moderate multiple osteophytes, definite narrowing of joint space 
and some sclerosis and possible deformity of bone ends 
• Grade 4 (severe): large osteophytes, marked narrowing of joint space, severe sclerosis 
and definite deformity of bone ends 
8.4 
ELECTROCARDIOGRAM 
For Part A, triplicate 12-lead ECGs will be performed at the Screening Visit, on Day 1 prior to 
receiving the bupivacaine spinal, during surgery before ATX-101 or bupivacaine HCl 
administration, Hour 6 and Hour 12 after the surgical procedure, Days 2 (Hour 24), 3 (Hour 48), 
4 (Hour 72), 5 (Hour 96), 6, 8, 15, 22, 30, and 56.   
For Part B, triplicate 12-lead ECGs will be performed at the Screening Visit, on Day 1 prior to 
receiving the bupivacaine spinal, and Day 56. 
Triplicate 12-lead ECGs are required any time a subject has an SAE or AESI.   
Triplicate ECGs will be taken 2 minutes apart (±1 minute) for each nominal timepoint. Subjects 
will be at rest in a supine or semi-recumbent position for 10 minutes before the ECGs are 
obtained. No TV, video games, etc. will be allowed during the rest or ECG period. The ECGs 
will be taken BEFORE PK sampling.  
ECGs will be analyzed by a central cardiac core lab and reports will be provided from the 
cardiac core lab to the clinical site for medical review. The Investigator or delegated medically 
qualified site staff will immediately review the ECGs for safety concerns, as well as later review 
the ECG reports and determine if any abnormal findings are considered clinically significant in 
their medical judgement and therefore required to be entered into the subject’s medical history 
(from the Screening Visit or the Day 1 before bupivacaine spinal) or recorded as adverse events.   
8.5 
LABORATORY ASSESSMENTS 
Laboratory Assessments will be performed at the Screening Visit, before surgery on Day 1, on 
Day 15, and at the Day 56 Visit. Specific laboratory tests are detailed below. Laboratory 
assessments are required any time a subject has an SAE or AESI.  
Screening laboratory values that are out of range will be identified and may be repeated at the 
Investigator’s discretion with Allay’s approval. The Investigator will determine if any out-of-
range laboratory values that emerge after treatment are clinically significant and record these as 
an AE. All clinically significant out-of-range laboratory values that emerge after treatment will 
be followed until resolution or the Day 56 Visit, whichever occurs first. See Appendix K for 
further information.    


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 58 of 128 
8.5.1 
Hematology 
The following hematologic assessments will be performed: hemoglobin, hematocrit, white blood 
cell count (total and differential), red blood cell count and platelet count.   
Hematology assessments will occur at the Screening Visit and at the Day 56 Visit. A hematology 
assessment is required anytime a subject has an SAE or AESI.  
8.5.2 
Chemistry 
The following chemistry assessments will be performed: sodium, potassium, creatinine, 
creatinine clearance, albumin, ALP, total and direct bilirubin, AST, ALT, blood urea nitrogen 
(BUN), creatinine kinase, gamma-glutamyl transferase (GGT), and phosphate.   
Blood chemistry assessments will occur at the Screening Visit and at the Day 56 Visit. A 
chemistry assessment is required anytime a subject has an SAE or AESI.  
8.5.3 
Drug Screen 
At the Screening Visit a urine drug screen will be performed for opiates (including oxycodone), 
amphetamines, methadone, barbiturates, benzodiazepines, cocaine, phencyclidine, 
methamphetamine, ecstasy (3,4-Methylenedioxymethamphetamine or MDMA), tricyclic 
antidepressant, and cannabinoids. If a subject has a positive urine drug screen at the Screening 
Visit, a screen may be repeated one time at the Sponsor’s discretion to confirm non-chronic use. 
The subject may be considered eligible for the trial if a repeat urine drug screen is negative.  
On Day 1 before surgery a urine drug screen for opioids will be performed. If the subject tests 
positive for opioids and the treating Investigator feels this is a false positive result, the medical 
monitor will be contacted to determine if the subject may be enrolled in the trial. The subject 
may only be enrolled if approved by the medical monitor. If enrollment is permitted, a 
confirmatory blood or urine sample (as applicable) from the subject on Day 1 before surgery will 
be sent to the blood and urine central lab.   
At the Day 15 Visit a urine drug screen will be performed for opiates (including oxycodone), 
amphetamines, methadone, barbiturates, benzodiazepines, cocaine, phencyclidine, 
methamphetamine, ecstasy (3,4-Methylenedioxymethamphetamine or MDMA), tricyclic 
antidepressant, and cannabinoids. It is expected that subjects taking rescue opioid medications 
will test positive for opioids at this visit.   
8.5.4 
Pregnancy Test 
A pregnancy test will occur at the Screening Visit, before surgery on Day 1, and at the Day 56 
Visit for females of childbearing potential. Pregnant females identified at the Screening Visit or 
on the day of surgery will not be eligible for the trial. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 59 of 128 
A urine pregnancy test from the Screening Visit and Day 56 Visit will be analyzed. A urine or 
serum pregnancy test will occur on the day of surgery (Day 1), before surgery, per standard of 
care at the clinical site.   
Female subjects who are not of childbearing potential must have a medical history recorded of 
surgical sterilization (≥6 months post-surgery at the time of screening) or post-menopausal (not 
experienced a menstrual period ≥2 years at the time of screening). 
8.6 
RANGE OF MOTION ASSESSMENT 
The ROM assessment will occur at the Screening Visit, on Days 2 (Hour 24), 3 (Hour 48), 4 
(Hour 72), 5 (Hour 96), 6, 8, 15, 22, 30, and 56. 
Range of motion will be conducted using a goniometer to measure flexion and extension for the 
subject per Sponsor provided ROM training.    
8.7 
PATIENT HEALTH QUESTIONNAIRE 9  
The PHQ-9 (Appendix G) will be conducted at the Screening Visit. The PHQ-9 questionnaire 
assesses for depression.   
If the subject exhibits signs of moderately severe or severe depression, as defined by a PHQ-9 
total score of ≥10; or suicidal ideation, as defined by a PHQ-9 score of ≥1 in response to 
question 9, then the subject will not be eligible for the trial.    
If the subject exhibits signs of moderately severe or severe depression, they should be informed 
of their result. The hospital/clinic staff should recommend the best course of action for the 
subject (eg counseling, referral to a specialist, hospitalization etc.) and document the outcome 
and advice in the subject records.  
8.8 
NEUROLOGICAL ASSESSMENTS 
The neurological assessments will be conducted during the Screening Visit, on Day 1 before 
surgery, and after surgery (assessment timing will be based on surgery closure which will be 
time 0) at Hours 3 and 6 (±30 minutes); Hours 9 and 12 (±1 hour); Hours 18 and 24 (±2 hours) 
unless the subject is sleeping. In the 24-Hour period, the neurological assessment can only be 
missed one time for the subject sleeping.   
The neurological assessments will be conducted on Days 3 (Hour 48), 4 (Hour 72), 5 (Hour 96), 
6, 8, 15, 22, 30, and 56.  
Neurological assessments are required any time a subject has an SAE or AESI. 
A gross motor and sensory exam will be conducted with a focus on the lower extremities. Motor 
examinations will focus on distal lower extremities dorsi flexion and plantar flexion of each foot 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 60 of 128 
(ankles and toes) against resistance. The gross sensory examination should focus on intact 
sensory examination to touch in the dorsal and plantar side of each foot.   
The subject will be queried on abnormal senses (ears/hearing, sight, touch, smell, and taste).   
Any abnormal, clinically significant findings from the neurological assessments will be recorded 
as an AE. 
8.9 
E-DIARY TRAINING 
The subject will be trained on the use of the e-diary at the Screening Visit and on Day 1 before 
surgery. Throughout the trial e-diary questions and concerns from the subject will be addressed 
and re-training will occur if needed at any time during the trial. 
If subject is temporarily unable to complete the e-diary questionnaires, a paper-based 
questionnaire may be utilized. Paper questionnaires will also be used if an Early Termination 
Visit is conducted.   
8.10 
E-DIARY DISPENSATION/RETURN 
The provisioned e-diary will be dispensed to the subject on Day 1 before surgery and will be 
returned at the Day 30 Visit. If the subject’s own device is used, the site staff will work with the 
subject to have the e-diary set-up before the subject has surgery.   
Questionnaires and surveys completed at the Screening Visit and the Day 56 Visit may utilize 
e-diaries maintained by the clinical site. If the subject does not return the provisioned e-diary at 
the Day 30 Visit or an Early Termination Visit before Day 30, then a site-maintained e-diary 
may be used to complete the self-administered questionnaires and surveys.     
8.11 
SUBJECT PAIN SCORE TRAINING 
The subject will be trained on the completion of the NRS pain intensity scales at the Screening 
Visit, on Day 1 before surgery, Day 2, Day 3, and after Day 15 (on Day 16). Standardized pain 
score training will be conducted by the site staff or through training videos (Appendix H). 
8.12 
RANDOMIZATION AND INVESTIGATIONAL PRODUCT ALLOCATION 
Randomization for allocation of investigational product may occur up to one business day before 
surgery. Randomization will occur through a web-based tool. In Part A, subjects who are deemed 
randomization failures (subjects who are randomized but do not receive investigational product), 
will be replaced. In Part B subjects will not be replaced. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 61 of 128 
8.13 
BUPIVACAINE PHARMACOKINETIC ASSESSMENT 
Pharmacokinetic samples are centrifuged within 2 hours of collection, and the supernatant 
aspirated and stored at -20˚C or -80˚C until shipped for testing at an external bioanalytical 
laboratory. Specific processing details will be provided in a PK/laboratory manual.  
8.13.1 
Blood Sample Collection for Pharmacokinetic Analysis 
For Part A, venous blood samples (4 mL) for plasma PK analysis are drawn on Day 1 before 
surgery (before bupivacaine spinal), during surgery prior to administration of ATX-101 or 
bupivacaine then 6 hours ±30 minutes and 12 hours ± 1 hour after surgical closure. PK samples 
will also be collected at Day 2 (Hour 24 ±2 hours), Day 3 (Hour 48 ±2 hours), Day 4 (Hour 72 
±2 hours), Day 5 (Hour 96 ±2 hours), on Days 6, 8, 15, 22, and 30. It is requested, if possible, 
that the PK samples from Days 6 to 30 are collected at approximately the time of surgical closure 
on Day 1.     
In Part A and Part B, a PK sample is required for bupivacaine monitoring anytime a subject has 
an SAE or AESI. A PK sample is also required if a subject terminates the study early on or 
before Day 30 (Part A only).   
The ECGs will be taken BEFORE PK sampling.  
8.13.2 
Bupivacaine Concentration Analysis 
Plasma bioanalysis of bupivacaine from PK samples collected in the trial will be performed by 
  
8.14 
INVESTIGATIONAL PRODUCT ADMINISTRATION 
8.14.1 
ATX-101 
A one-time administration of a single dose level of ATX-101 will be placed under direct 
visualization in the subject’s knee capsule following fixation of the knee implant prosthesis when 
tissue will not be disrupted any further by surgery, after any betadine or saline rinse, and after 
suction has occurred, but prior to initiation of surgical closure. ATX-101 will be placed in the 
suprapatellar pouch, medial gutter, and/or lateral gutter according to the Dosage and 
Administration Instructions. 
8.14.2 
Bupivacaine Hydrochloride-Active Comparator 
Active comparator bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 
mg/kg, will be administered via local periarticular infiltration or adductor canal block 
(Ultrasound guided saphenous nerve block), or in combination during surgery.  
The bupivacaine HCl may be provided by the Sponsor for use in the trial.  


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 62 of 128 
8.15 
WOUND HEALING ASSESSMENT 
The wound healing assessment will occur on Days 15, 22, 30, and 56 using the Southampton 
Wound Scoring System (Appendix I). 
Any score of Grade 2 or greater from the Southampton Wound Scoring System will be recorded 
as an AE and may be documented with photographic evidence. So as to be able to distinguish 
TKA incision/wound events from other events, the Investigator must report these events as 
“surgical wound” preceded by the description (eg surgical wound purulent discharge).   
8.16 
KNEE SOCIETY SCORE 
The Knee Society Score (Appendix J) will occur at the Screening Visit, on Days 15, 30, and 56. 
The Knee Society Score assesses knee joint and knee function.   
8.17 
SUBJECT SELF-ADMINISTERED E-DIARY ASSESSMENTS 
Subjects will use their own device or be provided with an e-diary as specified in Protocol Section 
8.10 to complete self-administered questionnaires and surveys as well as track opioid 
consumption. 
8.17.1 
Numeric Rating Scale at Rest for Pain Intensity & Location of Pain 
The NRS-R for pain intensity (Appendix H) is an 11-item scale from 0-10 where subjects rank 
the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10). 
The NRS-R will be collected during the Screening Visit, on Day 1 before surgery, approximately 
6 times on Day 1 after surgery, and approximately 3 times a day from Day 2 through Day 15. 
After the Day 15 Visit the NRS-R will be collected one time daily through Day 30 and again 
Day 56.  
The NRS-R will also be collected post-surgically through Day 30 every time the subject requires 
an opioid medication administration.   
Prior to obtaining the NRS-R it is recommended subjects be in a comfortable resting position 
(either seated or lying down) for at least 5 minutes prior to obtaining the pain intensity score.   
If the subject records a pain intensity score of 1 or greater, they will be asked to indicate the 
single area of their knee with the most intense pain (See Appendix L).    
8.17.2 
Numeric Rating Scale with Activity for Pain Intensity & Location of Pain 
The NRS with activity (NRS-A) for pain intensity (Appendix H) is an 11-item scale from 0-10 
where subjects rank the level of pain intensity after an activity. The NRS scale goes from No 
Pain (0) to Worst Imaginable Pain (10). The NRS-A will be conducted at the Screening Visit, 
once a day from Day 2 until the Day 30 Visit, and at Day 56.    


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 63 of 128 
Prior to the NRS-A collection the subject should complete one set of 8 to 10 repetitions of knee 
flexion/extension by sitting on the edge of a chair/bed and extending the leg straight.     
If the subject records a pain intensity score of 1 or greater, they will be asked to indicate the 
single area of their knee with the most intense pain (See Appendix L).   
8.17.3 
Quality of Recovery 15 Scale  
The QOR-15 (Appendix D) will be collected during the Screening Visit, one time daily from 
Day 2 through Day 30, and at the Day 56 Visit.   
The QOR-15 is a 15-item questionnaire designed to evaluate the early post-operative health 
status of subjects following surgery and anesthesia. 
8.17.4 
Knee Injury and Osteoarthritis Outcome Scale for Joint Replacement 
The KOOS, JR will be conducted at the Screening Visit, on Day 8, 15, 22, 30, and 56.  
The KOOS, JR questionnaire (Appendix E) is used to assess the subject’s opinion about their 
knee and associated problems. The assessments are taken directly from the parent KOOS 
questionnaire and focus on the three categories: joint pain, stiffness, and function in daily living.   
8.17.5 
Pain Manageability Assessment 
The pain manageability assessment (Appendix F) will be conducted at the Screening Visit, on 
Day 8, 15, 22, 30, and 56. 
 
 
     
8.17.6 
Recording Rescue Opioid Medication and Medication Compliance 
Each time a subject consumes an opioid from Day 1 after surgery until Day 30, a NRS-R for pain 
intensity must be completed along with opioid type, dose, and time.     
From Day 1 after surgery until Day 30 subjects will be asked daily about compliance with study 
provided medications (celecoxib and acetaminophen/paracetamol).  
8.17.7 
Physical Therapy Survey 
Each day, at the end of the day, starting on Day 1 through Day 30 a physical therapy survey will 
be completed including the type (eg in person, home exercises) of physical therapy completed.   
Subjects from some sites may be eligible for physical therapy through a digital platform. Allay 
may collect physical therapy information on these subjects.   


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 64 of 128 
9.0 
REPORTING SAFETY INFORMATION 
9.1 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
9.1.1 
Definition of Adverse Event 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have a causal relationship 
to this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of an 
investigational product, whether or not related to the investigational product.   
For each subject, AEs will be collected from the time of the investigational product 
administration through the Day 56 Visit. Adverse events will be followed until resolution of 
AE(s) or the Day 56 Visit, whichever occurs first. All AEs must be recorded regardless of the 
severity or relationship to investigational product. It is important that Investigators also report all 
AEs whether serious or non-serious. Events occurring prior to administration of the 
investigational product should be recorded as medical history.   
An AE does include a/an: 
• Exacerbation of a pre-existing illness 
• Increase in frequency or intensity of a pre-existing episodic event or condition 
• Continuous persistent disease or symptoms present at baseline which worsens following the 
start of the trial 
• New post-surgical findings such as erythema and swelling of the surgical site 
An AE does not include: 
• Planned medical or surgical procedures (eg, surgery, endoscopy, tooth extraction, 
transfusion); the condition that leads to the procedure is an AE. Planned surgical measures 
permitted by the clinical trial protocol and the condition(s) leading to these measures are not 
AEs. 
• Pre-existing diseases or conditions present or detected prior to the administration of the 
investigational product that do not worsen. 
• Situations where an untoward medical occurrence has not occurred (eg, social and/or 
convenience admissions). 
• The disease or disorder (post-TKA trial knee pain) being studied unless it represents an 
excessive exacerbation of the condition. 
Definitions for considering sinus bradycardia and respiratory depression AEs are in Appendix K. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 65 of 128 
9.1.2 
Procedures for Eliciting Adverse Events 
The Investigator shall report all directly observed AEs, all spontaneously reported AEs, and AEs 
discovered during the physical exam, laboratory testing, and/or other means. At each visit the 
Investigator or properly documented delegate will ask the subject a non-specific question (eg, 
“Have you noticed anything different since your last visit?”) to assess whether any AEs have 
been experienced since the last report or visit.  
9.1.3 
Reporting a Diagnosis, Not Signs or Symptoms 
In general, the use of a unifying diagnosis is preferred to listing individual symptoms. Grouping 
symptoms into a diagnosis should be done if each sign and/or symptom is a medically confirmed 
component of a diagnosis. If any aspect of a sign or symptom does not fit into the diagnosis, 
report the individual symptom as a separate AE. Two examples follow: 
• Fever, cough, rhinitis, and headache are diagnosed to be symptoms of an upper respiratory 
tract infection 
• Urinary frequency, flank pain, and fever are diagnosed to be symptoms of a mild renal 
infection. 
9.1.4 
Definition of Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, 
requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent 
or significant disability/incapacity or is a congenital anomaly/birth defect. An AE occurring at 
any dose or time during the trial should be classified as SERIOUS if the event results in any of 
the following: 
• Fatality: The AE resulted in death. All deaths are reported whether or not suspected of being 
related to trial treatment. Death is an outcome of an event. The event that resulted in the 
death should be recorded and reported. However, if the event resulting in death is not initially 
known, please report the death immediately and continue to seek additional information, 
including the cause of death. 
• Life-threatening condition: The AE was immediately life-threatening (ie, the AE placed the 
subject at immediate risk of death; it does not apply to an AE that hypothetically might have 
caused death if it were more severe). 
• Inpatient hospitalization (initial or prolonged): “Inpatient hospitalization” does not imply that 
the subject must have had an overnight stay in the hospital. If the subject was admitted to the 
hospital for less than a day for the purpose of treatment or observation, the definition of 
“Inpatient hospitalization” is met. Brief treatment in an outpatient clinic or Emergency 
department does not constitute “inpatient hospitalization.” For an event to meet the criteria 
for prolonged hospitalization, the subject must be in the hospital prior to the onset of the AE 
and that hospitalization was lengthened due to the AE. The following circumstances are NOT 
considered SAEs by the criterion described above: hospitalizations for diagnostic or elective 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 66 of 128 
medical/surgical procedures (ie, scheduled prior to trial enrollment or during the course of 
the trial) scheduled treatments and routine check-ups.   
• Disability: The AE was disabling (ie, the AE resulted in a significant, persistent, or 
permanent change, impairment, damage, or disruption in the subject’s body 
function/structure, physical activities, or quality of life). 
• Congenital anomaly: The AE was a congenital anomaly/birth defect (ie, an adverse outcome 
in a child or fetus of a subject exposed to trial treatment prior to conception or during 
pregnancy). 
• Other important medical condition: An AE that may not result in death, be life-threatening, 
or require hospitalization, but based upon appropriate medical judgement may jeopardize the 
subject or subject may require medical or surgical intervention to prevent one of the 
outcomes defined above. Examples of such events are intensive treatment in an emergency 
room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not 
result in hospitalization; or development of drug dependency or drug abuse. A new diagnosis 
of cancer should be considered serious and should be reported on the SAE form.  
9.1.5 
Medical Emergency 
In a medical emergency requiring immediate attention, trial site staff will apply appropriate 
medical intervention, according to current standards of care, and contact Allay medical monitor 
as soon as possible to alert them of the situation.  
Should severe cardiotoxic or neurotoxic events of local anesthetic systemic toxicity (LAST) 
occur and standard methods of treatment (eg oxygen, medication) fail, a lipid emulsion should be 
available in the event the hospital/clinic/facility staff assess it is in the best interest of the subject. 
Should an AESI present after the subject has been discharged from the hospital/clinic/facility the 
subject should return to the hospital/clinic/facility for further evaluation.      
9.2 
RELATIONSHIP TO INVESTIGATIONAL PRODUCT 
The Investigator will assess the causality of the investigational product to the AE using the 
following definitions:  
“Definitely related”, “Probably related” and “Possibly related” will be considered as “related” to 
the investigational product.  
 
 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 67 of 128 
Relationship 
Assessment Criteria 
Description 
Definitely related: 
• Event or laboratory test 
abnormality, with plausible time 
relationship to investigational 
product intake and  
• Cannot be explained by disease or 
other drugs. 
• A clinical event, including 
laboratory test abnormality, 
occurring in a plausible time 
relationship to investigational 
product administration, and which 
cannot be explained by concurrent 
disease or other drugs or chemicals.  
Probably related: 
• Event or laboratory test 
abnormality, with reasonable time 
relationship to investigational 
product intake and  
• Unlikely to be attributed to disease 
or other drugs.   
• A clinical event, including 
laboratory test abnormality, with a 
reasonable time sequence to 
administration of the investigational 
product, unlikely to be attributed to 
concurrent disease or other drugs or 
chemicals.  
Possibly related: 
• Event or laboratory test 
abnormality, with reasonable time 
relationship to investigational 
product intake but 
• Could also be explained by disease 
or other drugs. 
• A clinical event, including 
laboratory test abnormality, with a 
reasonable time sequence to 
administration of the investigational 
product, but which could also be 
explained by concurrent disease or 
other drugs or chemicals.  
“Unlikely related” and “Not related” will be considered as “not related” to the investigational 
product. 
Relationship 
Assessment Criteria 
Description 
Unlikely related: 
• Event or laboratory test 
abnormality, with a time to 
investigational product intake that 
makes a relationship improbable 
(but not impossible) and  
• Disease or other drugs provide 
plausible explanations 
• 
A clinical event, including 
laboratory test abnormality, with a 
temporal relationship to 
investigational product 
administration which makes a 
causal relationship improbable, 
and in which other drugs, 
chemicals or underlying disease 
provide plausible explanations. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 68 of 128 
Relationship 
Assessment Criteria 
Description 
Not related: 
• The AE is clearly not related to the 
investigational agent/procedure 
• 
Another cause of the event is most 
plausible; and/or a clinically 
plausible temporal sequence is 
inconsistent with the onset of the 
event and the trial intervention 
and/or a causal relationship is 
considered biologically 
implausible. 
Assessment of the relationship of the AE to investigational product will not be conducted by the 
treating surgeon since they are unblinded to trial treatment.    
9.3 
RELATIONSHIP TO THE TKA SURGERY 
The Investigator will assess the causality of the TKA surgery to the AE using the following 
definitions:  
“Definitely related” and “Probably related” and “Possibly related” will be considered as 
“related” to the TKA surgery.  
Relationship 
Assessment Criteria 
Description 
Definitely related: 
• Event or laboratory test 
abnormality, with plausible time 
relationship to TKA surgery and  
• Cannot be explained by disease or 
other drugs. 
• A clinical event, including laboratory 
test abnormality, occurring in a 
plausible time relationship to TKA 
surgery, and which cannot be 
explained by concurrent disease or 
other drugs or chemicals.  
Probably related: 
• Event or laboratory test 
abnormality, with reasonable time 
relationship to TKA surgery and  
• Unlikely to be attributed to 
disease or other drugs.   
• A clinical event, including laboratory 
test abnormality, with a reasonable 
time sequence to TKA surgery, 
unlikely to be attributed to concurrent 
disease or other drugs or chemicals.  
Possibly related: 
• Event or laboratory test 
abnormality, with reasonable time 
relationship to TKA surgery 
intake but 
• Could also be explained by 
disease or other drugs. 
• A clinical event, including laboratory 
test abnormality, with a reasonable 
time sequence to TKA surgery, but 
which could also be explained by 
concurrent disease or other drugs or 
chemicals.  
“Unlikely related” and “Not related” will be considered as “not related” to the TKA surgery. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 69 of 128 
Relationship 
Assessment Criteria 
Description 
Unlikely related: 
• Event or laboratory test 
abnormality, with a time to TKA 
surgery that makes a relationship 
improbable (but not impossible) 
and  
• Disease or other drugs provide 
plausible explanations 
• A clinical event, including laboratory 
test abnormality, with a temporal 
relationship to TKA surgery which 
makes a causal relationship 
improbable, and in which other drugs, 
chemicals or underlying disease 
provide plausible explanations. 
Not related: 
• The AE is clearly not related to the 
TKA surgery 
• Another cause of the event is most 
plausible; and/or a clinically plausible 
temporal sequence is inconsistent 
with the onset of the event and the 
TKA surgery and/or a causal 
relationship is considered biologically 
implausible. 
Assessment of the relationship of the AE to TKA surgery will not be conducted by the treating 
surgeon since they are unblinded to trial treatment. 
Direct relationship to the TKA surgery is required. As an example, if a subject is taking opioids 
due to the TKA surgical procedure and the subject has constipation as a result of the opioids, the 
constipation is not related to the TKA surgical procedure, but instead related to the opioid 
consumption.    
9.4 
RECORDING ADVERSE EVENTS 
Any AE occurrence during the trial must be recorded on source documentation at the site and on 
the AE CRF. Adverse events will be collected from the time of investigational product 
administration and through the Day 56 Visit. 
The trial site should observe the following guidelines when recording AEs: 
• Whenever possible, use recognized medical terms when recording events. Do not use 
colloquialisms and/or abbreviations. 
• The Investigator will evaluate the severity of each AE using the following definitions: 
• Mild: The event may be noticeable to the subject; does not influence daily activities; 
usually does not require intervention. 
• Moderate: The event may be of sufficient severity to make the subject uncomfortable, 
performance of daily activities may be influenced; intervention may be needed. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 70 of 128 
• Severe: The event may cause severe discomfort; usually interferes with daily activities: 
subject may not be able to continue in the trial; treatment or other intervention usually 
needed.  
• Medication administered to relieve symptoms of the AE will be recorded and the outcome of 
the AE will be recorded.   
For information on AEs from neurological assessments, laboratory findings, and wound healing 
refer to Sections 8.8, 8.5, and 8.15 respectively. 
9.5 
REPORTING ADVERSE EVENTS 
9.5.1 
Serious Adverse Event Reporting 
The Sponsor is under obligation to report certain SAEs to regulatory authorities related to 
investigational products in clinical trials. The Sponsor representative (medical monitor) must be 
notified within 24 hours when the Investigator determines that an AE meets the protocol 
definition (Section 9.1.4) of a SAE. 
The procedure for reporting SAEs is as follows: 
1) For fatal or life-threatening events, contact the Sponsor representative immediately by 
telephone: 
2) Within 24 hours of the Investigator’s knowledge of the event, 
 
 must be informed about all SAEs. A completed SAE report must be emailed to 
 within this 24-hour period.  
After receiving the SAE form, the Sponsor or
 may request 
additional information from the Investigator to ensure the timely completion of accurate safety 
reports. 
9.5.2 
Adverse Events of Special Interest  
Adverse Events of Special Interest (AESI) associated with LAST will also be collected in this 
trial and include the following:  
Central Nervous System Symptoms/Events:  


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 71 of 128 
• Tongue and perioral numbness 
• Tinnitus  
• Muscle fasciculations  
• Tremors  
• Seizures  
• Global CNS depression  
• Apnea (not sleep apnea) 
Cardiovascular Symptoms/Events:  
• Sinus bradycardia  
• Atrioventricular blocks 
• Conduction defects (prolonged PR or prolonged QRS)  
• Ventricular dysrhythmias  
• Cardiac arrest 
• Asystole 
Wound Healing Symptoms/Events 
• Wound dehiscence 
• Wound pus/purulent discharge (Grade 4 from Southampton Wound Scoring System) 
• Deep wound infection (Grade 5 from Southampton Wound Scoring System) 
• Cellulitis near the incision site (Grade 5 from Southampton Wound Scoring System) 
Should any AESI occur, the time of the event should be recorded, and a PK, Blood Chemistry 
and Hematology sample should be obtained as well as vital signs, neurological assessments, and 
a triplicate 12 lead ECG. Additionally, a consult with a doctor should occur.   
Should cardiotoxic events of LAST occur, a lipid emulsion should be available in the event the 
hospital/clinic/facility staff assess it is in the best interest of the subject. Should an AESI present 
after the subject has been discharged from the hospital/clinic the subject should return to the 
hospital/clinic/facility for further evaluation.      
9.5.3 
Suspected Unexpected Serious Adverse Reactions 
The Sponsor will determine if an SAE is a suspected, unexpected and serious adverse reaction 
(SUSAR). A SUSAR is a report of a SAE assessed to be possibly related to investigational 
medicinal product by either the Investigator or the clinical trial Sponsor and assessed to be 
unexpected (ie the nature or severity is not expected from the information provided) by the 
Sponsor. 


Allay Therapeutics, Inc 
 
Clinical Trial Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 72 of 128 
The Sponsor is required to submit a report about a SUSAR to regulatory/competent authorities 
and to Investigators participating in clinical trials where subjects are exposed to the 
investigational medicinal product. Reporting will be done in accordance with the applicable 
regulatory requirements.  
9.5.4 
Reporting of Adverse Events and Serious Adverse Events to the Investigational 
Review Board/Ethics Committee 
The Investigator must also comply with applicable requirements concerning reporting of SAEs to 
the IRB/EC that are new and have an impact on the continued ethical acceptability of the trial, or 
that may indicate the need for amendments to the trial protocol, including altered monitoring of 
safety. 
9.6 
PREGNANCY REPORTS 
An Investigator should immediately notify
 at 
 about pregnancy in a female clinical trial subject. 
Pregnancy will be captured on a pregnancy-specific form. 
The pregnancy must be followed up through the delivery or other fetal outcome. The Investigator 
shall promptly report to
 any abnormal fetal outcome, including 
congenital anomaly or birth defect, spontaneous or therapeutic abortion, still birth, premature 
birth, or other outcome other than live normal birth on an SAE form.   
9.7 
POSSIBLE ADVERSE EVENTS 
9.7.1 
Due to Bupivacaine 
Possible AEs: these events have been reported as side effects from bupivacaine use: 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 73 of 128 
• Allergic reaction (rare and may occur as 
a result of sensitivity to the local 
anesthetic) 
• Anaphylactic symptoms, severe 
asthmatic episodes 
• Angioneurotic edema (including 
laryngeal edema) 
• Anxiety  
• Atrioventricular block 
• Blurred vision  
• Bradycardia  
• Cardiac arrest 
• Cardiovascular collapse 
• Cardiovascular stimulations or 
cardiovascular depression  
• Changes in cardiac conduction 
• Chills  
• Confusion  
• Constrictions of the pupils  
• Convulsions  
• Decreased cardiac output  
• Depression 
• Depression of the myocardium  
• Dizziness 
• Drowsiness  
• Epinephrine/adrenaline response 
(increase in heart rate, and/or systolic 
blood pressure, circumoral pallor, 
palpitations. nervousness) 
• Erythema 
• Excitability 
• Fatality 
• Headache 
• Heart block  
• Hypotension  
• Hypertension 
• Impaired renal function 
• Nausea  
• Paresthesia 
• Peripheral vascular resistance 
• Persistent anesthesia  
• Prolonged severe hypertension 
• Pruritus 
• Refractoriness  
• Respiratory arrest  
• Respiratory depression  
• Respiratory paralysis 
• Restlessness 
• Severe persistent hypertension 
• Shivering  
• Sneezing  
• Syncope 
• Tachycardia 
• Tinnitus  
• Tremors 
• Unconsciousness 
• Under-ventilation or apnea  
• Urticaria 
• Ventricular arrhythmias  
• Ventricular fibrillation  
• Ventricular tachycardia  
• Vomiting 
• Weakness 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 74 of 128 
These events have been reported as side effects from bupivacaine use and are likely a result of 
the way bupivacaine was administered (eg injection) or due to the location of injection (eg 
head/neck area), they are unlikely to be associated with the use in this protocol; however, they 
have been listed below: 
• Arachnoiditis 
• Backache 
• Cranial nerve palsies 
• Fecal and urinary incontinence  
• Loss of cerebrospinal fluid 
• Loss of perineal sensation and sexual function  
• Loss of sphincter control 
• Meningism/meningismus 
• Paralysis 
• Paralysis of the lower extremities 
• Septic meningitis  
• Urinary retention 
Additional possible AEs related to anesthetic use include those in Section 9.5.2. 
 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 75 of 128 
9.7.2 
Due to General Surgery, TKA and Blood Collections 
Adverse Events related to general surgery, TKA, and blood collections are listed below: 
• Adhesions 
• Allergic reaction to suture or dressing 
• Altered leg length 
• Artificial joint failure or wear out 
• Bursitis 
• Bleeding/hemorrhage  
• Blood clots 
• Blood vessel (vascular) damage or injury 
• Broken bones (Femur, Tibia, Patella) 
• Bruising 
• Cellulitis 
• Complications for surgical anesthesia 
• Damage to neurovascular structures 
• Death 
• Delayed wound healing 
• Deep vein thrombosis (DVT) 
• Early failure  
• Erythema 
• Faintness  
• Hematoma 
• Incision site or knee infection 
• Infection 
• Infection at the blood draw site 
• Inflammation of the vein 
• Inflammation of the surgical site 
• Injury to muscle or soft tissue of the 
knee 
• Joint stiffness 
• Keloid like scar formation 
• Knee joint instability 
• Lung collapse 
• Myocardial infarction 
• Numbness  
• Nerve damage or injury 
• Pain 
• Pain or bruising at the site where blood 
is drawn 
• Prosthesis dislocation 
• Prosthesis failure 
• Pulmonary embolism 
• Thrombosis 
• Reaction to a blood transfusion 
• Re-operation and/or manipulation on the 
knee joint 
• Stroke 
• Stitch abscess (pus formation) 
• Swelling 
• Synovitis 
• Wound infection  
• Wound swelling, draining, or delayed 
healing


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 76 of 128 
10.0 
STATISTICS 
A comprehensive Statistical Analysis Plan will be developed for this trial. Demographic and 
baseline characteristics will be summarized descriptively by treatment group. Analysis methods 
presented in this statistics section applies to both Part A and Part B. Data from Part A and Part B 
will be analyzed separately. 
10.1 
SAMPLE SIZE CALCULATION 
Part A 
Approximately 165 subjects will be randomized with one (1) of the following three (3) treatment 
groups in a 1:1:1 ratio with approximately 55 subjects per group: 
• ATX-101, 1,000 mg dose (two ATX-101 implants)  
• ATX-101, 1,500 mg dose (three ATX-101 implants)  
• Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local 
periarticular infiltration or adductor canal block, or in combination  
Based on the literature review and discussion with experts in post-operative pain, it is believed 
that 55 subjects per group would provide sufficient information to inform dose response and dose 
selection for Part B. 
Part B 
Up to 140 subjects will be randomized to one (1) of the following two (2) treatment groups in a 
1:1 ratio with up to 70 subjects per group: 
• ATX-101 dose to be determined from Part A 
• Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg, via local 
periarticular infiltration or adductor canal block, or in combination  
The current planned sample size for Part B is up to 140 subjects. The actual number of subjects 
to be randomized will be determined based on data from Part A. 
10.2 
ANALYSIS POPULATIONS  
The Full Analysis Set (FAS) includes all subjects who are randomized and administered 
ATX-101 or bupivacaine HCl. Randomization failures (subjects who are randomized but did not 
receive investigational product) will be excluded from the FAS. The FAS will be used for the 
efficacy analyses and subject demographic and baseline characteristics. 
The Safety Analysis Set includes all subjects who are randomized and administered ATX-101 or 
bupivacaine HCl. Randomization failures (subjects who are randomized but did not receive 
investigational product) will be excluded from the Safety Analysis Set.  
The Safety Analysis Set will be used for all safety analyses. 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 77 of 128 
The PK Analysis Set includes all subjects who provide enough plasma samples for PK 
assessment of bupivacaine that allows for generation of at least one PK parameter of Tmax, Cmax, 
or AUC.   
10.3 
PRIMARY ENDPOINT ANALYSIS 
The primary efficacy endpoint will occur in Part B of the study and is the AUC for the NRS-R of 
pain intensity from 30 Minutes through a time point to be determined from Part A. The 
time-weighted AUC will be calculated using the trapezoidal rule based on the available NRS 
pain scores. Missing values will not be imputed with the exception of the final time point. The 
trapezoidal rule performs a linear interpolation between the 2 observed values on either side of a 
missing value. Actual times of each NRS-R score will be used for calculating the AUC. 
Prior to administration of rescue opioid medications, NRS-R scores will be recorded. The 
primary endpoint of AUC will be calculated with censoring pain scores after opioid use. NRS-R 
values will be censored for the duration of the effectiveness of rescue opioid medications. Actual 
durations of censoring will be dependent on each type of rescue opioid medication used. Detailed 
censoring durations for each type of rescue opioid medication will be documented in the 
Statistical Analysis Plan. 
The primary efficacy endpoint will be analyzed using an Analysis of Variance (ANOVA) model 
with a main effect of the treatment group. Summary statistics will be reported as well as the least 
square (LS) means, difference in the LS means, 95% confidence intervals (CI) and p-value for 
the contrast comparing the LS means. 
For Part B, the primary comparison will be between ATX-101 and bupivacaine HCl. A two-
sided alpha 0.05 will be spent on the primary comparison.  
For Part A, each dose of ATX-101 will be compared to the bupivacaine HCl group. In addition, 
the LS mean of each dose level group will be plotted with 95% CI to evaluate dose response. The 
AUC for the NRS-R of pain intensity from 30 Minutes through Hour 168 (Day 8 of the trial) will 
be evaluated. 
10.4 
KEY SECONDARY ENDPOINT ANALYSIS FOR PART B 
10.4.1 
Type I Error Control Procedure 
A stepdown procedure will be used to control the type I error. If the primary comparison for the 
primary endpoint is statistically significant, comparisons between ATX-101 and bupivacaine 
HCl for the key secondary endpoints will be carried out in the order shown below. Comparisons 
will be stopped once any proceeding comparison is not statistically significant. 
1. Area under the curve for NRS-R of pain intensity from 30 Minutes through Hour 168 
(Day 8 of the trial) 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 78 of 128 
2. Area under the curve for NRS-R of pain intensity from 30 Minutes through Hour 240 
(Day 11 of the trial) 
3. Area under the curve for NRS-R of pain intensity from 30 Minutes through Hour 336 
(Day 15 of the trial) 
4. Percentage of subjects who remain opioid free from Hour 72 through Day 30 
5. Total post-surgical consumption of opioid medications from surgical closure through 
Day 30 
10.4.2 
Area Under the Curve for Numeric Rating Scale at Rest of Pain Intensity from 
30 Minutes through Hours 168, 240, and 336 
The AUC of the NRS-R will be calculated from 30 Minutes through Hour 168 (Day 8 of the 
trial), Hour 240 (Day 11 of the trial), and Hour 336 (Day 15 of the trial) using the trapezoidal 
method as described in the primary endpoint section. Data will be analyzed using the same 
ANOVA model as in the analysis of the primary endpoint. Comparisons between ATX-101 and 
bupivacaine HCl will be carried out in the following order: Hour 168, Hour 240, and Hour 336. 
10.4.3 
Percentage of Subjects Who Remain Opioid Free from Hour 72 Through Day 30 
The percentage of subjects opioid free from Hour 72 through Day 30 will be analyzed using 
Fisher’s exact test. The number of subjects, percentage, and percentage difference between 
treatment groups will be summarized and their associated 95% CI will also be provided. 
10.4.4 
Total Post-Surgical Consumption of Opioid Medications from Surgical Closure 
Through Day 30 
For total post-surgical consumption of opioid medication, all opioids will be converted to an 
equianalgesic parenteral morphine amount (milligram morphine equivalent or MME) using 
standard conversion factors as laid out by the Center of Disease Control (CDC) [21]. Total 
post-surgical consumption of rescue opioid medications from surgical closure through Day 30 
will be analyzed using the Wilcoxon rank-sum test. 
10.5 
SECONDARY ENDPOINT ANALYSIS 
Secondary endpoints will be analyzed in Part A and Part B of the trial.  
10.5.1 
Area Under the Curve for Numeric Rating Scale at Rest for Each 24-Hour 
Period Through Hour 336 
The AUC of the NRS-R for pain intensity will be calculated for each day and cumulatively 
through the end of each day using the trapezoidal method as described in the primary endpoint 
section. Data will be analyzed using the same ANOVA model as in the analysis of the primary 
endpoint.  


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 79 of 128 
10.5.2 
Percentage of Subjects Opioid Free 
The percentage of subjects who remain opioid free from surgical closure to Day 30, from Hour 
72 (Day 4) to Day 30, Hour 96 (Day 5) to Day 30, Hour 168 (Day 8) to Day 30, Hour 336 (Day 
15) to Day 30 and Hour 504 (Day 22) to Day 30 will be evaluated. Opioid free data will be 
analyzed using Fisher’s exact test. The number of subjects, percentage, and percentage 
difference between treatment groups will be summarized by treatment group and associated 95% 
CI will be provided. 
10.5.3 
Total Post-Surgical Consumption of Opioids 
Opioid consumption will be summarized descriptively every 24-hour period through Day 30 and 
total opioids consumed over 30 days. In addition, opioid consumption will also be analyzed from 
the time of surgical closure to Hour 48 (Day 3), Hour 72 (Day 4), Hour 96 (Day 5), Hour 168 
(Day 8), Hour 336 (Day 15), and Day 30 using the Wilcoxon rank-sum test.   
10.5.4 
Time to First Rescue Opioid Medication 
The time to the first post-surgical rescue opioid medication will be calculated. Data will be 
summarized using the Kaplan Meier method and displayed graphically where appropriate. 
Confidence intervals for the 25th, 50th, and 75th percentiles will be reported. The Cox 
proportional hazards model will be fitted to compute the treatment hazard ratios and the 
corresponding 95% CI.   
10.6 
SAFETY ENDPOINTS 
Safety endpoints will be analyzed in Part A and Part B of the trial. 
10.6.1 
Adverse Events 
AEs verbatim descriptions will be coded using a current version of the Medical Dictionary for 
Regulatory Activities (MedDRA). A treatment emergent adverse event (TEAE) is defined as an 
AE that is new or worsening after the subject has received the investigational product. 
Summaries of incidence rates (frequencies and percentages) of TEAEs by MedDRA system 
organ class (SOC) and preferred term, by maximum severity, and by strongest relationship to 
investigational product and TKA surgical procedure will be provided. SAEs by MedDRA SOC 
and preferred term will also be provided. A subject will be counted only once by the highest 
severity grade within a SOC and preferred term, even if the subject experienced more than 1 
TEAE within a specific SOC and preferred term.  
Summaries of incidence rates (frequencies and percentages) of individual AESIs by MedDRA 
SOC and preferred term will be provided.  
All AEs, SAEs, and AESIs will be listed by subject. 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 80 of 128 
10.6.2 
Wound Healing Assessment 
The Southampton Wound Scoring System will be used to evaluate wound healing. Wound 
healing grades on Day 15, 22, 30, and 56 will be summarized descriptively.   
10.6.3 
Pharmacokinetic Analysis 
Individual concentrations of bupivacaine will be listed, graphed, and summarized by scheduled 
sampling time. Bupivacaine concentration will be summarized at each sampling timepoint using 
descriptive statistics.   
The PK parameters will be estimated using non-compartmental PK analysis for each subject with 
sufficient data to characterize the administered dose. The overall PK parameters for plasma 
bupivacaine will be presented (AUClast, AUC0-∞, Cmax, Tmax, T1/2) as well as dose specific PK 
parameters (Cmax, AUC) for each ATX-101 dose. Additional parameters will be detailed in the 
PK analysis plan. Actual sampling times will be used to calculate plasma-derived PK parameters. 
These parameters will be summarized by dose for comparison and a mean concentration figure 
with plots for each level of the ATX-101 doses and will be produced both with a linear y-axis 
and with a log y-axis. A PK analysis plan will detail the specific PK analyses. 
The PK analyses and PK report will be presented in a separate analytical report (Bioanalytical 
Report) and PK report. 
10.7 
EXPLORATORY ENDPOINTS 
Exploratory endpoints will be analyzed in Part A and Part B of the trial. Exploratory endpoints 
are defined below. Continuous endpoints will be summarized using descriptive statistics (number 
of participants, mean, standard deviation [SD], median, and maximum values) for by treatment 
group and trial visit, as appropriate. Categorical endpoints will be summarized as the number and 
percentage of participants per category by treatment group and trial visit, as appropriate. Time-
to-event endpoints will be summarized using the Kaplan Meier method by treatment group. 
• Percentage of subjects reporting being pain free on the NRS-R of pain intensity 
• Time to various degrees of flexion and extension  
• Reduction/incidence of opioid-related AEs 
• Evaluation of Quality of Recovery (QOR-15) 
• Evaluation of Knee Injury and Osteoarthritis Outcome Score for Joint Replacement 
(KOOS, JR) 
• Difference in pain intensity scores (NRS-R and NRS-A) between treatment groups  
• If a statistical difference in AUC of pain intensity NRS-R at 15 days is observed, the AUC 
for the NRS-R of pain intensity will be further evaluated between Days 16 and 30  
• Evaluation of the Knee Society Score 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 81 of 128 
10.8 
OTHER SAFETY ANALYSIS 
10.8.1 
Clinical Laboratory Tests 
Clinical laboratory (e.g., hematology and clinical chemistry) values will be evaluated for each 
laboratory parameter as appropriate. Abnormal laboratory values will be flagged and identified 
as outside (above or below) the normal range. Reference (normal) ranges for laboratory 
parameters will be provided. 
Descriptive summary statistics (eg, n, mean, SD, median, minimum, and maximum for 
continuous variables; n [%] for categorical variables) for laboratory parameters and their changes 
from baseline will be calculated. Laboratory values will be summarized by visit. 
10.8.2 
Electrocardiograms 
ECG data (12-lead) will be summarized and will be listed by subject and visit. 
10.8.3 
Vital Signs 
Descriptive summary statistics for vital sign parameters (systolic and diastolic blood pressure, 
pulse rate, body temperature, and oxygen saturation) and changes from baseline will be 
presented by visit.   
Vital signs data will be listed by subject and visit. 
10.8.4 
Physical Examination and Neurological Assessment Findings 
Physical examination and neurological assessment findings will be displayed in listings.   
10.8.5 
Patient Health Questionnaire 9 
Data from the screening PHQ-9 questionnaire will be presented in a subject listing.  
10.8.6 
Treatment Exposure and Disposition 
Exposure to treatment will be summarized descriptively. Summary tables for subject disposition 
and population assignment will be provided. 
10.8.7 
Interim Analysis 
For Part A, an interim analysis may be performed when approximately 50% of the initially 
planned enrollment has completed Day 30.  Enrollment will continue during the interim analysis. 
This interim analysis will be performed by the unblinded statistician separate from the team 
responsible for the conduct and analysis of the study. A Review Committee of at least two 
unblinded statisticians and a designated sponsor representative will review the data and 
recommend one of the following: 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 82 of 128 
• Keep the current sample size and continue Part A as planned 
• Stop Part A for efficacy (no further enrollment) 
• Increase the sample size in Part A  
The basis of this decision will be whether sufficient data have been collected to plan Part B, 
taking into account both safety and efficacy (including outcomes other than the primary). All 
part A data will be evaluated. In particular, data pertaining to selection of Part B primary 
endpoint, eg treatment effect and primary endpoint variability, will be evaluated for the planning 
of Part B.    
The Sponsor may make adjustments other than those detailed above; however, the blinded 
Sponsor team will receive no information other than the recommendations listed. If the interim 
analysis demonstrates sufficient data have been collected to plan Part B, then Part A may be 
stopped, unblinded and the final analysis will be completed on the population enrolled to date. 
Full details of the interim analysis will be described in a separate document including data 
available to the Review Committee, timing, and communication procedures. The designated 
sponsor representative will not participate in ongoing study conduct once unblinded to study 
results and will not have access to individual patient treatment assignments. Should Part A 
continue to full enrollment they likewise will be blinded to assignments and results until the final 
unblinding and analysis. 
11.0 
ETHICS 
This trial will be conducted in the hospital/facility, clinic, in the subject’s home, physical therapy 
facility, or other similar location, as agreed to by the subject and the trial staff under the 
supervision of medical personnel experienced in conducting clinical studies. The trial will be 
conducted in accordance with the International Conference on Harmonization (ICH) Guideline 
E6: Good Clinical Practice (GCP). 
11.1 
ETHICAL CONDUCT OF THE TRIAL 
The trial will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki (2013 revision) and are consistent with ICH Guideline E6: GCP and 
applicable regulatory requirements.   
11.2 
INVESTIGATIONAL REVIEW BOARD/ ETHICS COMMITTEEREVIEW 
The Investigator shall assure that an IRB/EC, constituted in accordance with ICH Guideline E6: 
GCP, or other federal or local guidelines, will provide initial and continuing review of the trial. 
The final trial protocol, including the final version of the informed consent, must be approved or 
given a favorable opinion in writing by an IRB/EC as appropriate. Prior to shipment of the 
investigational product and enrollment of trial subjects, documented IRB/EC approval of the 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 83 of 128 
protocol, informed consent, subject questionnaires/surveys, subject training, and any 
advertisement for subject recruitment (if used) must be obtained and provided to Allay or its 
designee(s). The written consent form which describes the trial with sufficient information for 
the subject to make an informed decision about his/her participation will be obtained before that 
subject begins any trial specific procedure. It must be signed by the subject and the Investigator-
designated healthcare professional obtaining the consent, and a copy of the signed document 
provided to the subject. 
The Investigator is responsible for informing the IRB/EC in accordance with local requirements 
of any amendment to the protocol or any changes in research activity (ie, completion, 
termination, or discontinuation of a trial) prior to implementation. In addition, the IRB/EC must 
approve all advertising used to recruit subjects for the trial. The protocol must be re-approved by 
the IRB/EC upon receipt of amendments and annually, as local regulations require.  
The Investigator is also responsible for providing the IRB/EC with reports of any reportable 
serious adverse reactions from any other trial conducted with the investigational product. Allay 
will provide this information to the Investigator. 
Progress reports and notifications of serious adverse drug reactions will be provided to the 
IRB/EC according to local regulations and guidelines. 
12.0 
ADMINISTRATIVE CONSIDERATIONS 
12.1 
RECORDING DATA 
The Investigator is required to initiate and maintain an adequate and accurate case history for 
each subject, capturing all clinical trial observations and other data. Data must be recorded in the 
designated CRFs approved by Allay. The Investigator or his/her qualified designee will enter all 
applicable data from the source documents into the appropriate portions of the CRFs. All 
information recorded on the CRFs for this clinical trial must be consistent with the subject’s 
source documentation. 
An electronic data capture (EDC) system will be used for entry of the data into CRFs. Entry and 
changes to the data will be made only by users authorized by Allay, and data entries and changes 
will be captured in an electronic audit trail. An explanation of any data change should be 
recorded in the CRF. 
The clinical trial data will be entered into a secure, validated data processing system, and a 
backup will be maintained. Any changes to the clinical trial data will be documented.  
12.2 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
12.2.1 
Trial Monitoring 
Allay or its designee will assign a Monitor to maintain contact with the Investigator and will visit 
the trial site for the purpose of discussing and/or reviewing data. 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 84 of 128 
A site initiation visit will be conducted by Allay or designee and, if available, the Monitor to 
discuss the protocol and the obligations of both the Sponsor and the Investigator. The 
Investigator must allow the Monitor to perform periodic, interim monitoring visits. The purposes 
of these visits are to: 
• Verify that signed and dated informed consent was obtained prior to each subject’s 
participation in the trial 
• Assess the progress of the trial 
• Review compliance with the trial protocol 
• Determine whether all AEs were appropriately reported 
• Determine whether the Investigator is maintaining the essential documents 
• Discuss any emergent problem 
• Check the CRF for accuracy and completeness 
• Validate the contents of the CRF against source documents 
• Perform drug accountability and assess the status of investigational product and storage, 
dispensing and destruction 
• Ensure the blind has been maintained 
All data required by the protocol must be reported accurately on the CRF and must be consistent 
with the source documents. Source documents are original documents, data and records (eg, 
hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, 
copies or transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, X-rays, ECGs or other diagnostic images, 
subject files, pharmacy records, and laboratory records). The Investigator will make available the 
source documentation for inspection. The information will be considered confidential and treated 
as such. 
The Monitor will perform a close-out visit at the conclusion of the Investigator’s involvement in 
the trial. 
The Clinical Monitoring Plan contains more complete details with regard to monitoring of this 
trial and specific duties of the blinded and unblinded monitors. 
12.2.2 
Audits and Inspection 
The trial may be evaluated by representatives of the US Food and Drug Administration (FDA), 
other government agencies, or national health agencies (where applicable), the IRB/EC, other 
national health authorities or the Sponsor who will be allowed access to trial documents.   


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 85 of 128 
All authorized personnel, including health authority inspector(s), Sponsor and designees, 
monitor(s), and auditor(s) will be given direct access to source data and documentation (eg, 
medical records, laboratory results, etc.) for source data verification, provided that subject 
confidentiality is maintained. 
The Investigator should promptly notify Allay of any audits scheduled or results of any 
unscheduled investigations performed by regulatory authorities. 
12.3 
QUALITY CONTROL AND QUALITY ASSURANCE 
The protocol shall be conducted as described unless there is a change that is intended to 
eliminate an apparent immediate hazard to the subject. Any such change must be reported 
immediately to Allay and the IRB/EC in accordance with IRB/EC requirements.   
Allay may conduct a quality assurance audit at its discretion. 
12.3.1 
General Responsibilities 
The trial will be conducted in full compliance with the Declaration of Helsinki (2013 revision), 
ICH Guideline E6: GCP, and any applicable national and local laws and regulations. 
The Investigator is responsible for distributing trial information and documentation to all 
appropriate staff members prior to and during the course of the trial as updated information 
becomes available. 
The Investigator is responsible for ensuring the privacy, health, and welfare of the subjects 
during and after the clinical trial and must ensure that fully functional resuscitation equipment 
and personnel trained in its use are immediately available in the event of an emergency. 
The Investigator must be familiar with the background and requirements of the trial and with the 
properties of the investigational product as described in the current version of the IB and 
prescribing information for the active comparator. 
The Investigator has the overall responsibility for the conduct and administration of the trial at 
the clinical site and for contacts with the Sponsor, IRB/EC, and local authorities. 
The Investigator is responsible for performing the trial in accordance with the protocol and the 
above guidelines and regulations, and for collecting, documenting, and reporting the data 
accurately. 
Data relating to the trial will be recorded in CRFs prepared by Allay or its designee. Data must 
be entered into the CRFs in English. The CRFs are to be completed at the time of the subject’s 
visit, with the exception of results of tests performed outside of the Investigator’s office, so that 
they always reflect the latest observations on the subjects participating in the trial. All CRFs 
should be entered in a timely fashion after each assessment.   


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 86 of 128 
The Investigators must verify that all data entries in the CRF are accurate and correct. All CRF 
entries, corrections and alterations must be made by the Investigator or other, authorized, 
trial-site personnel and only by individuals who have been trained on the CRF completion 
requirements for this trial, and who are using their own password/passcode for the electronic 
CRF system. 
The completed CRFs will be reviewed against source documents by the monitor at each 
monitoring visit. If any data, signatures, or form are missing or incorrect, the Investigator will be 
informed and corrections will be made. 
12.3.2 
Retention of Records 
The Investigator shall retain all trial related documentation, including the following: 
• Source data, including tracings, computer discs, or tapes 
• Investigator’s Brochure 
• Source Documents 
• Completed SAE forms 
• Protocol and amendment(s) 
• Drug accountability records 
• Regulatory documents and correspondence 
• Signed informed consents 
• Subject identification lists 
• Correspondence 
The Investigator will retain the trial documents for at least 2 years after the approval date for 
marketing the product in an ICH region and until there are no pending or contemplating 
marketing applications in any region or until 2 years after the investigational use of the 
investigational product is discontinued or 25 years, whichever is longer. If the Investigator leaves 
the institution, the records shall be transferred to an appropriate designee who accepts the 
responsibility for records retention. Written notice of transfer of documentation shall be provided 
to Allay. The Investigator must obtain written permission from Allay before destroying any trial 
documents. 
All changes to trial records should be documented and traceable. The media used to store trial 
documents should be in a form that keeps the documents complete and legible through the 
required retention period. All trial documents should be readily available, upon request, to Allay 
or designee and regulatory authorities. 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 87 of 128 
12.3.3 
Protocol Compliance 
This trial will be conducted in compliance with the protocol approved by the IRB/EC and 
according to current ICH Guideline E6: GCP standards. No deviation from the protocol will be 
implemented without the prior review and approval of the Sponsor except where it may be 
necessary to eliminate an immediate hazard to a research subject. In such a case, the deviation 
will be reported to Allay and the IRB/EC as soon as possible. 
Protocol amendments will be prepared and approved by the Sponsor or designee. All protocol 
amendments will be signed by the Investigator and submitted to the IRB/EC for review and 
approval prior to implementation. Documentation of IRB/EC approval must be forwarded to the 
Sponsor or designee. 
If an amendment significantly alters the trial design, increased potential risk to the subject, or 
otherwise affects statements in the informed consent, it must be revised accordingly and 
submitted to the IRB/EC for review and approval. The approved consent form must be signed by 
all new subjects and ongoing subjects if they are affected by the amendment or if the amendment 
contains new safety information or as required by the IRB/EC. 
12.3.4 
Subject Informed Consent 
The consent form must be approved by the IRB/EC and must contain all elements required by 
federal, state, local, and institutional regulations or requirements. 
The trial, including its objective, methods, and potential risks of subjects, will be completely 
explained to each prospective trial subject. It will also be explained to each subject that s/he is 
free to refuse entry or to withdraw from the trial at any time without prejudice to future 
treatment. Voluntary informed consent must be obtained from each eligible subject prior to 
screening for the trial (ie, before any protocol-defined procedures are performed). 
The subject’s willingness to participate will be documented in writing on the IRB/EC approved 
informed consent form, which will be signed and dated by the subject and the trial Investigator 
or designee. The Investigator will keep the original signed informed consent form, and a copy 
will be given to the subject. 
12.4 
LABORATORY ACCREDITATION 
A central laboratory facility will be used for analysis of clinical laboratory samples obtained 
under this protocol. The laboratory will demonstrate adequate licensure and accreditation. 
Reference ranges for all parameters will be available.   
12.5 
CONFIDENTIALITY REGARDING TRIAL SUBJECTS 
The Investigator must assure that the privacy of the subjects, including their identity and all 
personal medical information, will be maintained at all times. In the CRFs and other documents 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 88 of 128 
(laboratory reports, etc) submitted to the Sponsor, subjects will not be identified by name but by 
an identification code (eg, initials and subject identification numbers). 
Personal medical information will always be treated as confidential. 
12.6 
PUBLICATION POLICY 
By conducting this trial, the Investigator affirms to Allay that s/he will maintain, in strict 
confidence, information furnished by Allay or any representatives, including data generated from 
this trial, except as exempted for regulatory purposes. 
All data generated during the conduct of this trial is owned by Allay and may not be used by the 
Investigator or affiliates without the express written consent of Allay. 
Allay intends to have all trial results published in due course after completion of the trial and 
regulatory submission. All manuscripts, abstracts, or other presentation materials will be 
reviewed, and approved by Allay, prior to submission. Allay will have 90 calendar days to 
review and approve (in writing) the release of manuscripts, abstracts, and other presentation 
materials. This will allow Allay to protect proprietary information and allow both parties to 
provide comments based upon information that may not yet be available to the other.   
13.0 
APPENDICES 




Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 90 of 128 
a. In clinic visits may also be completed at a physical therapy facility or in the clinic/hospital/facility as long as all procedures can be conducted. 
b. Home visits may be completed at the subject’s home, a physical therapy facility, in the clinic/hospital/facility, or any other place agreed upon by the trial staff and the 
subject.  
c. Vitals signs include pulse, temperature, respiratory rate, systolic/diastolic blood pressure and oxygen saturation. Vital signs will be collected after the subject has been 
supine for 5 minutes. 
d. Physical examination is conducted at the Screening Visit and Day 56 Visit. The Screening Visit will record Kellgren Lawrence Classification (to classify severity of knee 
osteoarthritis), varus, valgus, and evaluation of ipsilateral hip osteoarthritis.  
e. ECGs will be taken in triplicate (2 minutes apart [±1 minute]) after the subject has been at rest in a supine position for 10 minutes without any other assessments being 
conducted. ECGs will be taken BEFORE PK sampling. 
f. Chemistry/Hematology are non-fasting and will be analyzed at a central lab. Chemistry tests include sodium, potassium, creatinine, creatinine clearance, albumin, ALP, 
total and direct bilirubin, AST, ALT, BUN, creatinine kinase, GGT, and phosphate. Hematology tests include hemoglobin, hematocrit, white blood cell count (total and 
differential), red blood cell count and platelet count. 
g. Urine Drug Screen is performed to include but not limited to opiates (including oxycodone), amphetamines, methadone, barbiturates, benzodiazepines, cocaine, 
phencyclidine, methamphetamine, ecstasy/MDMA, tricyclic antidepressant, and cannabinoids at the Screening Visit and at the Day 15 Visit. On Day 1, the subject will be 
tested for opiates only by urine dipstick (Section 8.5.3). 
h. The pregnancy test is only for females of child-bearing potential. The Screening Visit and Day 56 pregnancy test will be via urine.  
i. Range of motion assessment will be conducted using a goniometer and will evaluate flexion and extension of the knee. 
j. Neurological Assessments will determine if the patient has any symptoms of LAST by asking if they have had any changes to their senses (ears/hearing, sight, touch, smell, 
or taste). The neurological assessments will have a gross motor and sensory exam conducted with a focus on the lower extremities. Motor examinations will focus on distal 
lower extremities dorsi flexion and plantar flexion of the foot (ankles and toes) against resistance. The gross sensory examination should focus on intact sensory 
examination to touch in the dorsal and plantar side of the foot. 
k. Formal e-diary training must occur prior to surgery. Through the duration of the trial e-diary questions and concerns from the subject will be addressed and re-training will 
occur if needed at any time during the trial. 
l. If a provisioned e-diary is used by the subject, it will be dispensed on Day 1 before surgery and returned on the Day 30 Visit. The assessments conducted on the e-diary at 
the Screening Visit and Day 56 Visit may occur using an e-diary maintained by the site. If the subject early terminates before the Day 30 Visit, the e-diary will be returned 
at the Early Termination Visit. If the subject’s own device is used, the site staff will work with the subject to have the e-diary set-up before the subject has surgery.      
m. Subject pain score training will occur at the Screening Visit, on Day 1 before surgery, on Day 2, Day 3, and after Day 15. If needed, pain score training can occur anytime 
during the trial that the subject has questions or as determined by the site staff. Standardized pain score training will be conducted by the site staff or through training 
videos. 
n. Prior and concomitant medication usage is recorded from 30 days before the Screening Visit through Day 56 or Early Termination. At the Day 15 Visit, Day 30 Visit, and 
Early Termination Visit (if on or before Day 30) accountability of prescribed opioids will occur. 
o. Randomization for allocation of investigational product may occur up to one business day before surgery. 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 91 of 128 
p. Pharmacokinetic sampling will occur on Day 1 before surgery (before bupivacaine spinal), during surgery prior to administration of ATX-101 or the bupivacaine HCl  (-10 
minutes), then after surgical closure at Hour 6 (± 30 minutes), Hour 12 (± 1 hour), and on Days 2 (24 Hour), 3 (48 Hour), 4 (72 Hour), 5 (96 Hour), 6, 8, 15, 22, and 30. PK 
sampling will also occur at the Early Termination Visit if on or before the Day 30, as well as anytime the subject has an SAE or AESI. It is requested, if possible, that the 
PK samples from Days 6 to 15 are collected at approximately the time of surgical closure on Day 1. 
q. The Southampton Wound Scoring System (Appendix I) will be used to evaluate the TKA surgical wound for each subject.  
r. The Knee Society Score (Appendix J) will be used to evaluate the subject’s knee joint and function. 
s. Adverse Events are collected from the time of investigational product administration and through Day 56 or Early Termination. If an AESI or SAE occurs, then 
neurological assessment, vital signs, 12-lead ECG, Chemistry, Hematology, and PK sampling must occur.  
t. Subject self-administered e-diary questionnaires/surveys will be completed. NRS pain intensity scales include both at rest (NRS-R) and activity (NRS-A). Each time rescue 
opioid medications are taken, the NRS-R scale for pain intensity must be completed along with opioid type, dose, and time. Refer to Appendix C for further details on 
frequency of collection.  
 
 
 
 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 92 of 128 
Part A Schedule of Events for Day of Surgery Through Hour 96 (Day 5) 
Procedure 
 
Day of Surgery (Day 1) 
Day 2 
Day 3 
Day 4 
Day 5 
Before 
Surgery 
During 
Surgery 
30 Min 
& 1 
Hour 
3 
Hour 
6 
Hour 
9 
Hour 
12 
Hour 
18 
Hour 
24 
Hour 
30, 36 
& 42 
Hour 
48 
Hour 
54, 60, 
66 Hour 
72 
Hour 
78, 84, 
90 Hour 
96 Hour 
Window 
Before 
Spinal 
-10 min 
±10 min 
±30 
min 
±30 
min 
±1 
hour 
±1 
hour 
±2 
hour 
±2 
hour 
±2 
hour 
±2 
hour 
±2 hour 
±2 
hour 
±2 hour 
±2 hour 
96 Hour In-Patient Perioda 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Update Medical History 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review Entry Criteria 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vital Signsb 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
12 Lead ECGc 
X 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Drug Screend 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum or Urine Pregnancy 
Teste 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Range of Motion 
Assessmentf 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
Neurological Assessmentsg 
X 
 
 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
e-diary Trainingh 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e-diary Dispensation/Returni 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject NRS Pain Score 
Training for Pain Intensityj 
X 
 
 
 
 
 
 
 
X 
 
X 
 
 
 
 
Concomitant Medications 
and Opioid Accountabilityk 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Randomization and 
Investigational Product 
Allocationl 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacokinetic Samplingm 
X 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Investigational Product 
Administrationn 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse Eventso 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Subject Self-Administered 
Questionnaires/Surveysp 
X 
 
X 
X 
X 
X 
X 
X 
X 
Refer to Appendix C for frequency of self-administered 
e-diary questionnaires/surveys 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 93 of 128 
a. Subjects will remain under observation until Hour 96. Subjects may remain in the hospital/facility for 96 hours or may be discharged from the hospital/facility per standard 
of care and moved to another unit until the conclusion of the 96-hour in-patient monitoring period. 
b. Vitals Signs include pulse, temperature, respiratory rate, systolic/diastolic blood pressure and oxygen saturation. In a 24-hour period, vital signs can only be missed one 
time for the subject sleeping. Vital signs will be collected after the subject has been supine for 5 minutes. 
c. ECGs will be taken in triplicate (2 minutes apart [±1 minute]) after the subject has been at rest in a supine position for 10 minutes without any other assessments being 
conducted. ECGs will be taken BEFORE PK sampling.   
d. Urine Drug Screen is performed on Day 1 before surgery for opiates only by urine dipstick (Section 8.5.3). 
e. The pregnancy test is only for females of child-bearing potential. The Day 1 pregnancy test may be done via serum or urine per hospital standard of care. If females of 
child-bearing potential would not normally be tested on the day of surgery, then a urine pregnancy test will be conducted.   
f. Range of motion assessment will be conducted using a goniometer and will evaluate flexion and extension of the knee. 
g. Neurological Assessments will determine if the patient has any symptoms of LAST by asking if they have had any changes to their senses (ears/hearing, sight, touch, smell, 
or taste). The neurological assessments will have a gross motor and sensory exam conducted with a focus on the lower extremities. Motor examinations will focus on distal 
lower extremities dorsi flexion and plantar flexion of the foot (ankles and toes) against resistance. The gross sensory examination should focus on intact sensory 
examination to touch in the dorsal and plantar side of the foot. In the first 24-hour period, the neurological assessments can only be missed one time for the subject sleeping. 
h. Formal e-diary training must occur prior to surgery. Through the duration of the trial e-diary questions and concerns from the subject will be addressed and re-training will 
occur if needed at any time during the trial. 
i. If a provisioned e-diary is used by the subject, it will be dispensed on Day 1 before surgery and returned on the Day 30 Visit. If the subject early terminates before the Day 
30 Visit, the e-diary will be returned at the Early Termination Visit. If the subject’s own device is used, the site staff will work with the subject to have the e-diary set-up 
before the subject has surgery.      
j. Subject pain score training will occur at the Screening Visit, on Day 1 before surgery, on Day 2, Day 3, and after the Day 15. If needed, pain score training can occur 
anytime during the trial that the subject has questions or as determined by the site staff. Standardized pain score training will be conducted by the site staff or through 
training videos. 
k. Prior and concomitant medication usage is recorded from 30 days before the Screening Visit through Day 56 or Early Termination.  
l. Randomization for allocation of investigational product may occur up to one business day before surgery. 
m. Pharmacokinetic sampling will occur on Day 1 before surgery (before bupivicaine spinal), during surgery prior to administration of ATX-101 or the bupivacaine HCl  (-10 
minutes), then after surgical closure at Hour 6 (±30 minutes), Hour 12 (±1 hour), and on Days 2 (Hour 24), 3 (Hour 48), 4 (Hour 72), 5 (Hour 96), 6, 8, 15, 22, and 30. PK 
sampling will also occur at the Early Termination Visit if on or before the Day 30, as well as anytime the subject has an SAE or AESI. It is requested, if possible, that the 
PK samples from Days 6 to 15 are collected at approximately the time of surgical closure on Day 1. 
n. ATX-101 or bupivacaine HCl administration will only occur during the surgical procedure and prior to initiating capsule closure. ATX-101 will be placed in the knee 
capsule following fixation of the knee implant prosthesis when tissue will not be disrupted any further by surgery, after any betadine or saline rinse and after suction has 
occurred. 
o. Adverse Events are collected from the time of investigational product administration and through Day 56 or Early Termination.  


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 94 of 128 
p. Subject self-administered e-diary questionnaires/surveys will be completed. NRS pain intensity scales include both at rest (NRS-R) and activity (NRS-A). Each time rescue 
opioid medications are taken, the NRS-R scale for pain intensity must be completed along with opioid type, dose, and time. Refer to Appendix C for further details on 
frequency of collection.  
 
 






Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 97 of 128 
l. 
If a provisioned e-diary is used by the subject it will be dispensed on Day 1 before surgery and returned on the Day 30 Visit. The assessments conducted on the e-diary at 
the Screening Visit and Day 56 Visit may occur using an e-diary maintained by the site. If the subject early terminates before the Day 30 Visit the e-diary will be returned 
at the Early Termination Visit. If the subject’s own device is used the site staff will work with the subject to have the e-diary set-up before the subject has surgery. 
m. Subject pain score training will occur at the Screening Visit, on Day 1 before surgery, on Day 2, Day 3, and after the Day 15. If needed, pain score training can occur 
anytime during the trial that the subject has questions or as determined by the site staff. Standardized pain score training will be conducted by the site staff or through 
training videos. 
n. Prior and concomitant medication usage is recorded from 30 days before the Screening Visit through Day 56 or Early Termination. At the Day 15 Visit, Day 30 Visit, and 
Early Termination Visit (if on or before the Day 30) accountability of prescribed opioids will occur. 
o. The Southampton Wound Scoring System (Appendix I) will be used to evaluate the TKA surgical wound for each subject.  
p. The Knee Society Score (Appendix J) will be used to evaluate the subject’s knee joint and function. 
q. Adverse Events are collected from the time of first investigational product administration and through the Day 56 or Early Termination Visit.  
r. 
PK sampling is required any time a subject has an SAE or AESI. ECGs will be taken BEFORE PK sampling. 
s. 
Subject self-administered e-diary questionnaires/surveys will be completed. NRS pain intensity scales include both at rest (NRS-R) and activity (NRS-A). Each time 
rescue opioid medications are taken, the NRS-R scale for pain intensity must be completed along with opioid type, dose, and time. Refer to Appendix C for further details 
on frequency of collection.   
 
 
 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 98 of 128 
 
a. Subjects will remain under observation until Hour 24.  
b. Vitals Signs include pulse, temperature, respiratory rate, systolic/diastolic blood pressure and oxygen saturation. In the 24-hour period, vital signs can only be missed one 
time for the subject sleeping. Vital signs will be collected after the subject has been supine for 5 minutes. 
c. Urine Drug Screen is performed on Day 1 before surgery for opiates only by urine dipstick (Section 8.5.3). 
d. The pregnancy test is only for females of child-bearing potential. The Day 1 pregnancy test may be done via serum or urine per hospital standard of care. If females of 
child-bearing potential would not normally be tested on the day of surgery, then a urine pregnancy test will be conducted.   
e. Range of motion assessment will be conducted using a goniometer and will evaluate flexion and extension of the knee. 
f. Neurological Assessments will determine if the patient has any symptoms of LAST by asking if they have had any changes to their senses (ears/hearing, sight, touch, smell, 
or taste). The neurological assessments will have a gross motor and sensory exam conducted with a focus on the lower extremities. Motor examinations will focus on distal 
lower extremities dorsi flexion and plantar flexion of the foot (ankles and toes) against resistance. The gross sensory examination should focus on intact sensory 
examination to touch in the dorsal and plantar side of the foot. In the first 24-hour period, the neurological assessments can only be missed one time for the subject sleeping. 
Part B Schedule of Events for Day of Surgery Through Hour 24 (Day 2) 
Procedure 
Day of Surgery (Day 1) 
Day 2 
Before Surgery 
During Surgery 
30 Min & 1 Hour 
3 & 6 Hour 
9 & 12 Hour 
18 Hour 
24 Hour 
Window 
Before Spinal 
-10 min 
±10 min 
±30 min 
±1 hour 
±2 hour 
±2 hour 
24 Hour In-Patient Perioda 
X 
X 
X 
X 
X 
X 
X 
Update Medical History 
X 
 
 
 
 
 
 
Review Entry Criteria 
X 
X 
 
 
 
 
 
Vital Signsb 
X 
 
 
X 
X 
X 
X 
12-Lead ECG 
X 
 
 
 
 
 
 
Drug Screenc 
X 
 
 
 
 
 
 
Serum or Urine Pregnancy Testd 
X 
 
 
 
 
 
 
Range of Motion Assessmente 
 
 
 
 
 
 
X 
Neurological Assessmentsf 
X 
 
 
X 
X 
X 
X 
e-diary Trainingg 
X 
 
 
 
 
 
 
e-diary Dispensation/Returnh 
X 
 
 
 
 
 
 
Subject NRS Pain Score Training for Pain Intensityi 
X 
 
 
 
 
 
X 
Concomitant Medications and Opioid Accountabilityj 
X 
X 
X 
X 
X 
X 
X 
Randomization and Investigational Product Allocationk 
X 
 
 
 
 
 
 
Investigational Product Administrationl 
 
X 
 
 
 
 
 
Adverse Eventsm 
 
X 
X 
X 
X 
X 
X 
Subject Self-Administered Questionnaires/Surveysn 
X 
 
X 
X 
X 
X 
X 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 99 of 128 
g. Formal e-diary training must occur prior to surgery. Through the duration of the trial e-diary questions and concerns from the subject will be addressed and re-training will 
occur if needed at any time during the trial. 
h. If a provisioned e-diary is used by the subject, it will be dispensed on Day 1 before surgery and returned on the Day 30 Visit. If the subject early terminates before the Day 
30 Visit, the e-diary will be returned at the Early Termination Visit. If the subject’s own device is used, the site staff will work with the subject to have the e-diary set-up 
before the subject has surgery.      
i. Subject pain score training will occur at the Screening Visit, on Day 1 before surgery, on Day 2, Day 3, and after the Day 15. If needed, pain score training can occur 
anytime during the trial that the subject has questions or as determined by the site staff. Standardized pain score training will be conducted by the site staff or through 
training videos. 
j. Prior and concomitant medication usage is recorded from 30 days before the Screening Visit through Day 56 or Early Termination.  
k. Randomization for allocation of investigational product may occur up to one business day before surgery. 
l. ATX-101 or bupivacaine HCl administration will only occur during the surgical procedure and prior to initiating capsule closure. ATX-101 will be placed in the knee 
capsule following fixation of the knee implant prosthesis when tissue will not be disrupted any further by surgery, after any betadine or saline rinse and after suction has 
occurred. 
m. Adverse Events are collected from the time of investigational product administration and through Day 56 or Early Termination.  
n. Subject self-administered e-diary questionnaires/surveys will be completed. NRS pain intensity scales include both at rest (NRS-R) and activity (NRS-A). Each time rescue 
opioid medications are taken, the NRS-R scale for pain intensity must be completed along with opioid type, dose, and time. Refer to Appendix C for further details on 
frequency of collection.    


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 100 of 128 
APPENDIX C. SUBJECT SELF-ADMINISTERED E-DIARY PROCEDURES 
Visit Day 
Pain Intensity NRS-
Resting (Frequency)a & 
Location of Pain 
Quality 
of 
Recovery 
15 
KOOS, JR & 
Pain 
Manageability 
Pain Intensity 
NRS-Activity 
(Frequency) & 
Location of Pain 
Recording 
Rescue Opioid 
Medication Use 
& Assessment 
of Medication 
Complianceb 
Physical 
Therapy 
Surveyc 
Screeningc 
X 
X 
X 
X 
 
 
Day 1  
Before 
Surgery 
X 
  
  
  
 
 
Day 1  
After Surgery 
30 minutes, 1, 3, 6, 9, 12, & 
18 hours after Time 0 
  
  
 
X 
 
Day 2  
Hour 24 and/or  mid-day, & 
nightd 
X  
  
X 
X 
X 
Day 3 
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 4  
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 5  
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 6  
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 7 
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 8  
Three times (morning, mid-
day, & night) 
X 
X 
X 
X 
X 
Day 9  
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 10 
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 11 
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 12 
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 13 
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 14 
Three times (morning, mid-
day, & night) 
X 
  
X 
X 
X 
Day 15 
Three times (morning, mid-
day, & night) 
X 
 X 
X 
X 
X 
Day 16 
X 
X 
  
X 
X 
X 
Day 17 
X 
X 
  
X 
X 
X 
Day 18 
X 
X 
  
X 
X 
X 
Day 19 
X 
X 
  
X 
X 
X 
Day 20 
X 
X 
  
X 
X 
X 
Day 21 
X 
X 
  
X 
X 
X 
Day 22 
X 
X 
X 
X 
X 
X 
Day 23 
X 
X 
  
X 
X 
X 
Day 24 
X 
X 
  
X 
X 
X 
Day 25 
X 
X 
  
X 
X 
X 
Day 26 
X 
X 
  
X 
X 
X 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 101 of 128 
Visit Day 
Pain Intensity NRS-
Resting (Frequency)a & 
Location of Pain 
Quality 
of 
Recovery 
15 
KOOS, JR & 
Pain 
Manageability 
Pain Intensity 
NRS-Activity 
(Frequency) & 
Location of Pain 
Recording 
Rescue Opioid 
Medication Use 
& Assessment 
of Medication 
Complianceb 
Physical 
Therapy 
Surveyc 
Day 27 
X 
X 
  
X 
X 
X 
Day 28 
X 
X 
  
X 
X 
X 
Day 29 
X 
X 
  
X 
X 
X 
Day 30e 
X 
X 
X 
X 
X 
X 
Day 56e,f 
X 
X 
X 
X 
 
 
X=One time daily. 
aFor the first 24 hours after surgery, pain assessments will be conducted at 30 minutes and 1 hour (±10 min); 3 and 6 hours (±30 minutes); 9 
and 12 hours (±1 hour); 18 and 24 hours (±2 hours). After the first 24 hours from Day 2 to 15 subjects will move to a morning, mid-day, and 
evening assessment period where the morning assessment will be conducted from 3 am until 10:59 am, the mid-day assessment will occur 
from 11:00 am until 4:59 pm and the night assessment from 5:00 pm until 2:59 am.   
bPrior to consuming an opioid after surgery through the Day 30 Visit, subjects will be required to complete an NRS-R for pain intensity and 
indicate the opioid, dose, time, and type of opioid consumed. Each day subjects will be asked about consumption of other study medications.   
cAt the end of the day, starting on Day 1 through Day 30 a physical therapy survey will be completed including the type (eg in person, home 
exercises) of physical therapy completed. 
dAll subjects will skip the morning report on Day 2 as the assessments will be completed as part of the 24 Hour Visit. Depending upon the 
time of surgical closure on (Day 1) some subjects may not complete all assessments on Day 2 (eg the afternoon report).   
eIf a subject early terminates on or before Day 30, all Day 30 self-administered questionnaires should be completed. If a subject early 
terminates after Day 30 all Day 56 self-administered questionnaires should be completed.  
fQuestionnaires and surveys completed at the Screening Visit and the Day 56 Visit may utilize e-diaries maintained by the clinical site. 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 102 of 128 
APPENDIX D. QUALITY OF RECOVERY-15 PATIENT SURVEY 
 
Reference: Stark PA, Myles PS, Burke JA. Development and Psychometric Evaluation of a Postoperative Quality of 
Recovery Score. Anesthesiology 2013; 118(6):1332-1340 [22]. 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 103 of 128 
APPENDIX E. KNEE INJURY AND OSTEOARTHRITIS OUTCOME SCORE FOR 
JOINT REPLACEMENT  
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 104 of 128 
 
 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 105 of 128 
APPENDIX F. ABILITY TO MANAGE PAIN 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 106 of 128 
APPENDIX G. PATIENT HEALTH QUESTIONNAIRE 9  
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 107 of 128 
APPENDIX H. PAIN INTENSITY ASSESSMENTS USING THE NUMERIC RATING 
SCALE  
The NRS will be used for pain intensity at both Rest (NRS-R) and with Activity (NRS-A). 
0  
1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
No Pain 
 
 
 
 
 
 
 
Worst Imaginable Pain 
 
The subject should be asked about their pain scores on a scale from 0-10. Subjects will be asked 
at the Screening Visit and multiple times a day from Day 1 until the Day 15 Visit for NRS-R and 
for all NRS-A assessments “on a scale of 0 to 10, with 0 being no pain at all and 10 being the 
worst pain imaginable, how would you rate your pain RIGHT NOW?”.   
After the Day 15 Visit subjects will be asked to indicate for NRS-R assessments “on a scale of 0 
to 10, with 0 being no pain at all and 10 being the worst pain imaginable, how would you rate 
your USUAL (AVERAGE) pain in the last 24 hours?”.   
Subjects will be trained on how to record their pain scores using the information below.  
Standardized pain score training will be conducted by the site staff or through training videos. 
Scale 
Description 
 
0 
No Pain 
Mild 
1 
Pain is uncomfortable, nagging and annoying 
2  
3  
Moderate 
4  
Pain is bothering, troubling, interrupts concentration and you are considering or requesting 
medication  
5 
6  
Severe 
7 
Pain is preoccupying thoughts and is distressing; you may be unable to perform simple tasks or 
can barely speak you may have low groaning or wincing. 
8 
9 
10 
Pain is immobilizing; retching/crying 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 108 of 128 
The NRS-R for pain intensity will also be obtained just prior to consumption of every rescue 
opioid medication until the Day 30 Visit. When an opioid is consumed the subject will also 
indicate the type, dose, and time of consumption.  
Screening Visit to Day 15 Guidance Subject Pain Intensity Score Training 
Subjects will be trained on trial days as specified in Appendix A and Appendix B.   
Subjects will be told: In this clinical trial, you will be asked to rate your pain at different times 
using a number. When you rate your pain, we would like you to answer according to the pain 
you are experiencing in your surgical knee right now, not pain you might have experienced 
earlier in the day or at another point in time, not pain you are experiencing in another part of 
your body, and not pain from your surgical incision. You will score your pain from 0-10, with 0 
being no pain at all and 10 being the worst pain imaginable.  
You will be asked “on a scale of 0 to 10, with 0 being no pain at all and 10 being the worst pain 
imaginable, how would you rate your pain RIGHT NOW?”. 
 
“0” is no pain. “1, 2, or 3” is mild pain. This means pain that is uncomfortable, nagging, and 
annoying. “4, 5, or 6” is moderate pain. This means pain that is bothering, troubling, interrupts 
your concentration, and you are considering or requesting medication. “7, 8, or 9” is severe pain. 
This means pain that is preoccupying your thoughts and is distressing; you may be unable to 
perform simple tasks or can barely speak. You may have low groaning or wincing. “10” is also 
severe pain. This means pain that is immobilizing, and you are retching and crying.  
 
You will be asked to rate your pain at different times, after resting and being active.  
 
When you are asked to rate your pain after resting, you will be asked to be in a comfortable 
position, either seated or lying down for at least 5 minutes before scoring your pain. You will be 
asked to rate your pain before surgery and multiple times a day for the first two weeks after your 
surgery. You will also be asked to rate your pain after resting each time you take an opioid 
medication. If you take an opioid you will also record the type, dose, and time that you took the 
opioid.   
 
When you are asked to rate your pain after activity, you will be asked to complete a set of 8 to 10 
repetitions of a knee exercise where you will sit on the edge of a chair or bed and extend your leg 
straight off the floor and then back down to the floor. You will be asked to rate your pain with 
activity before surgery and once a day for the first two weeks after your surgery.   
 
Please ask the study staff if you have any questions regarding pain score completion. 
 
Day 16 to Day 56 Guidance for Subject Pain Intensity Score Training 
Subjects will be trained on trial days as specified in Appendix A and Appendix B.   


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 109 of 128 
Subjects will be told: In this clinical trial, you will be asked to rate your pain at different times 
using a number. When you rate your pain, we would like you to answer according to the usual or 
average pain you have experienced in the last 24 hours in your surgical knee. You should not 
consider pain you have experienced or are experiencing in another part of your body and not pain 
from your surgical incision. You will score your pain from 0-10, with 0 being no pain at all and 
10 being the worst pain imaginable.  
You will be asked “on a scale of 0 to 10, with 0 being no pain at all and 10 being the worst pain 
imaginable, how would you rate your USUAL (AVERAGE) pain in the last 24 hours?”. 
 
“0” is no pain. “1, 2, or 3” is mild pain. This means pain that is uncomfortable, nagging, and 
annoying. “4, 5, or 6” is moderate pain. This means pain that is bothering, troubling, interrupts 
concentration, and you are considering or requesting medication. “7, 8, or 9” is severe pain. This 
means pain that is preoccupying your thoughts and is distressing; you may be unable to perform 
simple tasks or can barely speak. You may have low groaning or wincing. “10” is also severe 
pain. This means pain that is immobilizing, and you are retching and crying.  
 
You will be asked to rate your pain at different times, after resting and being active.  
 
When you are asked to rate your pain after resting, you will be asked to be in a comfortable 
position, either seated or lying down for at least 5 minutes before scoring your pain. You will be 
asked to rate your pain one time a day for one month after your surgery. You will also be asked 
to rate your pain after resting each time you take an opioid medication. If you take an opioid, you 
will also record the type, dose, and time that you took the opioid.   
 
When you are asked to rate your pain after activity, you will be asked to complete a set of 8 to 10 
repetitions of a knee exercise where you will sit on the edge of a chair or bed and extend your leg 
straight off the floor and then back down to the floor. You will be asked to rate your pain with 
activity one time a day for one month after your surgery.  
 
Please ask the study staff if you have any questions regarding pain score completion. 
 
 
 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 110 of 128 
APPENDIX I. WOUND HEALING ASSESSMENT - SOUTHAMPTON WOUND 
SCORING SYSTEM 
WOUND HEALING GRADE and APPEARANCE 
Column A 
Column B 
Grade the wound healing by reviewing the definitions and 
ticking one (1) box below. Then choose one (1) additional 
and most severe description experienced from column B for 
that Grade. 
Tick the box that further describes the chosen Grade 
assessment from Column A (Grade 1- 4 only). If Grade 0 or 
5 were chosen, then leave column B blank. 
 
Grade 0 = 
Normal Healing 
 
 
 
Grade 1 = 
Normal Healing with Mild Bruising or Erythema 
 
 
 
 
 
Some bruising 
Considerable bruising 
Mild erythema 
 
Grade 2 = 
Erythema Plus Other Signs of Inflammation 
 
 
 
 
 
 
At one point 
Around sutures 
Along wound 
Around wound 
 
Grade 3 = 
Clear or Haemoserous Discharge 
 
 
 
 
 
At one point only (< 2 cm) 
Along wound (>2 cm) 
Large volume 
Prolonged > 3 days 
 
Grade 4 = 
Pus/Purulent Discharge 
 
 
 
At one point only (< 2 cm) 
Along wound (> 2 cm) 
 
Grade 5 = 
Deep or Severe Wound Infection, With or Without 
Tissue Breakdown 
 
 
 
References:  
Alam SI, Khan MY, Gul A, Jan QA. Surgical site infection. Professional Med J. 2014;21(2):377-38 [23].  
Bailey I. Community surveillance of complications after hernia surgery. BMJ. 1992;304:469-471 [24].  
 
 
 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 111 of 128 
APPENDIX J. KNEE SOCIETY SCORE 
The Knee Society Score’s shown below are representative samples, the official questionnaire 
may have modifications. The pre-operative and post-operative questionnaires are shown. 
Demographics information found on page 1 of the questionnaire will not be completed by the 
subject and surgeon assessment will not be completed. Only the questions being completed are 
shown below. 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 112 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 113 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 114 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 115 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 116 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 117 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 118 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 119 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 120 of 128 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 121 of 128 
 
   
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 122 of 128 
APPENDIX K. ADVERSE EVENT TOXICITY GRADING SCALE 
 
Vital Signs  
Mild (Grade 1) 
Moderate (Grade 2) 
Severe (Grade 3) 
 Fevera (°C)  
       (°F)  
38.0 – 38.4 
100.4 – 101.1 
38.5 – 38.9 
101.2 – 102.0 
>39.0 
>102.1 
Tachycardia - beats per 
minute 
101– 115 
116 – 130 
>130 
Bradycardia - beats per 
minute (bpm)b 
50 – 54 
45 – 49 
<45 
Sinus Bradycardia 
<50 bpm with patient 
aware, but no adverse 
symptoms 
< 50 bpm with symptoms 
(eg lightheaded) and 
medication required 
<50 bpm with syncope or 
symptomatic hypertension 
Hypertension (systolic) - 
mm Hgc, d 
141 – 150 
151 – 155 
>155 
Hypertension (diastolic) - 
mm Hg3c, d 
91 – 95 
96 – 100 
>100 
Hypotension (systolic) – 
mm Hg 
85 – 89 
80 – 84 
<80 
Respiratory Depression 
Drop in oxygen less than 
90% and requiring 
intermittent supplemental 
oxygen or requiring an 
intervention (eg jaw lift) 
Drop in oxygen less than 
90% and requiring 
continuous (>24 hours) 
supplemental oxygen 
Drop in oxygen less than 
90% and requiring an 
advanced intervention (eg 
intubation) 
a 
Temperature here is based upon oral. Non-oral measurements should be based upon clinical judgement when 
characterizing. 
b 
When resting heart rate is not between 60-100 beats per minute, use clinical judgement 
c 
When a patient has a history of elevated blood pressure or hypertension, clinical judgement should be used 
when characterizing a worsening of elevated blood pressure or hypertension.   
d 
 For individual readings of >140 or >90 clinical judgement will be used to determine if there is an adverse 
event. 
 
The laboratory values provided in the tables serve as guidelines and are dependent upon central laboratory normal 
parameters. Central laboratory normal reference ranges will be provided. 
 
Chemistrya 
Mild  
(Grade 1) 
Moderate 
(Grade 2) 
Severe 
(Grade 3) 
Sodium – Hyponatremia mmol/L 
132 – 134 
130 – 131 
<130 
Sodium – Hypernatremia mmol/Lb 
144 – 145 
146 – 147 
>147 
Potassium – Hyperkalemia mmol/Lb 
5.1 – 5.2 
5.3 – 5.4 
>5.4 
Potassium – Hypokalemia mmol/Lb 
3.5 – 3.6 
3.3 – 3.4 
<3.3 
Blood Urea Nitrogen 
BUN mg/dLb 
23 – 26 
27 – 31 
>31 
Creatinine – mg/dLb 
1.5 - 1.7 
1.8 – 2.0 
>2.0 
Phosphorous (Phosphate)– hypophosphatemia 
mg/dL 
2.3 - 2.5 
2.0-2.2 
<2.0 
Albumin – Hypoalbuminemia g/dL 
2.8 – 3.1 
2.5 – 2.7 
<2.5 
Alkaline phosphate U/L – increase by factorb 
1.1 – 2.0 x ULN 
2.1 – 3.0 x ULN 
>3.0 x ULN 
Aspartate Aminotransferase (ALT) U/L – 
increase by factorb 
1.1 – 2.5 x ULN 
2.6 – 5.0 x ULN 
>5.0 x ULN 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 123 of 128 
Chemistrya 
Mild  
(Grade 1) 
Moderate 
(Grade 2) 
Severe 
(Grade 3) 
Alanine Aminotransferase (AST) U/L – 
increase by factorb 
1.1 – 2.5 x ULN 
2.6 – 5.0 x ULN 
>5.0 x ULN 
Total Bilirubin – when accompanied 
by any increase in Liver Function Test 
increase by factor 
1.1 – 1.25 x ULN 
1.26 – 1.5 x ULN 
>1.5 x ULN 
Total Bilirubin – when Liver Function Test is 
normal; increase by factor 
1.1 – 1.5 x ULN 
1.6 – 2.0 x ULN 
>2.0 x ULN 
a 
Out of range screening values should be recorded as medical history. Clinical judgement should be utilized in 
determining post-enrollment laboratory adverse events. 
b 
See central laboratory normal reference ranges which may differ for values and gender.  
 
 
Hematologya 
Mild 
(Grade 1) 
Moderate 
(Grade 2) 
Severe 
(Grade 3) 
Hemoglobin - gm/dL (Female)b 
11.0 – 12. 0 
9.5 – 10.9 
<9.5 
Hemoglobin - gm/dL (Male) 
12.5 – 13.5 
10.5 – 12.4 
˂10.5 
WBC Increase - 10^3/uLb 
10.8 – 15.0 
15.1-20.0 
>20.0 
WBC Decrease - 10^3/uL 
2.5 – 3.5 
1.5 – 2.4 
<1.5 
Lymphocytes Decrease - 10^3/uLb 
7.5 – 10.0 
5.0 – 7.4 
˂5.0 
Neutrophils Decrease - 10^3/uLb 
1.5 – 2.0 
1.0 – 1.4 
˂1.0 
Eosinophils - 10^3/uL  
0.65 – 1.5 
1.6 – 5.0 
>5.0 
Platelets Decreased - 10^3/uLb 
125 – 140 
100 – 124 
<100 
a 
Out of range screening values should be recorded as medical history. Clinical judgement should be utilized in 
determining post-enrollment laboratory adverse events. 
b 
See central laboratory normal reference ranges which may differ for values and gender. 
 
 
 
 
 
 
 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 124 of 128 
APPENDIX L. LOCATION OF PAIN 
After subjects complete the NRS-R or NRS-A if they indicated a pain intensity score of 1 or 
greater, they will be asked to indicate a single location of the most intense pain. Subjects will be 
shown the below diagram of the knee and indicate if the pain is: 
• Above my kneecap 
• Below my kneecap 
• Behind my knee on the back of my leg  
• Deep inside of my knee (under my kneecap) 
• 
The side of my knee (away from my body) and above the joint line 
• The side of my knee (away from my body) and below the joint line 
• The side of my knee (toward my other knee) and above the joint line 
• The side of my knee (toward my other knee) and below the joint line 
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 125 of 128 
APPENDIX M. CYP3A INHIBITORS AND INDUCERS 
A global list has been provided.  The following medications should be avoided during the study. 
 
Potent CYP3A Inhibitors: 
 
• Amiodarone  
• Aprepitant  
• Chloramphenicol  
• Cimetidine  
• Ciprofloxacin  
• Clarithromycin 
• Cobicistat  
• Cyclosporin  
• Diltiazem  
• Dronedarone  
• Erythromycin  
• Fluconazole  
• Fluvoxamine  
• Imatinib  
• Itraconazole  
• Ketoconazole  
• Miconazole,  
• Nefazodone  
• Posaconazole  
• Protease inhibitors 
• Telithromycin  
• Valerian 
• Verapamil  
• Voriconazole  
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 126 of 128 
 
Potent CYP3A Inducers: 
 
• Anticonvulsants 
• Apalutamide  
• Barbiturates  
• Capsaicin 
• Efavirenz  
• Enzalutamide  
• Glucocorticoids  
• Modafinil  
• Nevirapine  
• Phenytoin  
• Pioglitazone  
• Quercetin 
• Rifabutin  
• Rifampicin 
• St. John’s Wort  
 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 127 of 128 
14.0 
REFERENCES 
1. 
Moucha CS, Weiser MC, Levin EJ. Current strategies in Anesthesia and Analgesia for 
Total Knee Arthroplasty. Am Acad Orthop Surg 2016; 34(2):60-73. 
2. 
NIH Consensus Statement of Total Knee Replacement. NIH Consens State Sci 
Statements. 2003;20(1):1-32. 
3. 
Van Manen M, Nace J, Mont MA. Management of Primary Knee Osteoarthritis and 
Indications for Total Knee Arthroplasty for General Practitioners. J Am Osteopath Assoc 
2012; 112(11):709-15. 
4. 
Husted H, Otte KS, Kristensen BB, Orsnes T, Wong C, Kehlet H. Low risk of 
thromboembolic complications after fast-track hip and knee arthroplasty. Acta 
orthopaedical 2010; 81 (5) 599-605. 
5. 
Gaffney CJ, Pelt CE, Gililland JM, Peters CL. Perioperative Pain Management in Hip 
and Knee Arthroplasty. Orthop Clin North Am. 2017;48(4):407-419. 
6. 
Namba RS, Inacio MCS, Pratt NL et al. Persistent Opioid Use Following Total Knee 
Arthroplasty: A Signal for Close Surveillance. J Arthroplasty. 2017 Sep 13. [Epub ahead 
of print] 
7. 
Cragg A, Hau JP, Woo SA et al. Risk Factors for Addiction Among Patients Receiving 
Prescribed Opioids: A Systematic Review Protocol. Systematics Reviews. 2017;6:265. 
8. 
Sun EC, Darnell BD, Baker LC et al. Incidence of and Risk FActors for Chronic Opioid 
Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Internal Medicine. 
2016;176(9):1286-93. 
9. 
Hospira, Inc. MARCAINETM (Bupivacaine Hydrochloride Injection, USP) [Prescribing 
Information]. US Food and Drug Administration website. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/016964s082lbl.pdf. Revised 
2020. Accessed 31 May 2021. 
10. 
Arthur GR, Wildsmith JAW, Tucker GT. Pharmacology of Local Anaesthetic Drugs. In: 
Wildsmith JAW, Armitage EN, eds. Principles and Practice of Regional Anaesthesia. 
London: Churchill Livingstone. 1993;29–45 
11. 
Carson BL. Local Anesthetics that Metabolize to 2,6-Xylidine or o-Toluidine – Final 
Review of Toxicological Literature. Integrated Laboratory Systems. October 2000. 
12. 
Emanuelsson BK, Zaric D, Nydahl P et al. Pharmacokinetics of Ropivacaine and 
Bupivacaine during 21 hours of Continuous Epidural Infusion in Healthy Male 
Volunteers. Anesthesia and Analgesia. 1995;81(6):1163-68. 
13. 
Kerr D. Local Infiltration Analgesia, A Technique to Improve Outcomes after Hip, Knee 
or Lumbar Spine Surgery. Informa Healthcare, 2012 July 16; ISBN: 978-1-43981-176-4. 


Allay Therapeutics, Inc 
 
Clinical Study Protocol 
ATX-101 
 
ATX-101-TKA-003 
Version: 02 June 2023 
CONFIDENTIAL 
 
Page 128 of 128 
14. 
Goyal N, McKenzie J, Sharkey PF et al. The 2012 Chitranjan Ranawat Award: 
Intraarticular Analgesia After TKA Reduces Pain: A Randomized, Double-Blinded, 
Placebo-Controlled, Prospective Study. Clinical Orthopaedics and Related Research. 
2013;471:64-75. 
15. 
Knudsen K, Beckman Suurküla M, Blomberg S et al. Central nervous and Cardiovascular 
Effects of i.v. Infusions of Ropivacaine, Bupivacaine and Placebo in Volunteers. British 
Journal Anaesthesia. 1997;78:507-14. 
16. 
Bardsley H, Gristwood R, Baker H et al. A Comparison of the Cardiovascular Effects of 
Levobupivacaine and rac-Bupivacaine Following Intravenous Administration to Healthy 
Volunteers. British Journal of Clinical Pharmacology. 1998;46(3):245-9. 
17. 
Tucker GT. Pharmocokinetics of Local Anaesthetics. British Journal of Anaesthesia. 
1986;58:717-31. 
18. 
Reynolds, E. Adverse Effects of Local Anesthetics. British Journal of Anaesthesia. 
1987;59:78-95. 
19. 
Berrisford RG, Sabanathan S, Mearns AJ et al. Plasma Concentrations of Bupivacaine 
and its Enantiomers During Continuous Extrapleural Intercostal Nerve Block. British 
Journal Anaesthesia. 1993;70:201-04. 
20. 
Kellgren JH, Lawrence JS. Radiological Assessment of Osteo-Arthrosis. Ann Rheum Dis 
1957; 16(4):494-502. 
21. 
https://www.cdc.gov/drugoverdose/prescribing/guideline.html  
22. 
Stark PA, Myles PS, Burke JA. Development and Psychometric Evaluation of a 
Postoperative Quality of Recovery Score. Anesthesiology 2013; 118(6):1332-1340. 
23. 
Alam SI, Khan MY, Gul A, Jan QA. Surgical site infection. Professional Med J. 
2014;21(2):377-381.  
24. 
Bailey I. Community surveillance of complications after hernia surgery. BMJ. 
1992;304:469-471.  

SAP_001.pdf: 
 
 
 
Official Title: 
A Phase 2B, Randomized, Double Blind, Active Comparator, Multicenter, Safety, 
and Efficacy Trial of ATX-101 in Subjects Undergoing Total Knee Arthroplasty 
(SPARK) 
NCT Number:  
NCT05260008 
Document Date:  20 Feb 2024 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 1 of 48
STATISTICAL ANALYSIS PLAN
A Phase 2B, Randomized, Double Blind, Active
Comparator, Multicenter, Safety, and Efficacy Trial of
ATX-101 in Subjects Undergoing Total Knee Arthroplasty (SPARK)
Protocol Number:
ATX-101-TKA-003
Sponsor:
Allay Therapeutics, Inc.
2720 Zanker Road San Jose, CA 95134
Protocol Version/Date:
Amendment 03 02Jun2023
SAP Version and Date:
Amendment 1, 20Feb2024
   


	





Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 3 of 48
Revision History
Version and Date
Reason of Revision
Comments
Version 1.0, 15Aug2023
Initial document
Amendment 1, 20Feb2024
Addition to Study Design for 
placebo group prior to Protocol 
Amendment 03
Updated KOOS Jr analysis.
Updated the sensitivity analyses.
Updated opioid related AEs
Clarification
Corrected per the protocol.
Added analyses.
Clarification.
   


	





Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 5 of 48
MME
Morphine Milligram Equivalent
n
Number 
NRS
Numeric Rating Scale
NRS-A
Numeric Rating Scale with Activity
NRS-R
Numeric Rating Scale at Rest
PACU
Post-Anesthesia Care Unit
PCA
Patient Controlled Anesthesia
PHQ-9
Patient Health Questionnaire 9
PI
Pain Intensity
PK
Pharmacokinetic
QoR-15
Quality of Recovery 15 Scale
SAE
Serious Adverse Event
SAP
Statistical Analysis Plan
SD
Standard Deviation
SDTM
Study Data Tabulation Model
SOC
System Organ Class
SPI
Time Weighted Sum of Pain Intensity
SPI-R
Time Weighted Sum of Pain Intensity Area Under the Curve
TFLs
Tables, Figures, and Listings
TKA
Total Knee Arthroplasty
WHO-DD
World Health Organization Drug Dictionary
WOCF
Worst Observation Carried Forward
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 6 of 48
wWOCF
Windowed Worst Observation Carried Forward
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 7 of 48
TABLE OF CONTENTS
1.0 INTRODUCTION TO THE STATISTICIAL ANALYSIS PLAN ..........................10 
2.0 INTRODUCTION TO THE STUDY ..........................................................................11 
2.1 Study Objectives........................................................................................................11 
2.2 Study Endpoints.........................................................................................................11 
2.2.1 
Primary Endpoint and Primary Estimand ............................................................... 11 
2.2.2 
Key Secondary Endpoints (Evaluated in Part B).................................................... 12 
2.2.3 
Secondary Endpoints .............................................................................................. 12 
2.2.4 
Safety Endpoints..................................................................................................... 13 
2.2.5 
Exploratory Endpoints ............................................................................................ 13 
2.3 Study Design .............................................................................................................13 
3.0 RANDOMIZATION AND BLINDING ......................................................................15 
4.0 SAMPLE SIZE CONSIDERATIONS.........................................................................16 
5.0 ANALYSIS POPULATIONS.......................................................................................17 
5.1 Full Analysis Set (FAS).............................................................................................17 
5.2 Safety Analysis Set....................................................................................................17 
5.3 PK Analysis Set.........................................................................................................17 
6.0 GENERAL STATISTICAL CONSIDERATIONS AND DEFINITONS ................18 
6.1 Baseline and Visit Windows .....................................................................................18 
6.2 Study Day ..................................................................................................................18 
6.3 Summary Statistics....................................................................................................18 
6.4 Calculation of AUC or NRS......................................................................................19 
6.5 Calculation Of Post-Surgical Opioid Consumption Compliance..............................19 
6.6 Data Handling Rules..................................................................................................19 
6.7 Imputation of NRS Pain Intensity Scores..................................................................20 
6.8 Interim Analysis ........................................................................................................21 
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 8 of 48
6.9 Reporting Plan...........................................................................................................22 
7.0 STATISTICAL ANALYSES........................................................................................23 
7.1 Subject Disposition and Withdrawals .......................................................................23 
7.2 Demographic and Baseline Characteristics...............................................................23 
7.3 Medical History.........................................................................................................23 
7.4 Prior and Concomitant Medications..........................................................................23 
7.5 Protocol Deviations ...................................................................................................24 
7.6 Study Drug Administration .......................................................................................24 
8.0 EFFICACY ENDPOINT EVALUATION ..................................................................25 
8.1 Primary Endpoint – Time weighted AUC (Part B) ...................................................25 
8.1.1 
Subgroup Analysis.................................................................................................. 25 
8.1.2 
Sensitivity Analysis ................................................................................................ 25 
8.2 Key Secondary Endpoint Analysis for Part B ...........................................................26 
8.3 Secondary Endpoint Analysis....................................................................................26 
8.3.1 
Area Under the Curve for Numeric Rating Scale at Rest for Each 24-Hour Period 
Through Hour 336................................................................................................................. 26 
8.3.2 
Percentage of Subjects Opioid Free........................................................................ 27 
8.3.3 
Total Post-Surgical Consumption of Opioids......................................................... 27 
8.3.4 
Time to First Rescue Opioid Medication................................................................ 27 
8.4 Exploratory Endpoints...............................................................................................27 
8.4.1 
Evaluation of Quality of Recovery (QOR-15)........................................................ 28 
8.4.2 
Evaluation of Knee Injury and Osteoarthritis Outcome Score for Joint Replacement 
(KOOS, JR)........................................................................................................................... 28 
8.4.3 
Physical Therapy Survey ........................................................................................ 29 
8.4.4 
Range of Motion (ROM) ........................................................................................ 29 
8.4.5 
PHQ-9 ..................................................................................................................... 29 
8.4.6 
Evaluation of the Knee Society Score .................................................................... 29 
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 9 of 48
9.0 SAFETY ENDPOINT EVALUATION.......................................................................31 
9.1 Adverse Events..........................................................................................................31 
9.2 Wound Healing Assessment......................................................................................31 
9.3 Clinical Laboratory Results.......................................................................................31 
9.4 12-Lead ECG.............................................................................................................32 
9.5 Vital Signs .................................................................................................................32 
9.6 Physical Examination and Neurological Assessment Findings.................................32 
10.0 DEVIATIONS FROM STATISTICAL PLAN AND OTHER ISSUES...................33 
11.0 APPENDICES................................................................................................................34 
11.1 Appendix A: SCHEDULE OF EVENTS FOR PART A..........................................34 
11.2 Appendix B: SCHEDULE OF EVENTS FOR PART B...........................................40 
11.3 Appendix C: Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors
45 
12.0 REFERENCES ..............................................................................................................48 
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 10 of 48
1.0 INTRODUCTION TO THE STATISTICIAL ANALYSIS PLAN 
The statistical analysis plan (SAP) is based on protocol ATX-101-TKA-003: A Phase 2B, 
Randomized, Double Blind, Active Comparator, Multicenter, Safety, and Efficacy Trial of 
ATX-101 in Subjects Undergoing Total Knee Arthroplasty (SPARK), Amendment 03 dated 02
June 2023. This SAP details the methodology to be used in analyzing the data and outlines the 
specifications in the Tables, Figures and Listings (TFLs) for data to be included for executing 
the final statistical analyses for this study. 
Pharmacokinetic (PK) and triplicate ECG data analyses are not included in the scope of this 
plan. 
The analyses specified in this document supersede any high-level analysis plan described in the 
protocol.
The study data collected in the Electronic Data Capture system will be mapped to Clinical Data 
Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) standard 
and analysis data will be derived following CDISC Analysis Data Model (ADaM) data 
standard.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 11 of 48
2.0 INTRODUCTION TO THE STUDY
2.1 Study Objectives 
x
To compare the efficacy of ATX-101 (1,000 mg or 1,500 mg) with that of bupivacaine 
HCl in subjects undergoing primary unilateral TKA
x
To evaluate the safety and tolerability of ATX-101
x
To characterize the PK profile following administration of ATX-101 (Part A only)
x
To compare opioid consumption of subjects administered ATX-101 with that of 
bupivacaine hydrochloride HCl 
x
To estimate the sample size, determine dose, and primary endpoint duration from Part 
A needed for Part B
x
To compare the efficacy of ATX-101 with that of bupivacaine HCl. in this trial 
population 
2.2 Study Endpoints 
2.2.1
Primary Endpoint and Primary Estimand
Primary Endpoint
x
The primary efficacy endpoint for Part A is AUC for the NRS-R of pain intensity from 
30 Minutes through Hour 168 (Day 8 of the trial).
x
The primary efficacy endpoint (evaluated in Part B) is to determine the area under the 
curve (AUC) for the Numeric Rating Scale at Rest (NRS-R) of pain intensity from 30 
Minutes through a time point to be determined from Part A.
Primary Estimand (evaluated in Part B)
Population
x
The analysis population will be Part B subjects meeting the protocol 
inclusion/exclusion criteria that were randomized and administered IP.
Variable
x
The primary endpoint will be the AUC of the NRS-R from 30 Minutes through a time 
point to be determined from Part A.
Intercurrent Events
x
A hypothetical strategy will be used in handling of intercurrent events.
x
The intercurrent event of use of opioid rescue medication will be handled by obtaining 
a NRS-R score prior to rescue medication administration and censoring subsequent 
scheduled NRS-R values that fall within the duration of efficacy of the rescue 
medication. The exception to this will be instances where the scheduled NRS values 
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 12 of 48
recorded within the censoring period are higher than the pre-rescue value; these will 
not be censored and will be included in calculation of the AUC. Censoring periods for 
each opioid rescue will be detailed in the SAP.
x
For the intercurrent event of sporadic missing values, no special handling or imputation 
will be performed; the trapezoidal rule is equivalent to performing a linear interpolation 
between the 2 observed values on either side of a missing value. 
x
For the intercurrent event of withdrawal, values will be imputed based on the reason 
for withdrawal. Only the last time point will be imputed for calculating the AUC; in 
this instance, the trapezoidal rule will calculate area by connecting the last observed 
value to the imputed last time point for the chosen AUC. For subjects withdrawing for 
adverse events (other than COVID), the value imputed will be the worst value 
observed prior to withdrawal. All other subjects (including those that withdraw solely
for COVID) will have their last observation carried forward.
Population-Level Summary
x
The population-level summary will be the difference in least-square means between 
treatment arms (analyzed as randomized) for the AUC chosen from Part A. This 
analysis will use an Analysis of Variance (ANOVA) model with a main effect of the 
treatment group.
x
The primary analysis will be followed by several sensitivity analyses. Further details 
on sensitivity analyses can be found in Section 8.1.2.
2.2.2
Key Secondary Endpoints (Evaluated in Part B)
Key secondary endpoints are to evaluate the: 
x
Area under the curve for the NRS-R of pain intensity from 30 Minutes through Hour 
168 (Day 8 of the trial), Hour 240 (Day 11 of the trial), and Hour 336 (Day 15 of the 
trial).
x
Percentage of subjects who remain opioid free from Hour 72 through Day 30.
x
Total post-surgical consumption of opioid medications from surgical closure through 
Day 30. 
2.2.3
Secondary Endpoints
Safety endpoints for both Part A and Part B are to evaluate the:
x
Area under the curve for the NRS-R of pain intensity for each 24-hour period through 
Hour 336 (Day 15 of the trial)
x
Percentage of subjects who remain opioid free
x
Total post-surgical consumption of rescue opioid medications
x
Time to first postsurgical use of rescue opioid medication.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 13 of 48
2.2.4
Safety Endpoints
Safety endpoints for both Part A and Part B are to evaluate the: 
Incidence of AEs, AESIs, and SAEs
x
Wound healing assessment using the Southampton Wound Scoring System
x
Characterization of the bupivacaine PK from ATX-101.
2.2.5
Exploratory Endpoints
Exploratory endpoints for both Part A and Part B will evaluate the:
x
Percentage of subjects reporting being pain free on the NRS-R of pain intensity
x
Time to various degrees of flexion and extension
x
Reduction/incidence of opioid-related AEs
x
Evaluation of Quality of Recovery 15 Scale (QOR-15)
x
Evaluation of Knee Injury and Osteoarthritis Outcome Score for Joint Replacement
(KOOS, JR)
x
Difference in pain intensity scores (NRS-R and Numeric Rating Scale with Activity 
[NRS-A]) between treatment groups
x
If a statistical difference in AUC of pain intensity NRS-R at Hour 336 (Day 15 of the 
trial) is observed, the AUC for the NRS-R of pain intensity will be further evaluated 
between Days 16 and 30 
x
Evaluation of the Knee Society Score.
2.3 Study Design
This is a two-part (Part A and Part B) Phase 2B, randomized, double-blind, active comparator 
multicenter trial in subjects undergoing primary unilateral TKA. Part A will be used to 
determine the sample size, dose, and primary endpoint duration for Part B of the trial.
In Part A of the trial, approximately 165 subjects will be randomized to one (1) of the 
following three (3) treatment groups in a 1:1:1 ratio with approximately 55 subjects per group:
x
ATX-101, 1,000 mg dose (two ATX-101 implants)
x
ATX-101, 1,500 mg dose, (three ATX-101 implants)
x
Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg via 
local periarticular infiltration or adductor canal block or in combination.
The trial was initiated under Protocol Version 00, and subjects were enrolled under Version 00 
and Protocol Amendment 01, which included a Saline Placebo control which was changed to a 
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 14 of 48
Bupivacaine HCl active comparator in Protocol Amendment 03. The Placebo group is included 
in the Part A study analyses.
In Part B of the trial, up to 140 subjects (total number will be determined from Part A) will be
randomized to one (1) of the following three (2) treatment groups in a 1:1:1 ratio with up to 70
subjects per group:
x
ATX-101 dose to be determined from Part A
x
Bupivacaine HCl 0.25% without epinephrine/adrenaline, maximum dose of 2 mg/kg via 
local periarticular infiltration or adductor canal block or in combination
Refer to Appendix A and Appendix B and the study protocol for further details of the schedule 
of events and procedures.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 15 of 48
3.0 RANDOMIZATION AND BLINDING
A randomization schedule will be computer generated.
Subjects will be randomized in a 1:1:1 ratio in Part A to a one-time administration of 1,000 mg 
ATX-101, 1,500 mg of ATX-101, or bupivacaine HCl.
Subjects will be randomized in a 1:1 ratio in Part B to a one-time administration of ATX-101
(1,000 mg or 1,500 mg determined from Part A), or bupivacaine HCl, 
In the event of a medical emergency when knowledge of the actual treatment becomes 
medically necessary to affect treatment options, prior to the end of the data base lock (Part A 
and Part B), the Investigator will be able to break the blind and obtain details of the treatment 
assigned to a subject. The Medical Monitor is to be informed immediately that the blind has 
been broken.
The surgical staff will not be blinded to the trial treatment, all other research staff (unless 
expressly specified in the site-specific Blinding Plan and the subject will remain blinded 
throughout the trial. Allay will remain blinded during the treatment phase of both Part A and 
Part B of the study until database lock occurs for Part A and Part B.
There will be unblinded clinical research associates (CRAs)/monitors who will be unblinded 
throughout the trial to ensure compliance with the trial protocol and investigational product 
accountability. Further information regarding investigational drug accountability can be found 
in Section 7.6. Blinded monitors will be monitoring safety and efficacy data at the sites.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 16 of 48
4.0 SAMPLE SIZE CONSIDERATIONS
Part A
Approximately 165 subjects will be randomized with one (1) of the following three (3) 
treatment groups in a 1:1:1 ratio with approximately 55 subjects per group:
•
ATX-101, 1,000 mg dose (two ATX-101 implants)
•
ATX-101, 1,500 mg dose (three ATX-101 implants)
•
0.25% bupivacaine HCl 125 mg 
Based on the literature review and discussion with experts in post-operative pain, it is believed 
that 55 subjects per treatment group would provide sufficient information to inform dose 
response and dose selection for Part B.
Part B
Up to 140 subjects will be randomized to one (1) of the following two (2) treatment groups in a 
1:1 ratio with up to 70 subjects per group:
•
ATX-101 dose to be determined from Part A
•
0.25% bupivacaine HCl 125 mg 
The current planned sample size for Part B is up to 140 subjects. The actual number of subjects 
to be randomized will be determined based on data from Part A. 
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 17 of 48
5.0 ANALYSIS POPULATIONS
5.1 Full Analysis Set (FAS)
The Full Analysis Set (FAS) includes all subjects who are randomized and administered 
ATX-101, or bupivacaine HCl. Randomization failures (subjects who are randomized but did 
not receive investigational product) will be excluded from the FAS. The FAS will be used for 
efficacy analyses and subject demographic and baseline characteristics.
5.2 Safety Analysis Set
The Safety Analysis Set includes all subjects who are randomized and administered ATX-101,
or bupivacaine HCl. Randomization failures (subjects who are randomized but did not receive 
investigational product) will be excluded from the Safety Analysis Set.
The Safety Analysis Set will be used for all safety analyses. 
5.3 PK Analysis Set
The PK Analysis Set includes all subjects who provide enough plasma samples for PK 
assessment of bupivacaine HCl that allows for generation of at least one PK parameter of Tmax,
Cmax, or AUC.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 18 of 48
6.0 GENERAL STATISTICAL CONSIDERATIONS AND DEFINITONS
6.1 Baseline and Visit Windows
Unless otherwise specified in this section, baseline, which is defined as the last non missing
assessment prior to receiving the study treatment, will be used in baseline and change from 
baseline analyses.  
The summary tables by visit will use the values from the scheduled timepoints/visits.
6.2 Study Day
For the purpose of analysis, Day 1 is defined as the surgery day.
6.3 Summary Statistics
Analysis will be summarized by Part A and Part B and overall, unless specified otherwise. 
Descriptive statistics (the number of subjects [n], mean, standard deviation [SD], median, 
minimum, and maximum) will be used to summarize continuous variables. Means and medians 
will be presented to one more decimal place than the recorded data. Standard deviations will be 
presented to two more decimal places than the recorded data. Minimum and maximum values 
will be presented using the same number of decimal places as the recorded data. Percentages 
will be presented to one decimal place.
Frequency distributions (number [n] and percentage of subjects [%]) will be used to summarize 
categorical or qualitative variables. In general, the denominator for the percentage calculation 
will be based upon the total number of subjects in the study population for the treatment 
groups, unless otherwise specified.
All statistical tests will be performed against a two-sided alternative hypothesis with a 
VLJQLILFDQFH OHYHO RI  Į   DQG DOO FRQILGHQFH LQWHUYDOV &,V FDOFXODWHG ZLOO EH WZR-
sided 95% CIs. All tests will be declared to be statistically significant if the calculated p-value 
LV   XQOHVV VSHFLILHG RWKHUZLVH 7HVWV IRU ELQRPLDO SURSRUWLRQV ZLOO EH FRQGXFWHG.
(1) using a normal approximation whenever each classification cell for each group to be 
compared contains expected cell counts of 5 or more subjects, or (2) using an exact method 
whenever any one classification cell for any one group to be compared contains expected cell 
counts of fewer than 5 subjects.
All analyses will be performed using SAS® software Version 9.4 or later.
For the listings, subjects will be listed under their randomized treatment, regardless of actual 
treatment received. Subjects who are randomized but do not receive study drug will be 
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 19 of 48
included in the listings with the treatment group identified as “ATX-01 Not Treated” or 
‘Bupivacaine, Not Treated’ depending on their randomized treatment. Subject listings of data 
will be presented for all enrolled subjects unless specified otherwise.
6.4 Calculation of AUC or NRS
Area under the curve (AUC) will be calculated using the trapezoidal method with the actual 
NRS pain intensity scores reported by the subject as follows. 
ܵܲܫെܴ= (ܴܰܵെܴଵ+ ܴܰܵെܴଶ)(ݐଶെݐଵ)
2
The trapezoidal rule performs a linear interpolation between the 2 observed values on either 
side of a missing value. Actual times of each NRS-R score will be used for calculating the 
AUC.
Missing values prior to early termination (ET) will be imputed according to the trapezoidal 
rule, and missing values after ET will be imputed.
x
using the last observation carried forward if the primary reason is not AE
x
using the worst observation carried forward if the primary reason is AE
Details are described in Section 6.7. Actual times not scheduled times, when available will be 
used in the calculations. Linear interpolation will be used to calculate the pain intensity score at 
the end of an interval.
6.5 Calculation Of Post-Surgical Opioid Consumption Compliance
The total number of opioid pills dispensed will be compared to those that are returned and 
consumed (eDiary data). Opioid accountability will be done for Day 15, Day 30 and ET (if 
before Day 30).  The percentage will be calculated using the following:
(Opioid Accountability / Opioid Pills Dispensed – Opioid Pills Consumed) * 100
6.6 Data Handling Rules
Opioid consumption will be converted to morphine equivalence in milligrams (MME)
according to the conversion factor in Appendix C. Numeric Rating Scale (NRS) pain scores 
taken after an opioid as rescue medication will be censored for the amount of time according to 
the NRS Censoring Time (Hours) in Table 1:
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 20 of 48
TABLE 1: NRS Censoring Rules
Opioid Type*
NRS Censoring Time (Hours)
Endone/Oxycodone (oral)
4
Hydromorphone (oral)
4
Hydromorphone (IM)
3
Hydromorphone (IV)
3
Fentanyl (IV)
0.5
Morphine (oral)
3
Morphine (IM)
2
Morphine (via PCA pump)
3
Palexia/Tapentadol (oral)
4
Panadeine Forte/Codeine
(oral)
4
Targin/Oxycodone & 
Naloxone (oral)
12
Tramadol (oral)
4
*Extended release opioid not allowed per protocol.
6.7 Imputation of NRS Pain Intensity Scores
For calculation of AUC of NRS pain intensity scores, data will be handles as follows: 
x
Trapezoidal Rule:
For the intercurrent event of sporadic missing values, no special handling or imputation 
will be performed; the trapezoidal rule is equivalent to performing a linear interpolation 
between the 2 observed values on either side of a missing value. 
x
Windowed Worst Observation Carried Forward (wWOCF) with Rescue Medication
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 21 of 48
The intercurrent event of use of opioid rescue medication will be handled by obtaining a 
NRS-R score prior to rescue medication administration and censoring subsequent scheduled 
NRS-R values that fall within the duration of efficacy of the rescue medication as described in 
Table 1. The exception to this will be instances where the scheduled NRS values recorded 
within the censoring period are higher than the pre-rescue value; these will not be censored and 
will be included in calculation of the AUC. This method of imputation is referred to as 
wWOCF. If no NRS score is available prior to the first rescue the worst observation from all 
available NRS scores from the subject will be used instead.
x
Last Observation Carried Forward (LOCF)
For the intercurrent event of withdrawal, values will be imputed based on the reason for 
withdrawal. Only the last time point will be imputed for calculating the AUC; in this instance, 
the trapezoidal rule will calculate area by connecting the last observed value to the imputed last 
time point for the chosen AUC. 
For subjects withdrawing for adverse events (other than COVID), the value imputed will be the 
worst value observed prior to withdrawal. All other subjects (including those that withdraw 
solely for COVID) will have their last observation carried forward.
6.8 Interim Analysis
For Part A, an interim analysis may be performed when approximately 50% of the initially 
planned enrollment has completed Day 30. Enrollment will continue during the interim 
analysis.
This interim analysis will be performed by the unblinded statistician separate from the team 
responsible for the conduct and analysis of the study. A Review Committee of at least two 
unblinded statisticians and a designated sponsor representative will review the data and 
recommend one of the following:
x
Keep the current sample size and continue Part A as planned
x
Stop Part A for efficacy (no further enrollment)
x
Increase the sample size in Part A
Analyses to be included in the interim analysis will be the following at a minimum:
x
Subject disposition
x
Demographic and baseline characteristics
x
Primary analysis of the AUC of pain intensity at rest from 30 minutes post-surgery.
x
AUC of pain intensity at rest for Each 24-Hour Period Through Hour 336 AUC of 
active pain intensity at by assessed time points
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 22 of 48
x
Summary of Post-Surgical Consumption of Opioid in Morphine Equivalent Milligram 
Dose
x
Safety analysis including lab results, vital signs, TEAE, SAE and AESI 
The basis of this decision will be whether sufficient data have been collected to plan Part B, 
taking into account both safety and efficacy (including outcomes other than the primary) to 
adequately size and power the study.). All part A data will be evaluated. In particular, data 
pertaining to selection of Part B primary endpoint, eg treatment effect and primary endpoint 
variability, will be evaluated for the planning of Part B.
The Sponsor may make adjustments other than those detailed above; however, the blinded
Sponsor team will receive no information other than the recommendations listed. If the interim
analysis demonstrates sufficient data have been collected to plan Part B, then Part A may be
stopped, unblinded and the final analysis will be completed on the population enrolled to date.
The designated sponsor representative will not participate in ongoing study conduct once 
unblinded to study results and will not have access to individual patient treatment assignments. 
Should Part A continue to full enrollment they likewise will be blinded to assignments and 
results until the final unblinding and analysis.
The same IA will be repeated when 100% of subjects complete D30 visit.
6.9 Reporting Plan 
There will be two reporting events for this study, in addition to the interim analysis.  One will 
be at the end of Part A and another one will be at the end of the study for Part B reporting.
The end of Part A analysis of data will be for all subjects who have completed Day 56 visit.  
Data that will be reviewed will be cleaned data according to edit checks in the Data Validation 
Specification and Data Review Plan and the Part A database locked. The purpose of the Part A 
analysis is to inform the development plan and Part B study design. 
End of Part B analysis of data will include all data in Part B portion of study.   
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 23 of 48
7.0 STATISTICAL ANALYSES
7.1 Subject Disposition and Withdrawals
The number and percentages of subjects screened, enrolled, received treatment (FAS), safety 
analysis set, PK analysis set, completed the study and discontinued from the study will be 
reported, along with the primary reason for discontinuation.
Percentages will be out of the safety population. Only counts will be reported for enrolled 
subjects.  
7.2 Demographic and Baseline Characteristics
Demographic/baseline characteristics collected at the Screening Visit and during the Pre-
Surgical Baseline Period will be summarized and presented. Descriptive statistics will be 
presented based on FAS population. 
Variables to be summarized include:
x
Age (years)
x
Sex (male, female)
x
Race
x
Height (cm)
x
Weight (kg)
x
BMI (kg/m2)
All demographics and baseline characteristics will be provided in a subject listing.
7.3 Medical History
Medical history will be coded using Medical Dictionary for Regulatory Activities (MedDRA).  
Conditions will be summarized by system organ class (SOC) and preferred term. In addition, 
conditions will be listed by the verbatim investigator description of the relevant medical 
condition, the coded terms (SOC, preferred term), start date, end date, and whether the 
condition is resolved or ongoing.
7.4 Prior and Concomitant Medications
Prior and concomitant medications (including intra-surgical and post-surgical concomitant
medications) will be coded with the World Health Organization Drug Dictionary (WHO-DD).
Prior and concomitant medication will be summarized using the FAS Population. Medications 
will be reported by drug class (Anatomical Therapeutic Chemical [ATC] Level 3) and 
preferred term; a subject will be counted only once for each medication.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 24 of 48
Prior and concomitant medications will be listed.
7.5 Protocol Deviations
All protocol deviations will be presented in a listing. All major deviations will be provided in a 
separate listing
7.6 Study Drug Administration
For Part A, the total number of ATX-101 implants, total ATX-101 dose administered, and the 
total dose for active comparator will be summarized. 
For Part B, the total number of ATX-101 implants, total dose administered for active 
comparator will be summarized.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 25 of 48
8.0 EFFICACY ENDPOINT EVALUATION
8.1 Primary Endpoint – Time weighted AUC (Part B)
The primary efficacy endpoint will occur in Part B of the study and is the AUC for the NRS-R
of pain intensity from 30 Minutes through a time point x (hour x or day x) which is to be 
determined from Part A.
The primary efficacy endpoint will be analyzed using an Analysis of Variance (ANOVA) 
model with a main effect of the treatment group. Summary statistics will be reported as well as 
the least square (LS) means, difference in the LS means, 95% confidence intervals (CI) and p-
value for the contrast comparing the LS means.
For Part B, the primary comparison will be between ATX-101 and bupivacaine HCl. A two-
sided alpha 0.05 will be spent on the primary comparison.
For Part A, the primary analysis is to compare each dose of ATX-101 to the bupivacaine HCl
group. In addition, the LS mean of each dose level group will be plotted with 95% CI to 
evaluate dose response. The AUC for the NRS-R of pain intensity from 30 Minutes through 
Hour 168 (Day 8 of the trial) will be evaluated.
Assuming that a subject has a 24-hour nominal value, SPI-R will be normalized to exactly 
24hrs.  Should the subject be missing the nominal 24-hour value, but have a subsequent NRS-R
recorded, linear interpolation will be performed to impute the 24-hour value by connecting the 
prior and subsequent values and calculating where the 24-hour value would fall on that line.
AUC will be calculated according to the handlings specified in Section 6.7. 
Censored NRS-R values will be retained in the database but will not be utilized for the SPI-R
calculations. 
8.1.1
Subgroup Analysis
The primary endpoint will be analyzed using the same ANOVA model by subgroups of 
subjects who previously received TKA and those who did not.
8.1.2
Sensitivity Analysis
In Part A, 
x
Additional analysis for the primary endpoint and other efficacy measures as well as
opioid consumption will be conducted comparing each dose of ATX-101 to combined 
group of bupivacaine HCl and Placebo using FAS.
x
The primary analysis will be repeated for sites who have enrolled >=10 subjects.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 26 of 48
8.2 Key Secondary Endpoint Analysis for Part B
A stepdown procedure will be used to control the type I error. If the primary comparison for 
the primary endpoint is statistically significant, comparisons between ATX-101 and 
bupivacaine HCl for the key secondary endpoints will be carried out in the order shown below. 
Comparisons will be stopped once any proceeding comparison is not statistically significant.
1. Area under the curve for NRS-R of pain intensity from 30 Minutes through Hour 168 
(Day8 of the trial)
2. Area under the curve for NRS-R of pain intensity from 30 Minutes through Hour 240 (Day 
11 of the trial)
3. Area under the curve for NRS-R of pain intensity from 30 Minutes through Hour 336 (Day 
15 of the trial)
4. Percentage of subjects who remain opioid free from Hour 72 through Day 30
5. Total post-surgical consumption of opioid medications from surgical closure through Day 
30.
The AUC of the NRS-R will be calculated from 30 Minutes through Hour 168 (Day 8 of the 
trial), Hour 240 (Day 11 of the trial), and Hour 336 (Day 15 of the trial) using the trapezoidal 
method as described in the primary endpoint section. Data will be analyzed using the same 
ANOVA model as in the analysis of the primary endpoint. Comparisons between ATX-101
and bupivacaine HCl will be carried out in the following order: Hour 168, Hour 240, and 
Hour 336.
For total post-surgical consumption of opioid medication, all opioids will be converted to an 
equianalgesic parenteral morphine amount (milligram morphine equivalent or MME) using 
standard conversion factors as laid out in Appendix 11.3. Subject’s total post-surgical 
consumption of rescue opioid medications from surgical closure through Day 30 will be 
analyzed using the Wilcoxon rank-sum test.
8.3 Secondary Endpoint Analysis 
8.3.1
Area Under the Curve for Numeric Rating Scale at Rest for Each 24-Hour Period 
Through Hour 336
The AUC of the NRS-R for pain intensity will be calculated for each day and cumulatively 
through the end of each day using the trapezoidal method as described in the primary endpoint 
section. Data will be analyzed using the same ANOVA model as in the analysis of the primary 
endpoint.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 27 of 48
8.3.2
Percentage of Subjects Opioid Free
The percentage of subjects who remain opioid free from surgical closure to Day 30, from 
Hour 72 (Day 4) to Day 30, Hour 96 (Day 5) to Day 30, Hour 168 (Day 8) to Day 30, 
Hour 336 (Day 15) to Day 30 and Hour 504 (Day 22) to Day 30 will be evaluated. Opioid free 
data will be analyzed using Fisher’s exact test. The number of subjects, percentage, and 
percentage difference between treatment groups will be summarized by treatment group and 
associated 95% CI will be provided.
8.3.3
Total Post-Surgical Consumption of Opioids
Opioid consumption will be summarized descriptively every 24-hour period through Day 30 
and total opioids consumed over 30 days. In addition, opioid consumption will also be 
analyzed from the time of surgical closure to Hour 48 (Day 3), Hour 72 (Day 4), Hour 96 
(Day 5), Hour 168 (Day 8), Hour 336 (Day 15), and Day 30 using the Wilcoxon rank-sum test.
8.3.4
Time to First Rescue Opioid Medication
The time to the first post-surgical rescue opioid medication will be calculated. Data will be 
summarized using the Kaplan Meier method and displayed graphically where appropriate. 
Confidence intervals for the 25th, 50th, and 75th percentiles will be reported. The Cox 
proportional hazards model will be fitted to compute the treatment hazard ratios and the 
corresponding 95% CI.
8.4 Exploratory Endpoints
Exploratory endpoints will be analyzed in Part A and Part B of the trial.
x
Pain Free on the NRS-R , which is defined as NRS-R=0, will be summarized. 
x
Time to pain free, which is defined as NRS-R=0, from surgery closure to Day 30 will 
be analyzed using KM method.
x
Time to the first rescue of opioid medication will be analyzed using KM method.
x
Time to Opioid free will be analyzed using Kaplan Meier method.
x
Number of subjects who are opioid free at 1 week, 2 weeks, 3 weeks and 4 weeks will 
be summarized. 
x
NRS-R and NRS-A as collected (without imputation) will be summarized by 
assessment timepoints. In addition, the group mean scores will be graphed by 
assessment timepoints in categories of 
o
No Pain – 0
o
Mild Pain – 1-3
o
Moderate Pain – 4-6
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 28 of 48
o
Severe Pain – 7-10
x
NRS-R and NRS-A as collected (without imputation) will be summarized by location 
of pain by assessment timepoints.
x
Other endpoints such as time to various degrees of flexion and extension and 
reduction/incidence of opioid-related AEs may be explored. 
8.4.1
Evaluation of Quality of Recovery (QOR-15)
The Quality of Recovery 15 Scale (QoR-15) outcome will be summarized descriptively as a 
continuous variable for each scale, by each assessment visit. Change from baseline values will 
be calculated, listed, and summarized similarly. The total score of the 15 questions will be 
calculated and included in the analysis.
8.4.2
Evaluation of Knee Injury and Osteoarthritis Outcome Score for Joint 
Replacement (KOOS, JR)
KOOS, JR contains the subscales of Stiffness (Question 1), Pain (Question 2-5) and Function, 
daily living (Question 6-7).
The responses will first be scored to 0-4 for 0 being None and 4 being Extreme.
KOOS, JR is scored by summing the raw response (range 0-28) and then converting it to an 
interval score using the table provided below. The interval score ranges from 0 to 100 where 0 
represents total knee disability and 100 represents perfect knee health.
Table 2: Converting Koos Score to Interval Score
Raw summed score
             (0-28)       
Interval score
(0 to 100 scale)
0
100.000
1
91.975
2
84.600
3
79.914
4
76.332
5
73.342
6
70.704
7
68.284
8
65.994
9
63.776
10
61.583
11
59.381
12
57.140
13
54.840
14
52.465
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 29 of 48
15
50.012
16
47.487
17
44.905
18
42.281
19
39.625
20
36.931
21
34.174
22
31.307
23
28.251
24
24.875
25
20.941
26
15.939
27
8.291
28
0.000
KOOS JR total scores will be summarized descriptively by subscales and assessment time 
point and change from baseline values will be calculated. In addition, the interval scores and 
change from baseline interval scores will be summarized descriptively by assessment time. A
separate listing will be presented for the KOOS JR raw scores, total score, and interval scores.
8.4.3
Physical Therapy Survey
The scores collected from the ability to manage pain will be listed.
8.4.4
Range of Motion (ROM)
Range of motion is defined as the degree of flexion minus the degree of extension.   
ROM data will be summarized by the extension and flexion limb by assessment time point.
In addition, the calculated ROM, as defined above, will be summarized descriptively by 
assessment time point.
Number of subjects that achieve 90 degrees of flexion will be summarized similarly by 
assessment time point.
Time to reach 90 degrees of flexion will be explored using KM method.
8.4.5
PHQ-9
PHQ-9 data for Q1-Q9 will be summarized by each question and the total score. All data 
collected will be listed.
8.4.6
Evaluation of the Knee Society Score
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 30 of 48
Maximum total points collected from the Knee Society score will be summarized by categories 
evaluated. All data collected on the questionnaire will be listed.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 31 of 48
9.0 SAFETY ENDPOINT EVALUATION
All summaries of the safety data will use the safety analysis set.
9.1 Adverse Events
All AEs will be coded and summarized by system organ class (SOC) and preferred terms based 
on the Medical Dictionary for Regulatory Activities (MedDRA) coding dictionary.
All AEs will be evaluated for those subjects who were administered any opioid and Opioid-
related AEs will be determined prior to the database lock (DBL).
Incidence (frequencies and percentages) of TEAEs by SOC and preferred terms will be 
summarized for the following:
x
TEAEs
x
TEAEs by maximum severity
x
TEAEs leading to study discontinuation TEAEs by the strongest relationship to:
o
Investigational product
o
TKA surgical procedure 
x
Serious AEs (SAEs)
x
AESI
x
Opioid-related AE.
Each subject will be counted only once within each summation level (SOC; preferred term). If 
a subject experiences more than one AE within a given summation level, the AE with the 
strongest relationship or the maximum severity, as appropriate, will be included in the 
summaries of relationship and severity.
Additionally, an overall summary table of TEAEs that include the total number of events as 
well of incidences of TEAE, TEAE by severity, AE by relationship, AEs leading to study 
discontinuation and SAEs will be provided.
In the AE data listings, all AEs will be displayed and AESI flagged.
9.2 Wound Healing Assessment
The Southampton Wound Scoring System will be used to evaluate wound healing. Wound 
healing grades on Day 15, 22, 30, and 56 will be summarized descriptively.
9.3 Clinical Laboratory Results  
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 32 of 48
Descriptive summaries for chemistry and hematology laboratory tests of observed (absolute) 
values and changes from baseline values will be presented for clinical laboratory values at each 
time point.
Laboratory values will be listed with the reference range.  Any values outside of reference 
range will be flagged.  
Urine pregnancy tests, and urine drug screen data will be presented in a listing
9.4 12-Lead ECG
12-Lead ECG results will be presented in a subject listing. As it is sometimes not possible to 
collect 3 ECGs (triplicate) at a specified timepoint, the values at that timepoint will include the 
average of the two ECGs, or the values of the single ECG that is collected at that timepoint. If 
one variable is not available, it will not preclude the inclusion of other variables in the analysis.
The number and percentage of subjects with normal, abnormal but not clinically significant, or 
abnormal and clinically significant will be summarized by assessment timepoints.
All other parameters of HR, QT, QTcF etc. will be summarized descriptively by assessment 
timepoints.
9.5 Vital Signs  
Vital signs measurements (systolic and diastolic blood pressure, pulse rate, body temperature, 
and oxygen saturation) will be summarized and listed by assessment visit. Additionally, the 
changes from baseline will be calculated and presented descriptively.
Vital signs data will be listed by subject and visit.
9.6 Physical Examination and Neurological Assessment Findings
Physical examination and neurological assessment findings will be displayed in listings.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-003
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 33 of 48
10.0
DEVIATIONS FROM STATISTICAL PLAN AND OTHER ISSUES
During the analysis and reporting process, any deviations from the statistical plan designed for 
this protocol will be described and justified in the clinical study report.
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 34 of 48
11.0
APPENDICES
11.1
Appendix A: SCHEDULE OF EVENTS FOR PART A
   


	

  
 
 
 
 
 
  
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 35 of 48
   


	

 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 36 of 48
   


	

 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
  
  
 
 
 
  
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
   
 
 
 
 
 
 
 
  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
  
  
 
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 37 of 48
   


	

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 38 of 48
   


	

 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
  
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
  
 
  
  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 39 of 48
   


	

 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 40 of 48
11.2
Appendix B: SCHEDULE OF EVENTS FOR PART B
   


	

  
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 41 of 48
   


	

  
 
 
 
 
 
  
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
   
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 42 of 48
   


	

 
  
 
  
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 43 of 48
   


	

  
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 44 of 48
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 45 of 48
11.3
Appendix C: Opioid Oral Morphine Milligram Equivalent (MME) Conversion 
Factors
   


	



Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 46 of 48
   


	

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
   
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 47 of 48
   


	

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allay Therapeutics, Inc.
Statistical Analysis Plan
Protocol ATX-101-TKA-001
Amendment 1, 20Feb2024
CONFIDENTIAL
Page 48 of 48
12.0
REFERENCES
1.
Center for Disease Control and Prevention (CDC) clinical guidance on dosage of opioids 
for treatment of chronic pain factsheet: Calculating Total Daily Dose of Opioids for Safer 
Dosage.
2.
Centers for Medicare & Medicaid Services (CMS) Opioid Products Indicated for Pain 
Management.  KMAP General Bulletin 18101, April 2018
https://cdn-links.lww.com/permalink/jpsn/a/jpsn_4_2_2015_04_23_manworren_jpsn-d-
14-00050r2_sdc1.pdf
   


	
